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This thesis contains some co
  
ntributions for statistical models studying the 
disease
d, focusing on possible advantages and disadvantages for each method.  
Softwa
 progression. Methods developed in this thesis are largely motivated by the 
applications to the medical sciences.  
Disease progression can be well described using multi-state models. These 
models may be considered as a generalization of the survival process where several 
(intermediate) events occur successively over time. Multi-state models offer a better 
understanding of the process of the illness, leading to a better knowledge of the 
evolution of the disease over time. Issues of interest include the estimation of 
progression rates, assessing the effects of individual risk factors, survival rates or 
prognostic forecasting. The influence of these intermediate events in survival is often 
analyzed using the Cox time-dependent regression model. This thesis contains a 
comprehensive review of several multi-state models for studying disease progression. 
Differences between these approaches and the time-dependent Cox regression model are 
discusse
re implementation of these models has been developed in the form of an R 
library. 
Traditionally, statistical methods for analyzing such models depend on the 
Markov assumption, for which future evolution only depends on the current state. By 
ignoring disease history behaviour, these models may carry severe limitations which 
can make the model inappropriate. One alternative approach is to use a semi-Markov 
assumption, in which the future of the process does not depend on the current time, but 
only on the duration in the current state. Finally, we developed a new non-Markov 
approach for which the future of the process depends on the current time, but also on the 
 x 
time of transition to the current state. These methodologies can be used for the 
estimation of transition probabilities, as well as many other interesting quantities. This 
pproach is evaluated using a simulation study and illustrated using data from a clinical 























































al Research of the University 
of Sant
by 
University of Minho, Prodep grant 5.3/N/189.015/01 and by Spanish Ministry of 








I would like to express my sincere thanks to my supervisors, Carmen Cadarso 
Suárez and Jacobo de Uña Álvarez for their encouragement, support and guidance 
during these last years. My thanks to Fernandez Sueiro and Willisch Domínguez from 
the Juan Canalejo University Hospital, and to the Portuguese Oncology Institute of 
Oporto for providing both the data and a clinician’s perspective on the problem. Thanks 
are also due to the Department of Statistics and Operation
iago de Compostela for their valuable teaching in the PhD courses. I would like 
also to thank my wife for her moral support. 





















List of Figures v
List of Tables ii
Chapter 1. Introduction 1
          1.1. Survival analysis…………………………………………………….. 2
          1.2. Multi-state models…………………………………………………… 12
          1.3. Applications……………………………… 16
          1.4. Outline of the thesis…………………………………………………. 20
Chapter 2. Generalities on multi-state processes 25
          2.1. Multi-state processes............................................................................ 26
          2.2. Commonly-used multi-state models.................................................... 28
          2.3. Sampling times.......................... 35
          2.4. Common simplifying assumptions....................................................... 37
Chapter 3. Multi-state Markov models 41
          3.1. Introduction.......................................................................................... 42
          3.2. Homogeneous Markov models............................................................ 44
          3.3. Non-homogeneous Markov models………......................................... 46
               3.3.1. Piecewise homogeneous Markov models.................................... 46
               3.3.2. Cox Markov models…………………......................................... 49
               3.3.3. Non-parametric Markov models……………………………….. 51
          3.4. Simulation study………………………………………….................. 54
 xiii
          3.5. Application to the Stanford Heart Transplantation study.................... 58




          3.7. Discussion............................................................................................ 75
Chapter 4. Multi-state non-Markov models 78
          4.1. Introduction.......................................................................................... 79
          4.2. Semi-Markov models........................................................................... 80
               4.2.1. Cox Semi-Markov models........................................................... 80
        4.3. Non-Markov models............................................................................ 81
               4.3.1. The illness-death model………………………………………... 82
                   4.3.1.1. Nonparametric estimation of transition probabilities.….... 84
                      4.3.1.2. Some asymptotic results..................................................... 95
                      4.3.1.3. Simulation study................................................................ 116
                      4.3.1.4. Application to PROVA data.............................................. 124
                      4.3.1.5. Conclusions........................................................................ 126
                      4.3.1.6. Cumulative Incidence functions........................................ 126
                    4.3.1.7. Inference on the joint distribution function of ( )12 13 23, ,T T T  127
  
he bivariate model…………………..…………...…….. 
.................................... 
          6.1. Concluding remarks............................................................................. 154
….………………..………………………….......... 
             4.3.2. Extension to more complex multi-state models........................... 129
                   4.3.2.1. T 130
                   4.3.2.2. The progressive four-state model…………...……..…….. 134
Chapter 5. Software 138
          5.1. Introduction...................................................... 139
          5.2. Software description………………..………………………….......... 141
Chapter 6. Concluding remarks and future research 153
          6.2. Future research… 155
 xiv
A. Appendix of Chapter 4 159
A.1 Analytic expressions for the transition probabilities in the various setting 
schemes presented in section 4.3.1.3 ……………………………………........... 
n study……………. 
utput for the Stomach cancer study…………………………….. 




A.2 Additional figures for section 4.3.1.3 ……………………………………… 164
B. Appendix of Chapter 5 194
B.1 Complete output for the Stanford Heart Transplantatio 195



















ith 95% pointwise confidence bands). (b) Hazard ratio estimation with 
 
3.4 stimated transition probabilities from state 1 (‘own heart’) to state 2 




1.1 Number of published articles in recent years using multi-state models…… 15
2.1 Mortality model for survival analysis……………………………………... 29
2.2 Progressive three-state model……………………………………………… 30
2.3 k-state progressive model………………………………………………….. 30
2.4 Illness-death model………………………………………………………... 31
2.5 Progressive illness-death model…………………………………………… 32
2.6 Illness-death model with recovery………………………………………… 33
2.7 Competing risks model………………………………………………......... 33
2.8 The bivariate model……………………………………………………….. 34
2.9 Evolution of an illness-death multi-state model…………………………… 36
2.10 Three-state progressive models……………………………………………. 
Illness-death model for Transplant Heart data…………………………….. 
(a) Hazard ratio estimation with penalized splines for year of acceptance
(w
penalized splines for age at acceptance (with 95% pointwise confidence 




3.3 Fitted survival probability for the mortality intensity from a multi-state 





(‘new heart’), obtained from the Cox Markov model (solid line), and the 
Transplantation data……………………….………………………………. 
 xvi
3.5 Comparison of probability survival curves………………………………... 
Multi-state model for Psoriatic Arthritis data.…………………………….. 
71
3.6 74
4.1 Curves obtained for setting 3 with 25s = , 200=N  and 32% of censored 
observations for Aalen-Johansen estimator (solid line) and non-
120
4.2 s-death model for PROVA trial……………………………………… 124
4.3 Estimated transition probabilities for Aalen-Johansen estimator (solid 
        
5.1 Extended illness-death model…..………………………………………….. 141
5.2 raphical output for the Cox Markov model. Stanford Heart 
148
5.3 ulti-state model for Stomach Cancer data….……………………………. 
 
149





Markovian estimator (solid bold line)……………………………………... 
 
Illnes
line) and non-Markov estimator (bold solid line)…………………………. 125


















List of Tables 
 
n ssion 
odel, according to sample size, over 500 replicates……………………... 57
3.2  
ox time-dependent model for a single sample with size 
3.1 Mean estimate of the covariate effect for the homogeneous Markov 
model, Cox Markov model and for the Cox time-depe dent regre
m
 
Covariate effect in homogeneous Markov model, Cox Markov model and 
C 500=n .............. 58
3.3 
orresponding standard errors. Stanford Heart Transplantation data……... 61
3.4 
tanford Heart Transplantation data………………………………………. 63
3.5  
ransplantation data ………………………………………………………. 64
3.6 
66
3.7 omparison of observed and predicted percentages of patients in each of 
ransplantation data………………………………………………………. 72
3.8 on-homogeneous model. Estimated transition rates and hazard rates on 
73
3.9 bserved transitions in the Psoriatic Arthritis data……….……………….. 74
4.1 
 
Time-dependent Cox regression models. Effect estimates and 
c
 
Estimated effects on the mortality intensity in transplanted patients. 
S
 
Final Cox Markov model for all transitions. Stanford Heart
T
 
Multi-state homogeneous Markov model. Estimated transition rates and 
hazard rates. Stanford Heart Transplantation data………………………... 
 
C
the three states for Cox Markov Model (CMM), Homogeneous Markov 








Summary statistics measuring integrated bias, integrated variance and 
integrated mean square error……................................................................. 
 
118
4.2 Estimates of integrated absolute bias, integrated variance and integrated 




4.3 Estimates of integrated absolute bias, integrated variance and integrated 





4.4 Estimates of integrated absolute bias, integrated variance and integrated 
mean square error for setting 3, according to fixed value s, censoring and 
123
5.1 put data file for the Stanford Heart Transplantation data……………….. 142
5.2  
















Sample of the output for the time-dependent Cox regression model. 
S
 
Sample of the output for the homogeneous Markov model. Stanford Heart
T
 
Sample of the output for the Cox Markov model. Stanford Heart 
T
 







































































1.1 Survival analysis 
 
This chapter is concerned with studying the time, T, between a well-defined time 
origin and a subsequent event. In biomedical applications, this is known as survival 
analysis, and the times may represent the survival time of a living organism or the time 
until a disease is cured. Although we are mainly interested with the application of these 
methodologies to data from epidemiological and clinical studies, these methods can also 
be applied to data from different areas, such as the social sciences, economics and 
engineering. 
It is common in survival analysis for some of the data to be censored. That is, 
the time elapsed before the occurrence of the event is not known; it is only known that 
this time exceeds some value (right-censoring) or that it is inferior to some value (left-
censoring). Some observations in survival analysis may not be observed for the full time 
to the event. For example, in a clinical study, some patients will have survived to the 
end of the study, while for others the survival status at the end of study is unknown 
because there is either loss to follow-up or they have died due to other causes unrelated 
to the study. In these studies, complete survival information will be available for some 
patients, while for others we do not know the exact survival time but rather the time 
elapsed from the entry in the study until last known survival time. In such cases, we say 
that the observation is right-censored. 
 Sometimes the survival time is less than that which is observed. This might 
occur if subjects are observed at intermittent visits, and only then it is observed that the 
event had occurred some time before. A typical example is the study concerning the 
time to recurrence of a tumour. When a patient is found to have a recurrence, the actual 








time of recurrence (since the operation) is less than the observed, and the observation is 
said to be left-censored. 
 Another form of censoring is interval-censoring, which is commonly present in 
clinical studies where the observations are made at intermittent visits. In these cases, the 
exact survival time is not observed; it is only known that the event occurred within an 
interval of time. The observation is said to be interval-censored. 
 Censored observations cannot be ignored since they carry important information 
about the survival, but because of censoring, special methods may be required to apply 
some model and to analyze the data.  
 Generic survival data is in the form  ( ),δY )C  , where Y T and 
( )
(min ,=
δ = ≤I T C  for which C are the censoring time  associated with T . With random 
censoring, we will assume that the time of censoring and the survival time T are 
independent. This assumption specifies that the probability of an event occurring in the 
erval [ [,t t dt+ , given that no event occur until time t, is the same for 
individuals in general and those whose censoring time is 
s
greater than t; that is, 
small int
( ) ( ),t T t dt T t t ≤ T t dt T t C t≤ < + ≥ = < + ≥ ≥P P . 
In addition to censoring, observations may be incomplete because of left-
truncation, that is, the observation is only considered if some condition bearing on 
subject history is met. For example, subjects may not be followed from time 0, but only 
from a later entry time, conditional on being alive at this entry time. 
  
Basic concepts 
Let T be a random non-negative variable representing the individual survival 
time from a homogeneous population.    











Assume T is an absolutely continuous variable with underlying density function 
. The distribution function of T is given by ( )f t
( ) ( ) ( )= ≤ =
t




 ( )S t
e value t, 
( ) ( ) 1= > = −PS t T t .       [1.2] 
The hazard function, ( )t
( )
α , is the probability that an individual “dies” at some 
time t, conditional that he survived until that time. Thus, the hazard function represents 





≤ < + ≥⎡ ⎤⎣ ⎦= P |lim
dt
t T t dt
t
dt
or , representing the probability that an event will 
T t
 ,     [1.3] 
( ) ( )α ≅ ≤ < + ≥P |t dt t T t dt T t
occur in the small time interval [ [,t t dt+ , given that no event occur until time t. The 
hazard function is also called risk, the failure rate, the mortality rate, or intensity. 




( ) ( )
t
A t u du .        [1.4] 
0
α= ∫
e can now obtain some useful relationships between each one of the
( ) ( )( )
f tt
S t
α = ,         [1.5] 




S t u duα⎛ ⎞= −⎜ ⎟⎝ ⎠∫







( ) ( )( )= −expS t A t ,        [1.7] 
and 
( ) ( ) ( )
0
α α⎛ ⎞= ×
 Because of relations [1.1]-[1.8], the distribution of T can be univocally specified 
through any one of the follo
−⎜ ⎟⎝ ⎠∫exp
t
f t t u du .      [1.8] 
wing functions: ( ) ( ) ( ) ( ) ( )  and   α⋅ ⋅ ⋅, , ,f F S ⋅ ⋅A .  
A basic task in survival analysis is the estimation of survival in the presence of 
red observations in a sample of dimension n with 
r for survival is the 
 
 
The Kaplan-Meier estimator 
censoring. If there are no censo
observed survival times, , the most natural estimato1 2, ,..., nt t t
empirical estimator, given by 




which is unbiased and is a consistent estimate of 
1 n= ≥∑ IS t t t ,        
( )S t . 
 Whenever observations are censored, alternative estimators are needed.  
 Suppose th
 w  
Kaplan and Meier (1958), obtained a nonparametric estimate of the survival 
function, called product-limit, which is the generalization of the empirical estimator for 
censored data.   
ere are n subjects with observed survival times, 1 2, ,..., nt t t . Some of 
these observations may be right-censored or there may be tied observations. If we now 
assume that e have k events ( )k n≤  and n k− censored observations, then we may 
write ( ) ( ) ( )1 2 ... kt t t< < <  for the t tim s (order statistics ed 
bjects at risk (alive and uncensored) just prior to 
k even e ) arranged in increas
order. Let in  denote the number of su






nt at that 
e time.  
 
 
the event time ( )it , and id  the number of  subjects who experienced the eve
sam










( )1jt t +≤ <  and  1 2, ,...,
 1= −S t ,        [1.9] 
for jt
⎜ ⎟∏
( ) j k= . 
The Kaplan-Meier function is a consistent estimator of ( )S t  which, under 
general conditions, can be considered a nonparametric maximum likelihood estimator. 
This estimator is a step function which steps d n at each event time (only), with ow
l ( ) 1=t  for ( )1t t< . TS his estimator can be used in the context of survival data subjected 
to inde  presence of left-
truncation, the estimation [1.9] is pe
subjects who have entered the study before time 
The variance of the Kaplan-Meier estimator is estimated by 
pendent right-censoring and for left-truncation as well. In the
rformed as earlier, but now the in  is the number of 
( )it and are still in the study just prior to 
( )it  (Borgan, 1998b).  
l ( )  ( ) ( )
2 2 idt S t
n n d
σ = −∑ ,        [1.10] 1
j
i i ii=
for j jt t t≤ <  and  1 2, ,...,j k=( ) ( )1+ . This estimator is known as Greenwood’s formula 
 The cumulative hazard may be estimated by the Nelson estimator (Nelson, 
1969), originally introduced to check graphically the fit of parametric models. This 
estimator is also known as Nelson-A
(Greenwood, 1926). 








A t =∑ ,          








( )1jt t +<  and  1 2, ,...,j k= . This estimator leads to an alternative estimator for ( )
the survivor function, 
 ( ) l ( ){ }expS t A t= − .         
 Fleming and Harrington (1984) propose an ator to the Nelson 
estimat
 alternative estim









⎧ ⎫= ⎨ ⎬−⎪ ⎪⎩ ⎭
1⎪ ⎪∑ ∑ .        
for  and  1 2, ,...,( ) ( )1j jt t t +≤ < j k= . 
 
The Cox proportional hazards model 
influence of one or more covariates on the variable of interest. In general, regression 
models are used to relate the variable of interest with covariates. 
A and a certain number
 a model is 
 a m  Cox model 
assumes that the hazard function of an individual i can be written as 
In many statistical studies, we are facing problems in which the main interest is 
to study the relationship between variables, or more particularly, to analyze the 
 classical model relating the hazard function  of covariates 
is given by the proportional hazards model, introduced by Cox (1972). Such
a popular choice because it is a semi-parametric model which is readily interpreted and 
in which censored observations are easily ccom odated. Formally, the
( ) ( ) ( )0 expi i it Z t Zα α β= T ,       [1.11] 
where ( )t0α  is a non-negative baseline hazard function, ( )T  
of p covariates, and  1 2, ,...,
1 2, ,...,i i i ipZ Z Z Z= a vector 
p( )β β β  the associated vector of unknown regression 
parameters. 
β=T






individuals with covariate vectors  and  is constant over time, 
 
 Model [1.11] implies proportionality of the hazards; that is, the hazard ratio for 
any two 1Z 2Z
( )
( ) ( ){ }T 1 2β= −exp Z Z ,  
w
. Th o









hich is independent of t , that is, the hazard function for any two patients is 
proportional over time portional hazards assumption can be checked by plotting 
a graph of ( )( )( )log log S t−  against t . Displayed curves must be parall
e pr
d t groups; if the curves cross, then a proportional hazards model is inappropriate. 
A more formal way for checking this assumption was suggested by Harrel and Le  
(1986). 
 The form of ( )t0α  can be one known parametric distribution (Exponential, 
Weibull, Gamma, etc) or a nonparametric function. If we assume a particular form for 
( )t0α   then we have a com letely parametric mp odel of proportional hazards, such as the 
exponential model, ( )0 tα α= , or the Weibull mode  ( ) ( ) 10α θ θl − s= rt r t . In these case , 
the full likelihood (not shown here) can be used to obtain the parameter estimates. 
 Assuming model [1.11], Cox formulated a partial likelihood (PL) function that 
does not depend on ( )t0α  and, therefore, allows the realization of inferences on β  
without the need for any assumptions on the baseline hazard function ( )t0α . The Partial 
log-likelihood PL  function takes the form 
( )






δ β== ⎬⎪∑ ,     [1.12] 













( ) represents the risk set at 1 2, ,..., nt t t itR
time , and it iδ  is an indicator of censoring, that takes the zero value if the survival time 







of the ith individual is censored and unity otherwise. This approach assumes no ties in 
the times at which events occur.  
Although survival times can be considered a continuous variable, the collection 
s re frequen  
<<
of survival data often involves an error measure and therefore tie a tly
observed. To include ties, adjustments are necessary. 
Suppose ( ) ( )tt ( )kt< ...  are the failure times for the  individuals in the 
mple
21 n
sa , and let id  be the number of subjects observed to fail at ( )it . Then the 
approximation due to Peto (1972) can be used: 
( )














where s  is the sum of the covariates of  d  subjects observed to fail at t , 
i ijs Z=∑ . 
=∏ idL ,      [1.13] 
j=
 
hazards is violated for the different levels. An important generalization that does not 
make difficult the estimation of
i i ( )i
1
id
 Other methods for adjustment of ties exist, namely, the proposals of Breslow 
(1974) and Efron (1977). 
 Sometimes there are important factors for which the proportionality of the
 β  consists in allowing ( )0 tα  to vary in certain subsets 
tified. Th
licative effect on 
the hazard.  The strata divide the subjects into different groups, each one with a 
different baseline hazard function but with common values for the vector coefficients. 
of the data.  This is the case when the population is stra is generalization is 
useful if, for example, some covariate does not seem to have a multip













=∑  be the 
sample size, where 
j
jn  is the number of subjects in the jth stratum. We then define the 
hazard function for an individual in the jth stratum of the factor as, 
( ) ( ) ( )0 expjt Z t Zα α β= T . 







=∏  where jL To obtain the estimates for  is the 
likelihoo 1 rd function [ .13] fo  the jn  observations in the jth stratum. 
are observed and 
individ
ovariates in the survival process can make the 
patient
h events is the time-dependent Cox regression 
model 
 In many clinical studies that generate survival data, patients 
ual data and covariate information are collected at several occasions through a 
follow-up period. Covariates whose values change over time, are called time-dependent 
covariates. The introduction of these c
s risk change from one time point to the next as the values of the covariates 
change. Time-dependent covariates might represent either a qualitative change in 
patient’s condition (presence of metastases, a change of treatment, etc.) or individual 
continuous information (tumour size, lymphocyte count, etc.). A classical approach for 
the analysis of the occurrence of suc
(Kalbfleisch and Prentice, 1980).  




β⎧ ⎫∑exp( ( ))pn Z tδ β== ∈ =
⎪ ⎪= ⎨ ⎬⎪⎩




i h R t j
PL ,     
where the covariates, time-dependent or not, can be updated or fixed.  
It should be noticed that the time-dependent Cox model does not require 
proportional hazards, that is, the hazard ratio for two individuals with fixed covariate 
vectors may not be constant over time. 
⎪⎭( ))j hj iZ t






e age of the model, since the parameterization of the 
In model [1.11], the effect of the covariate 
 
Advantages of the proportional hazards model include the ease of interpretation 
and its availability in the majority of statistical packages. However, this approach 
provides only constant estimates for the covariate effect over the whole study period, 
which can b  considered a disadvant
effect of covariates is very restricted.  
jZ  is assumed to be only through a 
linear combination of j jZβ . Often there is empirical evidence that the covariate effect 
may vary with time. One option is to use the Cox model, 




i i j ij
j
t Z t t Zα α β
=
⎛ ⎞= ⎜ ⎟∑ ,       
where ( ) ( ) ( )(
⎝ ⎠
)T1β β β= ,..., pt t t  is a vector of smooth unknown functions in . 
 
ni, 1986; Gray, 1994); or using local likelihood (Hastie and 
Tibshirani, 1986; Hastie and Tibshirani, 1987; Gentleman and Crowley, 1991). Here we 
are interested in the spline function methods. Among these, regression spline models 
replace the 
 t
Local methods and spline function methods are two non-linear approaches for 
such problems. There are two main approaches to local fitting methods: using local 
scoring (Hastie and Tibshira
( )j jj f Z∑ by the additive model : j jZβ
 ( ) ( ) ( )0 exp pi i j ijt Z t f Zα α ⎛ ⎞= ⎜ ⎟∑ ,       
1j=⎝ ⎠
( ) ,  1,...,where jf j p  are unspecified smooth covariate functions.  
These models are described in detail by Durrleman and Simon (1989), and 
Hastie and
⋅ =
 Tibshirani (1990), using backfitting estimators.  







Another possible approach is the smoothing splines (O’Sullivan, 1988; Hastie 
ese, cubic smoothing splines are the most used. 
oothing is achieved by imposing a penalty for curve roughness. 
 
and Tibshirani, 1990). Among th
Sm
Here, we shall use penalized splines, also known as P-splines, as introduced by 
Eilers and Marx (1996). The unknown functions ,  1,...,jf j p=  will now be specified as 









where ( )sB ⋅  are basis functions connected to knots and m is the number of basis 
functions. Obviously, the basis functions and location of knots depends on the function 
to be fitted. Eilers and Marx (1996) give several reasons for choosing B-splines. Basic 
references about splines are given by de Boor (1978).  
 A wide literature on the subjects discussed in this section include books by 
Kalbfleisch and Prentice (1980), Cox and Oakes (1984) and Fleming and Harrington 
(1991).   
 
 
1.2 Multi-state models 
The experience of a patient in a survival study may be thought of as a process 
that involves two states, with one possible transition from the ‘alive’ state to the ‘dead’ 
state. In some studies, however, the state representing those patients ‘alive’ may be 
partitioned into two or more intermediate (transient) states, each of which corresponding 
to a particular stage in the normal progress of the illness. The influence of these events 











in survival is often important in the patient’s outcome and can be handled using the Cox 
time-dependent regression model. In such cases, the event of interest is considered as 
the main event, while intermediate events are often included as time-dependent 
covariates in a proportional hazards model. The process ends when the patient enters the 
(absorbing, “dead”) state
essary after this event occurs. Thus, in survival analysis only two states are 
considered, and the event of interest is the passage from one state to another. As 
mentioned before, the proportional hazards model has the advantage of being easily 
interpreted and available in the majority of statistical packages.  
Multi-state models may be considered as a generalization of the basic framework 
dealing with survival data where survival is the ultimate outcome of interest but where 
intermediate (transient) states are identified. In contrast to survival data, in these 
models, a sequence of events is observed, leading to more than one observation per 
individual. In medicine, the states might be based on clinical symptoms (e.g. bleeding 
episodes), biological markers (e.g. CD4 T-lymphocyte cell counts; serum 
immunoglobulin levels), some scale of the disease (e.g. stages of cancer or HIV 
infection) or a non-fatal complication in the course of the illness (e.g. transplantation). 
A change of state is called a transition, or an event. States can be transient or absorbing, 
if no transitions emerge from the state (for example, death). The state structure 
identifies the states and the transitions allowed between states. There is no unique 
structure for the series of states. Some of the commonly-used state structure
ted in Chapter 2. 
Multi-state models have several advantages over the Cox proportional hazards 
model with time-dependent covariates. First, they provide a comprehensive view of the 
disease process, putting the incomplete information to more efficient use when portions 






 regression model for example. In fact, it is very unlikely that 
the ris
 interest in statistical methods for studying 
disease progression. Some diseases that h ve been studied using multi-state models 
include: HIV infection (Lagakos et al., 1988  Longini et al., 1989 and 1991 ; Gentleman 
et al., 1994; Satten and Longini, 1996; Aalen et al., 1997), breast cancer (Duffy and 
Chen, 1995; Chen et al., 1996; Pérez-ócon et al., 2001), cirrhosis of the liver (Kay, 
1986; Andersen et al., 2000), leukaemia (Klein et al., 1984 and 1994; Andersen et al., 
1999; Keiding et al., 2001; Chevret et al., 2000), asthma (Saint-Pierre et al., 2003), 
alzheimer’s (Commenges et al., 2004), transplantations (Hansen et al., 1994; Klotz and 
Sharples, 1994; Jackson and Sharples, 2002), diabetes (Andersen, 1988), diabetic 
retinopathy (Andersen, 1991; Marshall and Jones, 1995), malaria (Gottschau and Hogh, 
1995) and multiple sclerosis (Esbjerg et al., 1999). Multi-state models have been also 
 
of the history of an individual’s illness are known (efficiently handling heavily censored 
data). Secondly, in this framework, the so-called transition intensities provide the 
instantaneous hazard for movement out of one state into another. These intensity 
functions can be used to determine the mean sojourn time in a given state of illness, the 
number of individuals in different states at a certain moment, and survival proportions 
in each state. Finally, covariates in the transition intensities can also explain differences 
in the course of the illness among the population. In this way, multi-state models can 
reveal that different covariates affect different transitions, which would not be possible 
with other models, the Cox
k of death in patients that received different treatments would be the same. 
Furthermore, the prognostic factors associated with the risk of death can be different in 
these groups of patients. In conclusion, multi-state models dynamically evaluate the 
patient’s progress of disease, depending on the occurrence of intermediate events. 
Recent years have seen an increasing
a
;







used in other fields, such as signal processing (Juang and Rabiner, 1991) and reliability 
ngly used for modelling survival data in the case where 
 interest is to study how covariates affect survival. However, in spite 
f the advantages mentioned previously, there are still few applications in the literature 
sing multi-state models.   
analysis (Su et al., 2000). 
For example, a search on PUBMED using the terms “multistate model” and/or 
"multi-state model" takes us to 86 published articles. Figure 1.1 shows the evolution of 
the use of multi-state models up to September 2005. This figure shows that multi-state 
models have been increasi











Figure 1.1. Number of published articles in recent years using multi-state models.  
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plications of multi-state models have been done with 
 and Lawless, 1985; Kay, 1986). While the 
researc
t of them are self-contained. Moreover, 
1.3 Applications
 
ov (when we 
 The earlier ap
homogeneous Markov models (Kalbfleisch
h on such models has been increasing in recent years, there are still few 
applications on non-homogeneous models or non-Markov models. Furthermore, when 
using multi-state models, different patterns of censoring and the different state structure 
have to be considered. For these purposes, flexible estimation methods have been 
proposed along with software. Even so, we feel that the available software for these 
models is still scarce, difficult to use, and mos
although the use of such models has been increasingly suggested by several authors, we 
feel that the applications of such models are still insufficient in the literature. 
 In conclusion, and even with the limitations mentioned above, it is our belief that 
because of the development of more flexible estimation methods, and with the 
increasing power of numerical methods and computers, that multi-state models will be 
more and more applied in the medical sciences. 







Throughout this thesis we will use some databases to illustrate all presented 
methodologies. The Stanford Heart Transplant dataset is one of the most widely used 
examples in survival analysis. An additional advantage of this data is its wide 
availability to researchers. Because Stanford Heart Transplant data is Mark






herapy versus that of no treatment on risk of bleeding and survival. This database 




ansplant study began in October 1967. The available data 
in Crowley and Hu’s article (Crowley and Hu, 1977) covers the period up to April 1, 
1974. Some patients died befor  found. Of the 103 patients, 69 
 
consider time since entry in study as the time scale), we may use this database to 
compare some reviewed methods in Chapter 3. 
 One of the major aims of this thesis is to study non-Markov multi-state models. 
To illustrate proposed methodologies, we use data from a clinical trial of cirrhosis of the 
liver. PROVA clinical trial was conceived to evaluate the effect of propanolol and/or 
sclerot
was previously used by Andersen et al., (2000), who concluded (among other things) 
that the Markov assumption is not valid in this case.    
 In addition to these two databases we
bjects suffering from Psoriatic Arthritis from Galicia (Spain), and a database 
provided by the Portuguese Oncology Institute of Oporto to study the stomach cancer 
treatment in the north of
Stanford Heart Transplantation data 
The Stanford Heart Tr
e an appropriate heart was
received a heart transplant. The total number of deaths was 75; the remaining 28 
patients contributed with censored survival times.  
 For each individual were recorded the following: an indicator of his final vital 
status (censored or not), the survival times from the patient’s entry into the study (in 
days), and a covariate vector including age at acceptance, year of acceptance, previous 
surgery (coded as yes1 = ; no0 = ), and transplant (coded as yes1 = ; no0 = ). The 
covariate transplant is the only time-dependent covariate, while the other covariates 
included are fixed. 






state models to investigate 
e effect of the transplantation on survival. 
For the Stanford data, it i  the hazard of death before and 
ter th
l conceived to evaluate the effect 
s entered the study. Since their entry 
to the study, some patients had bleeding episodes, while others did not. The 
occurrence of these intermedi patient outcome and can be 
include
umber of deaths was 75.  
 
 
 In the context of multi-state modelling, we may consider the covariate 
‘transplant’ as an associated state of risk, and then use multi-
th
s interesting to compare
af e transplantation. We may also explore the potential fixed covariate effects in 
each of the transitions. 
Among others, Turnbull, Brown and Hu (1974), Mantel and Byar (1974) and 
Crowley and Hu (1977) have studied the Stanford Heart data to evaluate the influence 
of transplantation on hazard. 
 
PROVA clinical trial 
 PROVA was a Danish multi-centre clinical tria
of propanolol and/or sclerotherapy versus that of no treatment on risk of bleeding 
episodes and survival in patients with cirrhosis of the liver.  This data cover the period 
between 1985 and 1989. In this period, 286 patient
in
ate events may affect the 
d as a transient state in a multi-state model.  
 Before 1 January 1990, only 50 of the 286 patients developed bleeding episodes 
and from these, 29 died. The total n
Psoriatic Arthritis 
 Due to large number of people affected by Psoriasis and Psoriatic Arthritis 
(PsA), there is much demand for information on these chronic diseases. Here, we 
consider a sample of 419 subjects from Galicia (Spain). All these patients were 






esearch goals will determine the time scale to use. For example, in Psoriatic 
Arthrit
We consider a sample of 314 subjects drawn from the database provided by the 
ortuguese Oncology Institute of Oporto. This study is concerned with stomach cancer 
eatment in the north of Portugal.  
val times are recorded from the surgical removal of 
e tumour. Along with the survival time, the vital status and a covariate vector 
ing age, sex,
 the initial state (surgical intervention time) through one of two mutually 
exclusive states (‘m
 
diagnosed as suffering from PsA, and then some treatment was considered. This data 
was obtained retrospectively and conceived to investigate the age of developing PsA.  
Here, we are interested in investigating the evolution of the disease from birth up to the 
current state. For this purpose, a series of stages was considered: Psoriatic, Arthritis 
(inflammatory arthritis), PsA, Remission and Active. 
 The r
is data, since our interest focuses on the age of developing of Psoriatic Arthritis, 
then age is the appropriate choice for a time scale. 
 
Stomach cancer study 
P
tr
In this study, patient’s survi
th
includ  and clinical staging were recorded for each patient. Following 
removal of the tumour, 41 patients have a recurrence of stomach cancer while 53 
patients fall ill as a result of metastasis to other solid organs. In this context, patients 
may pass from
etastases’ and ‘recurrence’) to an absorbing state (death). In this 
study, our main goals include: (a) to obtain some informative events such as the mean 
sojourn time, transition rates and survival rates for each state; (b) to compare the 
mortality intensities; (c) to explore the potential fixed covariate effects in each of the 
transitions.  






we present some standard multi-state models, we 
conside
1986); and (iii) Markov models with piecewise constant intensities (Pérez-Ocón 
et al., 
transition intensities, regression coefficients, goodness-of-fit, etc). These checks are also 
 
It should be notice that patients only enter our study if the surgical procedure 
was considered curative, that is to say, if after the surgery there is no evidence of illness. 
During the 5-year follow-up period, the number of deaths was 68; 38 of which occurred 




1.4 Outline of the thesis. 
 
 Chapter 2 provides a deeper review of multi-state models. We introduce these 
models as stochastic processes; 
r some censoring patterns, and we discuss the most common simplifying 
assumptions.  
In Chapter 3, we review some possible approaches following the methodology 
of the multi-state Markov models. Specifically, we review the following models: (i) 
Cox Markov models (Andersen et al., 2000), where the transition intensities are 
modeled using different Cox models separately; (ii) time-homogeneous Markov models 
(Kay, 
2001). The reviewed methods are illustrated with the data of Stanford heart 
transplant study, providing some guidance about the use of these methodologies for 
studying the evolution of the disease. We also use this database to discuss hypothesis 
testing procedures and methods for model checking, such as the time-homogeneous 
assumption or the Markov assumption. Furthermore, when examining the data, one is 
often interested in testing several hypotheses about the model (e.g. hypothesis about the 






, focusing on possible 
advant
order to illustrate possible benefits 
of usin
 
illustrated (discussed) using Stanford database. Differences between these approaches 
and the time-dependent Cox regression model are discussed
ages and disadvantages for each method. Through this illustration, we show that 
multi-state models can provide new insights while confirming the results obtained when 
using the Cox regression model.  
Special attention must be paid to evaluating the covariate effect on the hazard. 
As mentioned before, the Cox model provides only constant estimates of the covariate 
effect over the whole study period. To avoid this problem, we used spline function 
methods (P-splines) to obtain a dynamic Cox model. Furthermore, we introduce these 
spline methods in multi-state models to find out possible non-linear covariate effect on 
the transition intensities. The use of these methods in the scope of multi-state models is 
new. 
While Multi-state Markov models provide non-biased estimates of the 
importance and ability of covariates to predict the course of the illness, these issues 
cannot be fully explored using Cox models alone. In 
g multi-state models, simulation studies were undertaken. Through these 
simulation studies we provide a useful description of why the Cox model can be 
misleading (with difficult interpretation) when used in the presence of time-dependent 
covariates. In this way, we show that a multi-state approach can provide a more 
conclusive analysis of the covariate effect than the Cox model.  
Because, in some cases, Markov models do not fit satisfactorily, alternative 
models must be considered. These models are considered in Chapter 4. One alternative 
approach is to use a semi-Markov assumption. In addition to the Cox semi-Markov 
models, we propose a new approach for illness-death models based on less restrictive 
assumptions than those based on the Markov property. To date, we believe this to be the 






me clinical studies, a model 
with th  
model is preferable. In several cases, a homogeneous model will be satisfactory, while 
in others not. Furthermore, possible comparisons between different multi-state models 
are rather difficult because each of the current programs requires its own input data 
structure. In addition, most of the available programs only provide the regression 
parame rs estimates and do not supply graphical output for the survival estimates nor 
for transition probabilities estimates. To overcome these difficulties, we have developed 
a user-friendly R library, called tdc.surv, which can be used to fit almost all the 
proposed models (the non-Markov model in Chapter 4 is the exception). Advantages of 
this software include the same data input for fitting the different models while providing 
the corresponding numerical and graphical outputs obtained:  parameter estimates with 
standar  errors for the covariates; transition rates; survival estimates; transition 
probabilities estimates; and flexible p-spline hazard ratio estimates for continuous 
covariates (Eilers and Marx, 1996). Moreover, users are able to include any number of 
 
first non-parametric modelling approach completely free from the Markov assumption. 
Along with theoretical properties, we have presented estimated transition probabilities 
and cumulative incidence functions for such models. A simulation study is performed to 
compare both Markovian and non-Markov approaches under a variety of scenarios. For 
illustration purposes, we have applied our methodology to data from the PROVA 
clinical trial, described above. In this chapter, we also show that these methods can be 
extended to more complex multi-state models. As a result of this work, a manuscript is 
being written and will be submitted for publication.  
As previously mentioned, one main difficulty in the implementation of multi-
state models is the lack of available software for these models; most of the current ones 
present some difficulties and limitations in practice.  In so
e Markov assumption may be appropriate, while for others the semi-Markov
te
d







covariates on the transition intensities. In this way, users may easily analyze the results 
offered by the various models in order to compare them and make decisions 
accord  A manuscript about this software has been submitted for publication. A 
detailed description of tdc.surv is presented in Chapter 5. 






































































2.1. Multi-state processes. 
 
specified r sition intensities that provide the instantaneous hazard for 
in continuous time allowing individuals to move between a finite number of states. 
From now on, we will represent the status of an individual by a stochastic 
process 
In a general multi-state model, an individual moves from one state to another 
over time. The next state to which the individual moves, and the time of change, are 
through t an
movement out of one state into another. These models are based on stochastic processes 
( ){ },  iX t t∈T  with ( )iX t  taking a finite number of values { }1,..., N , 
= [ )0, ,  τ τ ≤ ∞T , and fulfilling certain simplification assumptions. Thus, ( )iX t  
denotes the state occupied by the ith subject at time t and { }1,...,S N=  is a finite state 
space. Therefore, ( ){ },  iX t t∈T  have the information of the different transitions that 
occur to an individual over time, as well as the time at which these transitions take 
place.  
S∈ .  We shall call these probabilities, 
The process starts with the distribution of the initial state given by 
( ) ( )0 0 ,  jp X j j= =⎡ ⎤⎣ ⎦P ( ) ( )jp t X t j= =⎡ ⎤⎣ ⎦P
e t, a history, or 
, 
state occupation probabilities. With the evolution of the process over tim
tion,
interval 
filtra  , will be generated containing all information about the process over the t−F
[ )0, t , such as the number of transitions up to time t, states previously visited, 
This multi-state process is fully characterized through transition intensities or 
through transition probabilities between states  and , that we will express 
respectively by 
times of transitions, covariates, etc.   
h j
( )αhj t  and ( ) ( ) ( )( )= = =,hjp s t X t j X s hP .  Thus, while the 







m transition probabilities provide important measures to make long-ter predictions, each 
transition intensity, ( )αhj t , represents the instantaneous hazard of  progression to state j 
conditionally on occupying state h: 




t dt j X
t . 
This expres
j in the small tim  is 
approxim
α =+= =,hj X t hp t t dt Plim
dt dt
sion means that, given its prior history, the conditional probability of 
making a transition from state h into state e interval [ ),t t dt+
ately ( )αhj t dt  for small dt . 
 The process ( )iX ⋅  is then governed by an intensity matrix ( )tQ  with ( )jh,  entry 
( )αhj t  or by a transition probability matrix, ( )tsP ,  with ( )j  entryh, . For 
onvenience, we define
( )tsphj ,




=∑c , representing the hazard associated with the 
istribution of the sojourn time in state .  
or predictive purposes, many 
other quantities in multi-state analysis are expressed in terms of the intensity functions. 
( )no exit from state  by time exph t u duα
hd
 While the transition probabilities are important f
For example, the probability of no exit from state h at time t, given its history up to time 





⎧ ⎫⎪ ⎪= −⎨ ⎬⎪ ⎪⎩ ⎭
Following Commenges (Commenges, 2002), we then define the stochastic 
process as 
( ) ( )( )~ ; , 1,...,i hj
∫P . 
X t MSM t h j Nα =     [2.1]  
 It should be noted that, by defining ( )tX i  as in [2.1], we are assuming that the 
intensities are the same for all subjects. In practical situations, however, it might be 







ndent. For a general regression model we can 
rite 
where 
valuable to relate the individual characteristics with the intensity rates through a 
covariate vector, Z, possibly time-depe
w
( ) ( )( )T0α ϕ α β⋅ = ⋅ ,hji hj hj iZ  
( )⋅0hjα  is the baseline intensity function between states h and j, hjβ  is the vector 
of regression parameters, and iZ  is the covariate vector for subject i.  
 the proportional 
hazard
A popular choice that simplifies the model for inference is 
s assumption, which is obtained by choosing ( )( ) ( ) veuvu ⋅=⋅ ,ϕ , that is,  
 Z       [2.2]  
An alternative was proposed by Aalen for survival data and later used in multi-
 models, which is obtained by choosing 
( ) ( ) ( )T0α α β= exp hjhji hj it t
( )( ) ( ) vuvu +⋅=⋅ ,ϕstate , that is,  
( ) ( ) T0α α β= + hjhji hj it t Z  
In this case, the transition intensities in [2.1] will be then represented by 
       
( )αhj t Z .  
 
 
2.2. Commonly-used multi-state models. 
co plexity of a multi-state model greatly depends on the number of states 
defined and by the transitions allowed between these states. 
The simplest form of multi-state model is the “two-state” model, or mortality 











transient state, “alive”, and one possible transition from this state to an absorbing state, 
“dead”
nsition,
, representing some terminal event of interest. Patients enter the study at the 
“alive” state and then transfer to the “dead” state by some coefficient of tra  ( )tα , 
at time ss as transition intensity, is 
a generalization of the hazard function of survival analysis, as they provide the 
instantaneous hazard for movement out of one state into another. Note that for the 
mortality model, the only relevant information in 
 t.  This coefficient of transition, which we shall expre
t−F  is the individual status (alive or 
dead) along with the covariate history. 
 
Figure 2.1: Mortality model for survival analysis. 
 
These models have been discussed in more detail in Chapter 1.  
Note that the transition (occupation) probabilities are expressed by 
0, exp
 
( ) ( ) ( ) ( )1 11
t
0
p t p t u du S tα⎧ ⎫⎪ ⎪= = −⎨ ⎬⎪ ⎪⎩ ⎭∫  ,    [2.3] =
and 
 ( ) ( ) ( )2 12 0, 1p t p t S t= = − .       [2.4] 
 
Splitting the “Alive” state from the simple mortality model for survival data into 
two transient states, we therefore obtain the simplest progressive three-state model, 
illustrated in Figure 2.2. It has three states and the only possible transitions are 1 2→  
and 2 3→ . For this model, the entry time into state 2 is a relevant information in t−F . 
Note that for the progressive three-state model we assume that the transition intensity 
1. Alive 2. Dead
( )tα









: Progressive three-state model 
from state 2 into state 3 might depend, in some way, on the entry time in state 2, 
denoted by 12t . 
( )12 is the entry time into state 2tFigure 2.2 . 
 
When we refer to pr  to all processes for which 
each state has at most one transition into it, and none into the initial state.  
ogressive models, we are referring
The state occupation probabilities are now given by, 
t
( ) ( ) ( )1 11 12
0
0, expp t p t u duα= = −⎨ ⎬⎪
⎧ ⎫⎪ ⎪
⎪⎩ ⎭∫        





( ) ( ) ( ) ( ) ( )23xp ,p t p t u v dvα α⎡ ⎤⎧ ⎫⎪ ⎪⎢ ⎥= = −⎨ ⎬⎢ ⎥⎪ ⎪ ⎪ ⎪⎩ ⎭ ⎩ ⎭⎣ ⎦∫ ∫ v u dv duα
⎧ ⎫⎪ ⎪−⎨ ⎬∫   
( ) ( ) ( )3 1 21p t p t p t= − −          
  
The mortality model and the progressive three-state model are particular cases of 
the k-state progressive model. This model is illustrated in Figure 2.3. 
 
 
Figure 2.3: k-state progressive model. 
 
State 1 State 2 State 3
( )12 tα ( )23 12,t tα
State 1 State 2 State 3 State K
Another possible and extensively used model in the literature to describe the 
disease progression is the illness-death model (also known as disability model). This 
model is fully characterized by three transition intensities, each one describing the 







the incidence of the disease as well as death. One important 
roblem here is to evaluate whether previously diseased subjects have the same risk of 
death as those who have been healthy all their lives. This model is applied to the Heart 
Transplant data in Chapter 3, and to the PROVA data in Chapter 4.  
 
 
instantaneous risk of moving from one state to another, namely: the disease intensity 
(incidence), the death intensity without disease, and the death intensity after the 
occurrence of the disease. These models are widely used in the medical literature and 
can be used to study 
p
 
Figure 2.4: Illness-death model. 
1. Healthy 2. Diseased
3. Dead
( )12 tα
( )13 tα ( )23 12,t tα
Again, we assume that the transition intensity from state 2 into state 3 might 
depend on the entry time in state 2. For such a model, the probability of staying in the 
healthy state is given by  
t
( ) ( ) ( ) ( )( )1 11 12 13
0
0, expp t p t u u duα α⎧ ⎫⎪= = − +⎨ ⎬⎪ ⎪⎩ ⎭∫       
The probability of being in the diseased state is 
v du
⎫⎪⎬⎪⎭
   
and finally, the probability of having died is   
2 .         
⎪
( ) ( )
( ) ( ) ( )( ) ( )
2 12
12 12 13 23
0 0
0,
        exp exp ,
t u t
u
p t p t
u v v dv v u dα α α α
=
⎡ ⎤⎧ ⎫ ⎧⎪ ⎪ ⎪⎢ ⎥= − + −⎨ ⎬ ⎨⎢ ⎥⎪ ⎪ ⎪⎩ ⎭ ⎩⎣ ⎦∫ ∫ ∫
( ) ( ) ( )3 11p t p t p t= − −








 model can become more transparent (Hougaard, 2000). For example, when 
sing an illness-death model, it is not possible to know the previously visited states for a 
patient found in the ‘dead’ state. We can, however, extend these models to become 
progressive by adding an extra state, representing death after disease. This model is 




 In this mo  the healthy state, 
the current state includes the information on the states previously visited, and the order 
in which they have been visited.  
ay be 
is will m
individuals to move back and forth between the two states. Such a model is referred to 
as the illness-death model with recovery (see Figure 2.6). 
Note that the illness-death model of Figure 2.4 is not progressive since there are 
two transitions into the ‘death’ state. One disadvantage with non-progressive models is 
the impossibility to know the states visited before and the visiting order just by knowing 
the current occupied state. Even so, in some cases the state structure can be changed so 
that the
u
1. Healthy 3. Dead followingdisease2. Diseased
4. Dead prior to
disease
Figure 2.5: Progressive illness-death model. 
del, if we assume that all patients enter the study in
Reversibility between the “healthy” state and the “diseased” state m
considered although th ake the analysis more difficult. These models allow 
 








Figure 2.6: Illness-death model with recovery 
 
The competing risks model (Andersen et al., 2002) is another multi-state model 
which extends the simple mortality model for survival data in which each individual 
may ‘die’ due to any of several causes. As shown in Figure 2.7, there is one transient 




Figure 2.7: Competing risks model. 
 For the competing risks model, the hazard for the total mortality is given by 
. Thus, the survival function is given by  
sorbing “death” states correspond
d












S t u duα⎧ ⎫⎪ ⎪= −⎨ ⎬⎪ ⎪⎩ ∫ ⎭         
1. “Alive”
N. “Dead, cause N-1”
3. “Dead, cause 2”




1. Healthy 2. Diseased
3. Dead







hen, the occupation probabilities are given by 
 
T
( ) ( ) ( )0,p t p t S t= =         





⎧ ⎫⎪ ⎪= = −⎨ ⎬
20 0⎪ ⎪⎩ ⎭
 
 model (Hougaard, 2000), depicted in Figure 2.8, is the multi-state 
odel for bivariate parallel data, with states ‘both alive’, ‘individual 1 dead’, 
ndividual 2 dead’ and ‘both dead’.  






Figure 2.8: The bivariate model. 
 
Although model depicted in Figure 2.8 is non-progressive, we can however, 
make this model progressive using a similar procedure as those shown above for the 
illness-death model.  
For the bivariate model, the occupation probabilities are given by 




p t p t u u duα α⎧ ⎫⎪ ⎪
2. Individual 1 dead
1 11 12 13= = ⎪
− +⎨ ⎬⎪⎩ ⎭
2p t =
∫ ,      
( ) ( )
( ) ( ) ( )( ) ( )
12
12 12 13 24
0 0
0,




u v v dv v u dv duα α α α⎡ ⎤⎧ ⎫ ⎧ ⎫⎪ ⎪ ⎪ ⎪⎢ ⎥⎢ ⎥⎪ ⎪ ⎪ ⎪
= − + −⎨ ⎬ ⎨ ⎬
⎩ ⎭ ⎩ ⎭⎣ ⎦∫ ∫ ∫
   
1. Both alive




( )24 12,t tα
( ),t tα34 13






 ( ) ( )




        exp exp ,
t u t
u
p t p t
u v v dv v u dv duα α α α
=
⎡ ⎤⎧ ⎫ ⎧ ⎫⎪ ⎪ ⎪ ⎪
13 12 13 34⎢ ⎥= − + −⎨ ⎬ ⎨ ⎬⎢ ⎥⎪ ⎪ ⎪ ⎪⎩ ⎭ ⎩ ⎭⎣ ⎦
3 .        
 
The choice of the appropriate state structure depends on the available data as 
well as the research goal. Goals for the data analysis will be determinant for the choice 
of the events and the time scale. For example, in the Psoriatic Arthritis data we are 
interested in studying the evolution of the disease through age. Thus, age is the 
appropriate choice for the time scale. An overview of different time scale can be found 




s was not observed, 
d from its origin, leading to left-censored observations. Usually, 
atients are observed at intermittent follow-up visits, at which time individual data and 
ovariate information are collected, but the information from the periods between visits 
∫ ∫ ∫    
and 
( ) ( ) ( ) ( )4 1 21p t p t p t p t= − − −
 
2.3. Sampling times. 
In medical applications, measurements of a disease are often made at several 
times, providing incomplete observations in some way. Because the process cannot be 
observed over an infinite time period, at times it will be ended before an absorbing state 
is reached.  In these situations the whole trajectory of the proces
providing in this way right-censored observation times. It can also happen that the 
process is not observe
p
c







 not available. In such cases the transition times of movement between states are not 
 visits are not known; these 
e process has not been observed at 
 
Figure 2.9: Evolution of an illness-death multi-state model. 
 
 Also frequent is the presence of left-truncation when dealing with multi-state 
models. For example, a common occurrence in the illness-death model is that for one 
patient to be selected, he must be in the “Healthy” state. Note that censoring and 
truncation are two different concepts. Censoring indicates that the information about the 
process is only partially observed, whereas truncation represents an exclusion of a part 
0                               3                              6                             Time
is
exactly observed and the states occupied in between
observations are said to be interval-censored.  
Figure 2.9, illustrates a possible evolution of a patient in the illness-death model. 
The process of Figure 2.9 is observed at four occasions during the time period of 9 
months, being the states occupied at times 0, 3, 6 and 9 months, the only information 
available. Following this figure we do not know the exact time of transition between the 
“Healthy” state and the “Diseased” state. More, if th
time 6, for some reason, the transition between the “Healthy” state and the “Diseased” 
state was not observed at all.  











of the information because it is not observed. In most cases, the truncation and 
censoring mechanisms are assumed independent from the process.  
 Ideal data collection should record every event or transition along with transition 




2.4. C . 
 
arious possible models for the transition rates between states can be 
accomm
ost common
characterized by one of the following assumptions:  
1. Time-Homogeneity: the intensities are constant over time, that is, transition intensities 
are independent of . Therefore we have 
ommon simplifying assumptions
V
odated in expression [2.1]. Transition intensities can depend on the states 
previously visited, the time since the last event, covariates, etc. Furthermore, they may 
be constant over time or not. The m  models (see Figure 2.10) are 
t ( ) ( )α α=hj hjt Z Z . 
on the previous history of the individual. Th
2. The Markov assumption: future evolution only depends on the current state and not 
at is, transition intensities do not depend on 
other information prior to time t.  
3. The semi-Markov assumption: future evolution not only depends on the time t since 
origin, but also on the time spent in the current state h, that is, tt hj− , where t  is the 
transition time from h to j. If we assume, in addition, that the transitions do not depend 
hj
directly on t, we will have intensity functions of the general form ( )α −hj hjt t Z . 
 








Figure 2.10: Three-state progressive models. 
(a) Homogeneous Markov model; (b) Non-homogeneous Markov model; 
(c) Semi-Markov model (  is the transition time from state 1 to state 2). 
 
Because of their simplicity, Markov models are the most used in the literature. In 
ct, if the state structure has a large number of states, non-Markovian models can 




ra ( ){ },  0X t t ≥  is a Markov process, if for any 
 with , and ,  s t 0 s t≤ < ( ) { }, , 1, 2,...,h j x u n∈  with h j≤ , we have 
( ) ( ) ( ) ( ) ( ) ( ), ,0X t j X s h X u x u u s X t j X s h⎡ ⎤ ⎡= = = ≤ < = = =⎣ ⎦ ⎣P P ⎤⎦ . 
e s depends only on the state occupied at time s. 
Traditionally, semi-Markov models are considered when the Markov assumption 
odels the transition intensities depend on 
Thus, the future of the process after tim
is violated. For these m −tF  only through the 
ate currently occupied, the elapsed time since the transition and the covariates. In 
hapter 4 we consider a different approach to non-Markov modelling, for which, in 
ddition to the current time, the transition intensities are allowed to depend also on the 
ntry time on the current state.  
By choosing the best state structure for the data, the assumption about the model 









(a)                 
23α
(b)               
( )t12α
( )t23α
(c)                
( )t12α
( )1223 tt −α







xample, in some models, the states visited before, along with their order, are implicit 
st by knowing the currently occupied state. We have seen above that, in some models, 
e state structure can be changed so that non-progressive models become progressive 
st by adding extra states.  











































































 While in the previous chapter we discussed generalities of the multi-state 
models
, we 
odels relying on the Mar
models only on the current state and not on the previous history of the individual may 
ls can particularly 
e helpful for evaluating the transition p
some of the commonly-used multi-state Markov models.  
 Let 
3.1. Introduction. 
, such as the state structure and the most common assumptions, in the present 
chapter and the next, we will go more deeply into statistical modelling. Here
consider those m kov assumption. The dependence of Markov 
be seen as advantage for such models. The simplicity of these mode
b robabilities. In this chapter, we will review 
( ){ },  iX t t∈T  be the stochastic process with finite state space 
{ }1,..., 0 s u t≤ < <S = N . Using the theorem of total probability, for , we may write, 
( ) ( ) ( ) ( ) ( ) ( ) ( ),
k S
X t j X s h X
∈
⎡ ⎤ ⎡= = =⎣ ⎦ ⎣ ⎦ ⎣ ⎦∑P
If we assume that the process is Markovian, then the state of the process depends only 
on the current state. Thus the above equality can be simplified by 
t j X u k X s h X u k X s h⎤ ⎡ ⎤= = = = =P P . 
( ) ( ) ( ) ( ) ( ) ( )
k S
X t j X s h X t j X u k X u k X s h
∈
⎡ ⎤ ⎡ ⎤ ⎡ ⎤= = = = = = =⎣ ⎦ ⎣ ⎦ ⎣ ⎦∑P P P . 
We therefore obtain the Chapman-Kolmogorov equation, 
)hj hk kj
k S
( ) ( ) (, , ,p s t p s u p u t
∈
=∑ ,  0 s u t≤ < < . 
We may now derive
)
  Kolmogorov’s equations. Because 
( ) ( ) ( ) ( ) ({ }, , , ,hj hj hk kj kj
k S
,p s t dt p s t p s u p u t dt p u t
∈
+ − = + −∑ , 
ividing both sides by  and taking the limit as , we obtain  dt 0dt →d
( ) ( ) ( ), ,hj hk kj
k S
,p s t p s u p u t
t t∈
∂ ∂=∂ ∂∑ . 
 







orov’s forward equation 
 
Then taking u t→  we obtain the so-called Kolmog
( ) ( ) ( ) ( ) (, , ,hj hk kj hj jj )p s t p s t t p s t tα α
k jt ≠
∂ = +∑ . ∂
Thus, in Markov models, the transition probability matrix can be calculated from 
the intensity matrix, Q , by solving the forward Kolmogorov differential equation, 
 ( ) ( ) ( )tQtsPtdP ,=          
dt
 For the illness-death model, we have the following s: 
 
 equation
( ) ( )[ ]tspts
dt 11
11 ,, α    [3.1] 
 
( ) ( )ttdp 1312 α+−= ,  
( ) ( ) ( ) ( ) ( )ttspttsptsdp12 ,,, αα −= ,     [3.2] 
and 
dt 23121211
 ( ) ( ) (ttspts
dt
)2322 ,, α−= .       [3.3] 
 The solutions of these equations are: 
dp22
( ) ( ) ( )( )tsAtsAetsp ,,11 1312, +−= , 
( ) ( )tsAetsp ,22 23, −= , 
and 
( ) ( ) ( ) ( )∫= t
s
dutupuusptsp ,,, 22121112 α ; 




where ( ) ( )∫= hjhj duutsA α,  is the cumulative or integrated
t
s









 Because homogeneous Markov models ignore both tim
 referred to as the “simplest case” multi-state model. In fact, earlier applications 
have been done with th
analyse d
homogeneous Markov models, all transitions are assumed to be constant as 
functio
ous Markov models. 
e and history, they are 
often
ese models. Such models have been used by various authors to 
ifferent diseases (breast cancer, liver cancer, leukaemia, diabetes, etc). 
In 
ns of time. Therefore, each transition probability ( ),hjp s t  depends only on the 
time difference , that is,t s−  ( ) ( )0,hj,hjp s t p t s= − . To simplify notation, we will use 
a matrix depending on only one argument in time ( ) ( )0,hj hjp t s p t s− = − . In other 
words, ( ) ( ) ( )hjp t X t u j X u h⎡ ⎤== + =⎣P
s 
⎦  for any 0u ≥ . We can rewrite 
Kolmogorov’s forward equation a
( ) ( ) ( )hj hk kj hj jj
k j




∂ = +∂ ∑ . 
Then, the transition probabilities can be simply expressed in terms of the 
transition intensities, through the Kolmogorov relation ( ) (expP t tQ )=  (Cox and 
Miller, 1965). For the illness-death model, the intensity matrix is given by 
( )12 13 12 13α α α α
23 230
0 0 0









Solutions for equations [3.1]-[3.3] are now the follow
( ) ( )tetp 131211 αα +−=









+−− tt eetp ,   
     
 







,  ( ) tetp 2322 α−=        








− −+− t ee    
and 
.         
plex and require using special 
software. 
to relate the transition intensities 
13121 ααα +−= +−
t
tetp ,  
( ) tetp 23123 α−−=
Equations for more than three states are more com
For homogeneous processes, expression [2.1] reduces to 
( ) ( )( )1α =∼ ; , ,...,i hjX t MSM Z h j N , and then we may use Cox proportional hazards 
models of type   
( ) ( )Tα α β= exp ,       [3.4] 
hj
hj hj hjZ Z
α  with covariates Z. 
Under model [3.4], inference is conducted by a general likelihood, which is 




d ( )iX ⋅  is observed at times 




general multi-state model, with a pair of states con
( ) ( )( )1,, , +riirii tXtX   . The general likelihood is then the product of all the terms over all 
the individuals and all the transitions (Kay, 1986),   
























where )( ) ( ( )riri ttr ,1,1, −++  is the contribution t h 
individual for the pair of states 
tXtXri pl iirii ,, ,= o the likelihood for the it
( ) ( )( )1, +rit  observed.  
 
, , irii XtX   
 
ogeneous Markov models. 
 
 In some applications, the hypothesis of homogeneity may be unrealistic since the 
illness ogenous model is
recommended. Several non-parametric approaches to non-homogeneous processes have 
ature (Frydma ; Joly et al., 2002). An alternative 
intervals and then ecewise constant intensities model (Pérez-Ocón et al., 
2001; Saint-Pierre et al., 2003), leading to transition intensity functions as step 




3.3.1. Piecewise homogeneous Markov model. 
 
Here we consider a piecewise process where the transition intensities are defined 




tends to evolve over time. In these occasions, a non-hom  then 
been proposed in the liter n, 1995
(parametric) procedure consists of partitioning the whole study period in two or more 
 fitting a pi




,      0




Z     t θ
t Z
Z     t θ
αα α θ −
⎧ ≤ ≤⎪= ⎨ < ≤⎪⎩
        , kl  ,...,3 ,2=     
 







whe 1,...,re 1−= k( )θθθ  is the vector of points cut-off ( )∞=<<<< − kk θθθθ 121 ... . 
Transition intensities ( )lhj Zα , kl  ,...,3 ,2=  are often expressed according to the Cox 
model [3.4].  
The likelihood function is built following parametric methodological procedures. 
Let us assume k-1 cut points: 0 1 20 , , ,..., kθ θ θ θ= = ∞  and let us define one piecewise 
intensities matrix: 
(( ) )( )1 0 11
  , 






≤ <⎧= ⎨ ≤ <⎩
t Z
Z t
       Z t kl  ,...,3 ,2=  
Assuming that the process ( )iX ⋅  is observed at times imiii ttt ,1,0, ... <<< , the 














( ) ( )( )riritXtXri ttpl riirii ,1,,, 1,, −= ++
th individual for the pair of states 
 is the 
contribution to the likelihood for the i
( ) ( )( )1,, , +riirii tXtX    observed.  
Let us define the following intervals: 1θ θ +⎡ ⎡= ⎣ ⎣,q q qB   and  ] ]1θ θ += ,s s sC    with 
. Then, each contribution  is constructed as follows: 
1.  and , then   
1,...,2,1, −= ksq ril ,
if qri Bt ∈, qri Ct ∈+1,
( ) ( ) ( )
( )
, , 1 ,,
i r i r i rX t X t t t+ −, , 1
q i




2. if qri Bt ∈,  and 11, ++ ∈ qri Ct , then  
 
(
( ) ( ) ( )
)
( ) ( ) ( )
( )1
,
q i q iQ Z Q Z
i r t t














   2≥
 
3. if qri Bt ∈,  and lri Ct ∈+1,    with − ql , then 
( ) ( )( ) ( ) ( )
( )
( ) ( ) ( )1,1 ,, , ,, , , 1 1,, , 1
2
u uX t X tq i rX t X t i i r i i ri i r i i r i r lX t X ti i r i i r
l
t t++ + −+
−
( ) ( )( )1 1, q i u i l i
Q Z Q Z
i r
u q







Assuming an illness-death model, the survival function, 
×⎜ ⎟
⎝ ⎠∏ . 
( )S t Z  is expressed as: 
1. If [ [0 1,t θ θ∈ ,  ( ) ( ) ( ) ( ) ( )1 111|S t Z p t= 12| |Q Z Q ZZ p t Z+ ; 
2. If [ [1 2,t θ θ∈ ,  
( ) ( ) ( ) ( ) ( ) ( ) ( ){ }
( ) ( ) ( ) ( )
1 2 2
1 2
11 1 11 1 12 1
12 1 22 1
| | | |
               | | ;
Q Z Q Z Q Z
Q Z Q Z
S t Z p Z p t Z p t Z
p Z p t Z
θ θ θ
θ θ




3.   If θ θ−∈ ⎡ ⎡⎣ ⎣,q qt   with , 3≥q
( ) ( ) ( ) ( ) ( ) ( ) ( ){ }
( ) ( ) ( ) ( ) ( )
1
12 1 22 1 22 1              | | |






Q Z Q Z
p Z p Z p t Z
p Z p Z
θ θ θ θ
θ θ θ θ
−
=
− −+ × − × − +
















 The assumption of time-homogeneity may be assessed using a piecewise model 
(Kay, 1986). Likelihood ratio tests can be used to compare the piecewise model with the 
time ho
has approximately a 
( )




11 1 12 1
2 1
| | | |




Q Z Q ZQ Z





u u i i
i u










( ) (22 1          |uQ Z u up θ θ −× −∏
 




mogeneous model. Under the null hypothesis of homogeneity, the test statistic 
2
k rχ −  distribution, wher
der . Alternatively, the local score test can be 
used. A complete description of this method can be found in Kalbfleisch and Lawless 
(1985). 
e r  is the number of parameters under 0  
and k  the number of parameters un
H
 1H







 Cox Markov models. 
 
For simplicity, assume the illness-death model of Figure 2.4. The transition 
intensities, 
3.3.2.
( )αhj t Z , are modelled using Cox-like models of the form 
( ) ( ) ( )T0α α β= exphji i hj hj it Z t Z ,      [3.5] 
assuming the process to be Markovian. 
the hazard of ‘death’ without disease,  For ( )13α t Z , survival times from 
diseased patients are taken as censored in disease time. Patients who are healthy also 
contribute with censored survival times. For the disease intensity, ( )12α t Z , the final 
 the beginning of the disease. Survival times of patients who did not 
become diseased are taken as censo  whether they have 
died without having been diseased. Finally, to model 
point is the time of
red, whether they are alive or
( )23
the occurrence of the disease, we only ente
α t Z , the death intensity after 
r the survival times truncated on disease 
time, censored or not, of the individuals that experienced the disease. Note that patients 
are at risk only after entering state 2. 
Let now m ( ) n ( ) m( )Tβ= expA t Z A t Z  be the estimate of the cumulative 0hj hj hj
intensity function with n ( )0hjA ⋅  the Breslow estimator for du .  
transition probabilities 
( ) ( )0 0
0
t
hj hjt uΑ α= ∫
The estimation of the 
) ( ) ( )( ),( ,hjp s t Z X t j X s h Z= = =P  s t≤  and jh ≤  for a given covariate vector Z , 
are expressed in the following way: 
m ( ) m ( )311 1
2=< ≤
⎛ ⎞
⎜ ⎟⎝ ⎠jjs u t
1= −⎜ ⎟∑∏,p s t Z d A u Z ,      
 








m ( ) m ( ) m ( ) m ( )( )11 11 12 131= − − −, ,p s t Z p s t Z d A t Z d A t Z ,     
m ( ) m ( ) m ( )m ( )12 11 12 22
≤
= − +∑, | , | , |
u t




m ( ) m ( )( )22 231
< ≤s u t
= −∏, |p s t Z d A u Z ,        
therefore,  
m ( ) m ( ) m ( ) m ( ) m ( )( )12 11 12 12 231= − + − −, | , | , |p s t Z p s t Z d A t Z p s t Z d A t Z , 
m ( ) m ( ) m ( )13 11 121= − −, | , | , |p s t Z p s t Z p s t Z , 
and   
m ( ) m ( )23 221= −, | , |p s t Z p s t Z .  
Note, however, that the probability of having died without ever being diseased 
can be estimated by  
n ( ) m ( ) m ( )13 11 13= −∑, | , |nd
< ≤s u t
p s t Z p s u Z d A u Z .  
( )S t Z The conditional survival probability which is defined as  
( ) ( ) ( )11 120, 0,S t Z p t Z p t Z= + , can now be estimated by  
 ( ) m ( ) m ( )0, 0,S t Z p t Z p t Z= + , 
hazards. For example, for the illness-death model, one approach that is often used is to 
the bas zards for transition 1 3→  and for the 2 3→  transition to be 
proportional. In such
11 12
with changes in its values at observed failure times.  
Note that in some cases we may assume some conditions about the baseline 
assume eline ha
 cases, the model is given by  
 






 ( ) ( ) ( )T13 130 13α α β= expt Z t Z   
and  
( ) ( ) ( )T23 130 23α α β= +expt Z t Z
These models can be fitted using most of the statistical packages as long as we 
use a counting process notation, representing each patient with several observations. 
More details on these models, such as the variance of the estimated transition 
probabilities, were discussed in the book of Andersen et al. (1993). 
 In this section we will present the simple case of a nonparametric Markov model 
without covariates. This approach can be thought of as the generalization of the Kaplan-
Meier estimate of the simple mortality model. For survival data, the transition 
probability from the ‘alive’ state in
Kaplan-Meier estimator (see [1.9] and [2.4]). In this section, we propose a 
generalization of this approach 
states. Such a generalization was considered by Aalen and Johansen (1978), and is 
denoted as the Aalen-Johansen estimator. Again, for simplicity, we start by assuming 
the illness-death model, and later extend such an
for the illness-death model, it is enough to consider the transition probabilities ,p s t , 





3.3.3. Non-parametric Markov models. 
 
to the ‘dead’ state may be estimated using the 
to general multi-state models with a finite number of 
 approach to general models. Note that 
( )11
( )12 ,p s t  and ( )22 ,p s t ; all the others can be obtained from these ones. Because the 
 







      
       
 
( ) ( ) ( )11 12 13, exp
t
s
p s t u u duα α⎧ ⎫⎪ ⎪= − +⎨ ⎬⎪ ⎪⎩ ⎭∫
( ) ( )22 23, exp
t
s
p s t u duα⎧ ⎫⎪ ⎪= −⎨ ⎬⎪ ⎪⎩ ⎭∫
( ) ( ) ( ) ( )12 11 12 22, , ,
t
s
p s t p s u u p u t duα= ∫       
Assume that we have a sample of n subjects with observe e and death 
times, 1 2, ,..., nt t t . If we now assume th  we have  events and n k− censored 
observations, then we may write ( ) ( )1 kt t
d diseas
at  k
2 ...t ( )< < <
ber of  diseas
subjec ely, just prior to the event time . Further, let 
subjects who become di
numbers of healthy and diseased subjects who die at that same time. Then the above 
transition probabilities may be estimated by 
 for the k event times arranged in 
increased order. Let now 1in  and 2in  denote the num  healthy and e 
( )it , while 13id  and 23id  denote, respectively, the 
ts, respectiv ( )it 12id  be the number of 
seased at time 
m ( )




, 1 i i
i
d dp s t
n












22 = −⎜ ⎟
nd 
⎝ ⎠∏ ,       [3.7] 
a
m ( ) m ( )( )
( )







dp s t p s t p t t
n−< ≤
= ∑ , .     [3.8] 
Because [3.6] and [3.7] are Kaplan-Meier estimators, we may use Greenwood’s 
rmula [1.10] to achieve a variance estimator for such transition probabilities, whereas, fo
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ate j at time , and let  be the num er of subjects in 
state h just prior to time . For each
np s t p t t d
n









For general cases, explicit expressions for the transition probabilities like those 
mentioned above cannot be given. For such cases, consider hjid  the number of 
transitions from state h into st ( )it hin b
 ( )it  { }1,...,i k∈  consider the intensity matrix  with iQ




α =  for 
hji





 for ( ),h h . We may then express the transition probability 
rms of the in trix. The Aalen-Johansen estimator takes the form 
l( ),P s t I Q
matrix P  in te tensity ma
( )
( )is t t
iπ< ≤
where I is the identity matrix. 
 An indispensable assumption here is that censoring is independent, so that 
censoring times do not carry information nsition between states. 
= + , 
 on the hazard of tra














e est n of 
an arise is whe
events through a multi-state model provides a better knowledge about how the covariate 
affects the hazard. In this section, we intend to illustrate how the covariate effect can be 
wrongly interpreted when using simple regression models such as the Cox time-
dependent regression model.  
For simplicity, we have chosen to generate a homogeneous Markov process. We 





In situations where th imatio the covariate effect is of interest, one 
question that c ther the inclusion of information on the intermediate 
 
time-dependent regression model. 
We consider the illness-death model and the population vector as ( )231312 ,, TTT  
where, hjT  is the potential sojourn time in state h prior to transition to state j. 
 al in state 1 is then exposed to two mutually exclusive events, for 
which only the first (small) of these events is observed. Therefore, patient histories can 
be decoupled in two groups, 321 →→  ( )1312 if TT ≤  or 31→  12T< e 
assume also that individual’s times are at of being right-censored by some 
censoring variable C, denoting the potential censoring time. Thus, individuals times can 
be censored in state 1 
( )13 if T . W
risk 
( )( )1312 ,min if TTC <  or in state 2 
)if ,<C C . 
e illness-d odel leads to the tim
which
is observed and 0 otherwise.  
( ) and min+ ≤T T T T
 Note that th eath m e-dependent Cox model, for 
 the time-dependent covariate is coded as 1, if a transition from state 2 into state 3 
( 12 23 12 13
 







uniform distribution with a minimum of 0 and a maximum of 10. To achieve a linear 
covaria
For each individual, we generate the observations for one covariate, Z, from a 
te effect on transition 31→  and 32 →  (and no effect on transition 1 2→ ), the 
sojourn times 12 13 23,   ,  and T T T  were independently generated from three exponential 
distributions, with rate parameters 231312  and , , ααα  respectively, where: 
( )12 120.05 exp Zα β= × × , 
( )13 130.04 exp Zα β= × ×  
and 
( )23 230.05 exp Zα β= × × , 
with 12 0β = , 13 0.08β =  and 23 0.09β = − . 
Censoring times were generated by a uniform distribution with minimum 0 and 
maximum 80 (yielding a percentage of about 27% of censored observations). Note that 
since ( )231312 ,, TTT  are exponentially distributed and mutually independent, we are 
generating a homogeneous Markov process. Under this setting, when using a mul e 
model, a significant covariate effect is expected only on transitions 1 3→  and 2 3→ . 
By choosing a covariate effect on transition 2 3→  opposite to the effect of the same 
covariate on transition 1 3→ , we intend to show that this may eliminate the covariate 
effect when using a Cox time-dependent regression model. 
For this configuration, 500K
ti-stat
=  data sets were generated with two different 
sample sizes of  200=n  and 500n = . In Table 3.1, we present the mean estimate 




∑ , and the mean 





= = ∑ . 
 








in any sense better than those obtained from the Cox time-dependent regression model. 
While estimators for the Cox model can not be interpretable at all, both multi-state 
m l 
v
n this table, we also present the percentage of observed significant effects 
( )POSE . 
As shown in Table 3.1, both multi-state models give rise to estimators which are 
odels yielded good estimates (compare the mean estimates in Table 3.1 with the rea
alues β ). Note that for any multi-state modehj l, and espec ally f m
Markov m ean estim nd 
 are very precise, whereas for transition  it is n r zero (s mething that 
would be expected hene  covaria  effect does no exist). T e s ion 
showed that increasing the sample size redu es the variance an  increases he or 
all models  models, leading to a more precise ate 
effect). Fo en anal zing the mogeneous Markov model 
we observe that the estima iate ef ct is accurate an  statistica y nt 
(i.e., present) on 472 replicates for transition  and on 412 for transition 3
Furthermore, for the sample size 
i or the ho ogeneous 
odel, the m ate for the covariate effect on transitions 1 3→  a
2 3→ 1 2→ ea o
 w er thev te t h imulat
c d  t  POSE f
 (but mainly for multi-state covari
r the sample size 500n = , wh y ho
ted covar fe d ll significa
1 3→ 2 → . 
1000n =  the covariate eff t is alwa  p or 
both transitions (results not shown). For the same
ec ys resent f
 500K =  replicates, the covariate 
effect is sta plicates (14.2%) when using a Cox time-
nerated process is time-homogeneous (thus, 
favourable to the homogeneous Markov model) the Cox Markov model also achieved 
good results. Moreover, such a model is the one presenting better results for the POSE 
in all transitions leaving state 1. 
ates obtained for the homogeneous Markov model, Cox 
Markov model and Cox time-dependent regression model for a single sample with size 
tistically significant in 71 re
dependent regression model. As shown in Table 3.1, the obtained mean hazard rate 
estimate is close to one.  Although the ge
Table 3.2 shows the estim
 








vanish when only a or the hazard rate is nalyz n c
models r if rate te  on  and 
.   
 
Table 3.1. Mean estima  of the covaria t  ho arkov 
model, Cox Markov model and for the C e odel, 
accordin licat
 Model 
500 . Through this example, it is shown that the effect of important covariates m
model f  a ed. I ontrast, both multi-state 







g to sample size, over 500 rep es.  




0 Cox Markov model 
 





32 →  
21→  
31→  
32 →  
 












































Homogeneous Markov model 









32 →  
















































  SE = Standard Error; POSE = Percentage of observed significant effects. 
 







Table 3.2. Covariate effect in homogeneous Markov model, Cox Markov 
model and Cox time-dependent model for a single sample with size . 
Model HR 95%CI  for HR  
500=n
βˆ  
Homogeneous Markov model 
Cox Markov model 
 
































32 →  
21→  
31→  
32 →  -0.098 0.906 0.847-0.
          HR = Hazard Ratio; CI=Confidence Interval. 
 
For illustration, we have applied reviewed methods of previous sections to data 
 In the context of multi-state modelling, we may consider the covariate 
‘transplan
3.1. In this model, for a given patient, ‘own heart’ corresponds to having his/her own 
heart, whereas ‘new heart’ represents having had a transplant. Typically, a patient enters 
the study in the ‘own heart’ state; after the transplant, he moves to the transplanted 
population, that is, to the ‘new heart’ state. With this multi-state formulation of the 
Stanford data, main goals of this study include: (a) to assess whether or not there exists 
a beneficial effect of heart transplant on survival, which will be carried out by 
 
 
3.5. Application to the Stanford Heart Transplantation study. 
 
from the Stanford’s Heart Transplant study described in detail in Chapter 1.  
t’ as an associated state of risk, and then use the illness-death model of Figure 
comparing the transition intensities ( )t  and ( )t , and also (b) to explore the 13α 23α
potential fixed covariate effects in each of the transitions. 
 










  1. ‘ Own heart’      2.  ‘New heart’ 
 3.  ‘Dead’
( )12 tα 
( ) 13 t α ( )23 tα 
 
e-dependent Cox regression models, all of them 
splant, among other covariates. Numerical results obtained 
fr rent models are presented in Table 3.3. Model comparisons 
mation Criterion (AIC), which is defined as  
2 log-likelihood 2
om fitting eleven diffe
have been done using the Akaike’s Infor
including the effect of tran
being p  the number of estim
preferable models.  
For all the fitted m
ated parameters. Smaller values for the AIC suggest 
odels, the influence of age at acceptance on haza ositive, 
while effects of year and surgery are both negative. When analyzing the f odels 
showing a smaller AIC (i.e. models V, and IX-XI), we see that the effect of the 
transplant leads to a small reduction in risk, but without reaching statistical significance. 
For example, for model IX, age (Hazard Ratio, HR:1.027; 95% confidence interval, 
95%CI: 1.001-1.055) and year of acceptance 
 
Figure 3.1. Illness-death model for Transplant Heart data. 
 
 
Time-dependent Cox regression model 
 We have constructed various tim
( )HR:0.864;95%CI:0.753-0.992  are both 
important factors, while surgery has no significant effect ( )p-value 0.05> . Figure 3.2(a) 
displays the smoothed hazard ratio for the covariate year, obtained by using penalized 
AIC p= − × + , 
rd is p
itted m








rcent pointwise confidence bands. This plot suggests that, 
nths dim in f the hazard ratio  
t afterwards. However, when we exclude the patients accepted in the first year of 
e, the negative effect of year on hazard (
during the first mo  a inish g o  occurs, remaining nearly
constan
the programm l 0.0955β = − ) is then negligib
cant and, by itself,
le     
ffect of age is signifi  
the transplant effect. Figure 3.2 (b) shows the smoothed hazard 
lines, along with the corresponding 95 percent 
According to thi apparent that the effect of age 
being quadratic, as it was previously suggested by Crowley 
(p-value=0.27). As shown in Table 3.3, the e
changes the direction of 
ratio for this covariate using penalized sp
pointwise confidence bands. s figure, it is 
splines together with the 95 pe
is non-linear and closer to 
 
and Hu (1977).  
  
. Time-dependent Cox regression models. Effect estimates and corresponding standard errors. Stanford Heart Transplantation data. 








  SE  
0.127 (0.301) 
0.67 





















  SE  
0.123 (0.303) 
0.68 
 -0.191 (0.070) 
0.01 








  SE  
0.158 (0.297) 
0.59 
  -0.749 (0.360) 
0.04 




























 -0.773 (0.360) 
0.03 























  SE  
-0.282 (0.514) 
0.58 
 -0.265 (0.105) 
0.01 






































 l ( )
XI P value
β
−  0.24 0.03 0.02 0.07 0.16 
  SE -0.621 (0.531) 0.030 (0.014) -0.253 (0.105) -0.664 (0.368)  0.197 (0.140) 589.10 
SE=Standard error; AIC=Akaike Information Criterion.
  
 
u .2 ) ard ratio estimation  es for year o ce c it % ntw co azard 
o m n  penalized splines fo ta (with 95% p n an alo w atic fit ( a  line). 
n H  splantation data. 
 
f ac ptan e (w h 95  poi ise nfidence bands). (b) H
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Validity of Markov’s assumption 
 The models studied in this chapter rely on the Markov assumption. Before the 
analyses of the Stanford data, we will check the validity of this ass on, verifying 
that the transition rate, ( )t23α , is not affected by the time since transplant. We, 
therefore, consider 1 "age"Z =  and 2 "time since transplant"Z =  as the covariates, and 
then we fit the following two hazards: ( )t Z Zα β β β+ +  for patients with 0 1 1 2 3exp( )2
transplant, and ( )0 1 1  for patients without. The results obtained (see Table 
3.4) show that effect the of time since the transplant is not significant (p-value=0.93), 
indicating that the transplant do
clude that Markov’s model is 
d Hear tation data. 
ramete Es te SE 
exp( )t Zα β
es not lead to an increase in mortality in the period 
immediately after surgery. This allows us to con
satisfactory for the Stanford data (with time since entry in study as the time scale). 
Further details about this issue are discussed in Chapter 6. 
 




r tima P-value 
   (age) .0 5 0.031 0 15 <0.01β
   (indicator of transplant .3  ) -0.015 0 36 0.962β







 The Cox Markov model [3.5] allows us to observe how the covariate effects 
behave when transition intensities are modelled separately. Through this multi-state 
methodology we pretend to show that these methods can provide new biological 
insights while confirming some of the results obtained using the time-dependent Cox 
SE error. 
Co  Marko  Mod  
 
  







model. Results obtained f Table 3.5. It can be seen rom fitting this model are given in 
that year of acceptance, which revealed a strong effect on survival in the Cox model, 
under the Cox Markov model only shows a significant effect on ( )13 tα  (HR:0.753; 
95%CI: 0.606-0.936), although this covariate ceases to be a significant predictor when 
the patients admitted in the first year were excluded from the study. Age showed a 
linear effect on each transition, and is the best predictor for the mortality transition 
( )t23α  of transplanted patients ( )HR:1.050;95%CI:1.008 1.100− , as well as for 
transition ( ) , corresponding to receive a new heart 12 tα
( )HR:1.032;95%CI:1.004-1.060
mortality intensity in patients without transplant 
. Interestingly, age has no significant effect on the 
( )HR:1.020;95%CI:0.984 1.057− , 
suggesting that the effect of age enters through the transplant incidence. As shown in 
Table 3.5, there is no effect of a previous surgery in any transition. 
 
 Table 3.5. Final Cox Markov model for all transitions. Stanford Heart Transplantation 
data. 
Transitions Covariate lβ  SE HR 95% CI for HR p-value
 














1.004 – 1.060 
0.873 – 1.150 












0.984 – 1.057 
0.229 – 2.768 
0.27 
0.72 
Year -0.023 0.097 0.977 
08 – 1.100 
0.808 – 1.180 
0.02 
0.81 
1 3→  Year -0.283 0.111 0.753 0.606 – 0.936 0.01 
 Age  0.050 0.021 1.050 1.0
2 3→  
Surgery (yes=1,no=0) -0.817 0.455 0.442 0.181 – 1.080 0.07 
 S
 













ts obtained from the fitted model 
(see Table 3.6) are in good agreement with those obtained when using the Cox Markov 
mode  in any 
of the previously studied m  
transplanted patients . Results ind te that age is the 
only covariate showing a significant linear effect in all transitions. This occurs even for 
the mo in patients without a transplant, something that did not occur 
when using the Cox Markov modelling approach. We have also observed that the 
acceptance time in the study (year) is a significant predictor, though only for mortality 
intensity in patients without transplant 
Homogeneous Markov Model 
 In comparison with the preceding studied models, the homogeneous Markov 
s a detailed description of the survival process, making use of all the 
available information to estimate the transition probabilities and intensity rates. By 
applying this modelling approach, we refit the Stanford data including the potential 
effects of age, year and surgery in all transitions. Resul
l. Some exceptions are the surgery effect, which was not a significant factor
odels but now reveals a significant effect on survival for
( )HR:0.306;95%CI:0.128 0.730− ica
rtality intensity 
( )HR:0.739;95%CI:0.595 0.919− .  
 We have also observed that the fitted homogeneous Markov model leads to very 
similar effects of age in the three transitions (see Table 3.6). To assume that these 
effects are equal, we use the Wald test statistic, yielding a value of 1.163, revealing non 
significant differences between them (Marshall and Jones, 1995).  
eous 
Ma ko
surgery in the mortality transition of transplanted patients. Notice that this new model 
e over-fitting  the process, lik
In view of the results obtained, we then consider a simplified homogen
r v model, including the (same) potential effect of age in all transitions, the effect 
of year only in the mortality transition of patients without transplant, and the effect of 
prevents th  of data with redundant parameters. In elihood 
  







ratio tests (LRT) w
from zero (Kay,1986) . This statistic has an approximately 
ere used to test if the regression parameters are statistically different 
1
2χ  distribution under 
H 0 hj 0: β = . Estimated parameters for the simplified model (results not shown) did not 
differ substantially from those obtained by the initial model (shown in Table 3.6). 
Therefore, hypothesis testing can be carried out using either LRT or Wald tests although 
opinions regarding which is optimal lack consistency.  
 
Table 3.6. Multi-state homogeneous Markov model. Estimated 
transition rates and hazard rates. Stanford Heart Transplantation data. 
TR (SE)  
m
12α  ( )0017.00137.0    
m
13α  ( )0011.00054.0    
m
23α  ( )0003.00018.0    
HR   (95%CI)  
       Age  
21→  ( )1.068  1.039 1.098−  
31→  ( )1.056  1.020 1.093−  
32 →  ( )125.1030.1076.1 −   
      Year  
21→  ( )0.975  0.852 1.116−  
31→  ( )0.739  0.595 0.919−  
32 →  ( )325.1928.0109.1 −   
       Surgery  
21→  ( )539.2737.0368.1 −   
31→  ( )0.959  0.277 3.315−  
32 →  ( )730.0128.0306.0 −   
TR=T ror; HR=Hazard ratio; CI=Confidence Interval. 
 
given by 
ransition rate; SE=Standard er
 
Further, we have used Wald’s test to verify whether or not a relation between 
transplant and survival exists (Kay, 1986). Formally, the hypothesis of no relation is 
23130




−= , being : αα =H , and then Wald’s test reduces to 
  







m m( )rv11 13 23va α α− . With our data, under the null hypothesis the W statistic (which 
survival probabilities, 13
=
follows a ) yields a value of 18.5, suggesting that the transplant is significantly 
associat inishing in mortality risk. In Figure 3.3 we also compare fitted 
2
1χ
ed to a dim
mp  and 23mp , confirming the beneficial effect of the transplant. 































Figure 3.3. Fitted survival probability for the mortality intensity from 
Heart Transplantation data. 
Note however that likelihood ratio tests (fitting unrestricted and restricted 
models) can also be used for constructing a test of H  against the general alternative 
 
a multi-state homogeneous continuous-time Markov model. Stanford 
 
(under the null hypothesis the test statistic has an approximately  distribution) 












 The goodness-of-fit of a multi-state model can be assessed by comparing the 
observed and predicted number of patients undergoing each transition. Table 3.7 (page 
72) reports the observed percentages of patients in states “own heart”, “new heart” and 
“dead”, together with the corresponding expected percentages obtained from the fitted 
homogeneous Markov model. For comparison purposes, we also included the expected 
percentages obtained from all fitted multi-state models. In this table, we can observe 
that, for lower survival times, the mortality is underestimated from the fitted 
homogeneous Markov model. In many cases, these discrepancies can be explained by 
the failure of the Markov assumption. Another possibility is that the transition rates vary 
 heart’ to state ‘new heart’ 
(approximately 73% from the total) occur up to 51 days of survival. Figure 3.4 
compares the resulting transition probabilities 
with time, so that the model is non-homogeneous. This is the case for the Stanford data; 
it is seen that most of the transitions from state ‘own
( )12 0,p t z  from the fitted Cox Markov 
model and homogeneous Markov model, respectively. This figure seems to point out 
that the Cox Markov model explains in a better way how transition rates vary with time, 
indicating a rapid increase of the transition probability  up  to  51  days, then decreasing 
quickly afterwards. Taken as a whole, these results suggest that a homogeneous model 
may be inappropriate.  To assess the assumption of time homogeneity, Kay (1986) 
suggests the use of a piecewise model. Again, likelihood ratio tests can be used to 
compare the piecewise model with the homogeneous model. For the Stanford Heart 
Transplantation data the test statistic (which follows a 24χ ) suggests the use of a non-
res from time-homogeneity 
is via a local score test (K
 
homogeneous model. Another method for verifying departu
albfleisch and Lawless, 1985). 
 
  









ated transition probabilities from state 1 (‘own heart’) to state 2 (‘new 





ed line). Stanford Heart Transplantation data. 
 
Non-homogeneous model 
In this section, we construct a piecewise constant intensities model with one cut-
off point, specified from the Stanford data covariates that showed a significant effect 
when fitting the homogeneous model. After examining the likelihood for several cut-off 
points θ , a value of 90θ =  days was selected, and two intervals 
( days 90  time ≤ , time >90 days ) were then considered. Focusing mainly on  the short-
term survival period of 90 days, results in Table 3.7 indicate that, for the non-
homogeneous model, the agreement between predicted and observed percentages of 
patient ach transition is globally satisfactory, being clearly better than that which 
was obtained previously by using an homogeneous model.  
Estimated mortality rates and covariate effects produced from fitting the non-




























resulting estimates for the mortality intensity were lower in transp nts, 
though only in the second interval ( time  >90 days ) a significant difference was found. 
When examining the fixed covariate effects, we see that, for   time ≤ t 
acceptance is a significant predictor in all transitions 
lanted patie
days 90 , age a
( )HR:1.032;95%CI , 
while the effect of year is only significant on the mortality intensity in pa ut 
transplant ( )HR:0.716;95%CI:0.571 0.899−  and the effect of surgery only on the 
mortality intensity in transplanted patients 
:1.011 1.053−
tients witho
( )0.968 . For the 





second interval ( time >90 days ), however, the only significant covariate was age at 
acceptance ( )HR:1.061;95%CI:1.008 1.116− .  
Finally, turn e-dependent Cox m
four mu ) shows the re ival 
functions, S t , obtained from f odels to Stanford data. The range of 
time has been restricted to 90 days to em ifferences between the four 
functions. In view of results of Table 3.7,  the upperm
model. All the other proposed models 
ulting survival f  for 





ing to the comparison of the tim
lti-state models described here, Figure 3.5(a
 ( ) itting all these m
phasize the d
it is not surprising that
curve corresponds to the homogeneous Markov 






























































































Figure 3.5. (a) Comparison of probability survival curves for time up to 90 days. Homogeneous Markov model (····), Non-homogeneous model 
(– · –), Time dependent Cox model (– – –), Cox Markov model (—). (b) Survival probabilities curves for the Homogeneous Markov model (····), 







Ta . ison of  percentages of patients in each of the three states for Cox Markov Model (CMM), Homogeneous  
NHM). Stanford Heart Transplantation data. 
ur   
s
a “Own heart” 
   NH
State 2  
Observed  CMM      M      NHM 
te 3  “Dead”
Observed M     HMM  
ble 3 7. Compar
S vival Time
(day ) 
 observed and predicted
Markov Model (HMM) and Non-Homogeneous Model (
St te 1  
Observed    CMM       HMM M 
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rates on transition intensities. Stanford Heart Transplantation data. 
 
Table 3.8. Non-homogeneous model. Estimated transition rates and hazard 
 days  90time ≤  days  90time >  
Number of parameters 6 4 
TR (SE)   
m
12α  ( )0024.0  0194.0  ( )0013.0  0028.0  
m
13α  ( )0.0068 0.0015  ( )0011.0  0022.0  
m
23α  ( )0012.0  0052.0  ( )0.0006 0.0002  
HR   (95%CI)   
Age ( )1.032  1.011 1.053− ( )1.061  1.008 1.116−  
Year   
            1→3            ( )0.716  0.571 0.899−
 
 
Surgery   
              2→3 ( )0.131  0.018 0.968−
 
 
TR=Trans  Interval. 
 
 
3.6. Application to th  Psoriatic Arthritis da . 
 
The purpose of  tion uss  ap ti  a multi-state Markov 
odel to a database on Psoriatic Arthritis (described in detail in Chapter 1). Here, the 
applica
 the purpose of investigating the evolution of the disease, several stages 
ere considered from birth up to current state: Birth, Psoriatic, Arthritis, PsA and states 
r the actual stage of the disease, Remission and Active. It is assumed that transitions 
om one state to the next occur irreversibly. The states and the allowed transitions 




 this sec  is to disc  the plica on of
m
tion of a Markov process allows a simplification in the modelling since the 
transition intensities are assumed to be independent of the history of the process 













n in Figure 3.6. Table 3.9 summarizes the observed transitions 




between states are show
between th
is (PsA), then age is the appropriate choice for time scale.  
 
Figure 3.6. multi-state model for Psoriatic Arthritis data. 
 
 
Table 3.9. Observed transitions in the Psoriatic Arthritis data. 
 













  2 3 4 5 6 
1 263 35 32 0 0 
2 0 0 263 0 0 
3 0 0 35 0 0 Fr
om
 
4 0 0 2 176 154 
  
 
In this case several issues must be considered when the interest is to analyse the 
transition intensities. For example, because this dataset was obtained retrospectively, we 
















ally to the number of covariates. To overcome some of 
poorly is due to the fact that the survival 
rocess is not time-homogeneous. 
While the time-dependent Cox regression model suggested a negligible effect of 
e transplant, the multi-state homogeneous Markov model indicated that the transplant 




Multi-state models have some advantages over the time-dependent Cox 
regression model. Among others, these models (a) allow estimates for the number of 
patients in various states; (b) can reveal the effect of each covariate on different 
transitions; and (c) express the time-dependent covariates in a simpler way. Although 
multi-state models may be preferable to the Cox regression model, there are some 
limitations to the use of such models: (a) multi-state methodology requires some 
assumptions concerning a Markov or semi-Markov structure of the data; (b) most of the 
existent software assume the process is Markov and time-homogeneous, which can be 
very restrictive; (c) some of the multi-state models may require large sample sizes in 
order that accurate estimates may be achieved; (d) when using covariates, the number of 
parameters increases proportion
these difficulties, model assessment techniques can be used.  
When analyzing Stanford Heart data using the multi-state methodology, the 
Markov assumption was satisfactory. Goodness-of-fit was tested for all multi-state 
models, showing that the Cox Markov model and the piecewise model are more suitable 
than the homogeneous model. When applying a homogeneous Markov model, we 
verified that this model underestimates the ‘short-term’ mortality. The reason why this 













iecewise model only confirmed such an association when the ‘long-term’ survival is 
nalyzed. 
 Through a simulation study we have shown that the covariate effect on hazard 
can be deeply influenced by the effect of the same covariate through only one transition. 
In fact, when analyzing Stanford data we showed that the acceptance time covariate 
(year), considered the most important predictor in the Cox regression model, only 
shows a statistically significant effect in the mortality transition for patients without 
transplant. Some of the multi-state models used here have shown a significant negative 
influence of previous surgery on hazard in mortality transition for transplanted patients; 
that is, having a previous surgery enlarges the survival of transplanted patients. Age at 
acceptance, on the other hand, was revealed to be a significant predictor of survival in 
any of the studied models, and its positive effect on the hazard indicates that younger 
patients have a better survival. 
 In conclusion, the multi-state modelling offers a flexible tool for the study of 
covariate effects on the various transition rates. These models may bring out important 
biological insights which may be ignored when using Cox regression models alone. In 
practice, multi-state models can be used to thoroughly examine and confirm conclusions 
obtained by applying simpler survival models. Therefore, we should not see the multi-
state models as merely an alternative to the time-dependent Cox model but rather as 



















































these models may carry severe limitations 
 to use a semi-Markov assumption in which future of 
e process does not depend on the current time but rather on the duration in the current 
ate. Semi-Markov models (Andersen et al., 2000) are also called “clock reset” models, 
ecause each time the patient enters a new state time is reset to 0. The aim of the present 
odels and propose a new non-Markov 











Traditionally, statistical methods for analyzing multi-state models depend on the 
Markov assumption. Under the Markov assumption, the transition intensities depend on 
the current time and the state currently occupied; they do not depend on the patient 
history (length of stay in the current state; patient characteristics measured before, etc.). 
By ignoring the disease history behaviour, 
which can make the model inappropriate. It is a fact that the future health of recently 
diseased individuals may be different from those who have been diseased for a long 




chapter is to review Cox semi-Markov m
approach, f
 time, but also on the time of transition to the current state. For examp n 
ring the illness-death model (see Figure 2.4), we obtain a non-Markovian model 
by allowing the mortality inten after the occurrence of the disease 
( )transition  2 3→  to depend on the current time as well as th ti ransition to the 
diseased state.  
 
  










 Transition intensities can depend on the current state, states previously visited, 
the entry time in each state, the time since the entry into the current state, covariates, 
etc. As mentioned before, these models can rapidly become very complicated nd 
therefore simpler models are necessary.  If the process is not Markov, then              
semi-Markov models can be a wise choice.  




.2.1 Cox semi-Markov models. 




depends only on the state currently occupied, the elapsed time since the entry into the 




( )1 j t Zα , 
he difference between Markov and semi-Markov 
models are expressed on transition, . According to semi-Markov models, future 
2,3j = , are modelled as in [3.5]. T
2 3→
evolution not only depends on the current state, but also on 12t  ( )12t t≤ , the time that 
the individual remains in that same state. Therefore, these transitions intensities will be 
expressed as   
( ) ( ) ( )T23 12 230 12 23α α− = − expi it t Z t t Zβ i       
 
 









The transition probabilities depend on the history of the process through the time 
12t , ( )12, ,hjp s t Z t , and can be estimated by, 
m ( ) m ( )( )22 12 23 121
< ≤s u t
= − −∏, | ,p s t Z t d A u t Z , 
) m ( ) m ( )( )12 23 120 1+ − − −, |m ( ) m ( ) (m12 11 120 0= −, | , |p t Z p t Z d A t Z p t Z d A t t Z , 
and 
m ( ) m ( )= −,23 22 121| , | ,p s t Z p s t Z t .  
 The rest of the transition probabilities are estimated as in the Cox Markov model 
of section 3.3.2.  
The survival probability ( )S t Z  

can now be estimated by  
( ) m ( ) m ( )11 120, 0,S t Z p t Z p t Z= +   
with changes on its values at observed failure times.  
.3. Non-Markov models. 
 





There are few references to non-Markov multi-state models in the literature, 
some exceptions are the works of Strauss and Shavelle (1998), Aalen, Borgan and 
Fekjaer, (2001), Datta and Satten (2001), and Glidden (2002). Strauss and Shavelle 
(1998) developed an extension of the Kapl
transition probabilities, avoiding the Markov assumption. The proposed estimator is 
constructed by partitioning the survival probability in proportion to the number of live 
and uncensored patients in each state.  Aalen et al. (2001) and Datta and Satten (2001) 










process under independent censoring. Later, Glidden (2002) developed robust 
confidence bands for those event curves. 
ving th
to compare estimators d
stimate ti ). For this purpose, w
initially consider the illness-death model. Later, we consider the extension of this 




4.3.1 The illness-death model. 
 
Assume that we have an illness-death model. Let 
studied the performance of the Aalen-Johansen of stage pancy 
probabilities when the process is no ovian. These authors established the 
consistency of Aalen-Johansen estim  the prevalence functions in a non-Markov 
Our research on non-Markov models has two main goals. The first goal is to 
develop an approach based on less restrictive assumptions than those based on the 
Markov property by completely remo e Markov assumption. The second goal is 
eveloped here for the transition probabilities with Aalen-
Johansen e s (derived under the Markov assump on e 
( ) ( ){ }0 0 1, ,X t t X≥ =  denote 
 non-homogeneous stochastic process. We assume that a finite number of independent 
istories from the process are observed. We then represent the stochastic behaviour of 
e process by a random vector  where  is the potential sojourn time in 
h prior to transition to state j. 
An individual in the healthy state is exposed to two mutually exclusive events, 
e” and “death”, which do not occur simultaneously, and so only the first (small) 
e therefore divide patient’s history (“course”) into two 
a
h




of these events is observed. W
  









groups according to whether the disease occurred ( )1 2 3→ →  or not ( )1 3→ . The 
history belongs to the second group if 13 12T T<  and then a transition from state 1 into 
12 3T T  a transition from state 1 to state 2 occurs at 
time 12T , and later at time 12 23T T  a transition from state 2 into state 3 takes place. 
 Of course, several issues influence the observation of the variables hjT . Right-
censoring may appear due to time limitation in the following-up, l llow-up cases, 
13 12T T
state 3 is observed. Otherwise ≤
ost to fo
etc. On the other hand, whenever 
( )1
+
< , one gets a right-censored value of 12T  
( )13with censoring time T , and no information on  is available. In the s e
ts a righ d value of
23T am  way, 
whenever 12 13T T≤ , one ge t-censore  13T  ( )12with censoring time T . 
ter, we assume that comple
not be observed due to right-censoring. Therefore, individual’s times are at risk of being 
right-censored by some censoring variable  (denoting the potential censoring time). 
In this way, individual’s times can be censored before t
Throughout this chap te information for each individual may 
C
he illness 
( )( )12 13i.e., <min ,C T T  or after the illness ( )( )13in ,T C12 23 12i.e.,  and < + ≤mC T T T . 

















1.1. N nparametric estimation of transition probabilities. 
 
In this section, our main target is the estimation of the transition probability, 
4.3. o
( ) ( ) ( )( ),hjp s t X t j X s h= = = s tP , < , which gives the probability of being in state j 
at time t
enough to consider the estimation of the transition probabilities 
, conditionally on being in state h at time s. In multi-state modelling these are 
one of the most important targets to be estimated. For the illness-death model, it is 
( ) ( )11 ,p s t , 12 ,p s t  and 
( )22 ,p s t . All the others can be obtained from these since 
( ) ( ) ( )13 11 12, 1 , ,p s t p s t p s t= − −  and ( ) ( )23 22, 1 ,p s t p s t= − .  
 Therefore we have, 
( ) ( )11 12 13 12 13, , ,p s t T t T t T s T s= > > > >P ,     [4.1] 
( ) ( ), , , ,12 12 12 13 12 23 12 13p s t T T T t T s T s= + > > >P ,   .2] T t T≤ ≤ [4
( ) ( )22 12 12 13 12 23 12 12 13 12 23, , , , ,p s t T t T T T T t T s T T T T s= ≤ ≤ + > ≤ ≤ + >P . [4.3] 
hese quantities [4.1]-[4.3] are determined by the joint distribution ,T . T  of 13 23,T T( )12
Specifically, knowledge of the distribution of ( )13min 12 ,Z T T  is enough for the 
,
=
recovery of ( )11p s t : 




while expectations of type 
>= P , 
( ) ( ) ( )12 12 23 12 13,S T T T T Tφ φ= + ≤⎡ ⎤⎣ ⎦E I
( )12 ,
 arise when handling 
p s t  ( ) ( ) ( )( ),, , ,s tu u s u t tφ φ= = < ≤ >v vv I , 




φ= >P , 
  









and ( )22 ,p s t  ( )  ( ) ( )( ),, , ,s tu u u s tφ φ= = ≤ >Iv v v , 









The relevance of s from the fact that they 
do not rely on the Ma i-state models. Under the 
Markov assumption, the conditional probability of moving from one state to another 
only depends on the state currently occupied. These probabilities are not influenced by 
the states prev ited and he 
illness- idua
t ry time, , a fact that may be unrealistic in 
me a  assumption
the proposed estimation methods come
rkov assumption, typically used in mult
iously vis  the times of transition among them. In the case of t
death model, this assumption implies that the survival prognosis of an indiv l 
being in state 2 does no depend on the ent  12T
so pplications. From a mathematical perspective, the Markov  restricts 
the distribution of ( )12 13 23, ,T T T  to those distributions satisfying, for any s t< , the 
equation 
 
12 23 12 23 12 12 13⎡ ⎤
12 23 12 23 12 0 12 13 0                 0
+ > + >
⎡ ⎤= + > + > = ≤ ∀ < ≤⎣ ⎦, ,T T t T T s T s T T s sP
that is, the conditional independence between
≤ ≤ =⎣ ⎦, ,T T t T T s T s T TP     [4.4] 
 12 23T T+  and  given that s , 
T T≤
ition probab
the current time and on the time of entry into state 2, . 
Suppose a sample of n individuals under study followed from an entry time to 
death or censoring. We denote the sample information as  
12T 12 23T T+ >
12 13 , 12 . 
Proposed non-Markov estimators allow the trans ilities to depend on 
T s≤
12T
( )( )1δ δ δ ρ δ η−, , . , ,i i i i i i i iU V , 1 i n≤ ≤  







h are assumed t allwhic o be independent and identic y distributed copies of 
( )( )1, , . , ,U Vδ δ δρ η− , where  δ
( )12 13min , ,U T T= C  is the observed sojourn time in state 1; 
C  is an indicator of whether a transition  occurs; 
n ,
( )( )12 13δ = ≤min ,T TI  1 2→
( )23 12miV T C T−  is the observed soj
≤ −C T
= ourn time in state 2; 
( )23 2ρ = TI  , so that δρ  is an indicator o hether a tran ition 2 31 f w s  occurs; 
η = ≤I
→
( ) ( )1 δ η−13T C , so that  is an indicator of whether a transition 1 3  occurs. 
Note that, u
→
0δ = , no information on ( ),V ρ  is available; while, if 1δ = , nder 
then the observation of η  is not possible.  
ble data for some individual will be, ( )13 0 0 0 1, , , ,T  if in the  Therefore, the availa
( )process a direct transition from state 1 into state 3 occurs; 12 231 1 0, , , ,T T  if a transition 
 state 1 into state 2 occurs and 12 ,T−
if the individuals transfers from state 1 to state 2 at time , and afterwards have a 
ensored sojourn time in state 2; and finally 
from afterwards a transition to state 3; 12 1 0 0, , ,T C  ( )
12T
( )0 0 0 0, , , ,C  if the individual does not 
iding a censored sojourn time in state 1.  
a on of the transition probability [4 , we need to make inference 
c
leave state 1, prov
For the estim ti .1]
on Z , whose distribution function we denote by ( ) ( )= ≤H t Z tP . In such cases, since 
Z C=  and we observe U ( )min , ( ) ( )1 Z Cγ δ δ η= + − = ≤I
tor  (Kaplan and Meier, 1958)  based  on the pairs  
, we consider the Kaplan-











et  be the ordered U-values, and let iL ] ( ) ( ) ( )1 2 ... nU U U≤ ≤ ≤ [  bγ e the concomitant of the 
r statis ( )ith orde tic, ( )iU . The Kaplan-Meier of H t  is defined as 
,       [4.5]   l ( ) ( )( )
1=
= ≤∑n Hin i
i
H t W U tI






⎛ ⎞= −⎜ ⎟∏iiH
j1 1
γ
− + − +⎝ ⎠
j
inW n i n j
he Kap
Note that  for any censored observation .   
Since C and Z are assumed to be independent, then 




lH consistently estimates the 
 Thus, the transition probability [4.1] can be estimated by, 
distribution of Z.  




H tp s t
H s
.        [4.6] 
 The above estimator [4.6] is equivalent to the Aalen-Johansen estimator [3.6]. 
Now, in order to introduce an estimator for the expectations of type ( )S φ , we 
need the following two lemmas. 
 
Lemma 1.  Let  ( )( ) ( )( )12 13 12 23 12 13 13T T T T T T T T= ≤ + + >I I  be  the  survival  time of 
the process. Then: ( )i  ( ) ( )1T C δ η ( )ii  ( )min ,U V T Cδ+ =δρ≤ = − +I ; and . 
roof.  P
Note first that 
( ) ( ) ( ) ( ) ( )12 13 13 12 13 12 231 T T T C T T T T Cδ η δρ− + = > ≤ + ≤ + ≤I I I I . 
 
Now write 
( ) ( ) ( ) ( ) ( )12 13 12 13T C T T T C T T T C≤ = > ≤ + ≤ ≤I I I I I . 
Use the definition of T  to show . For ( )i ( )ii  write 
  









 ( )( ) ( )( )12 13 12 13U V T T U V T T U Vδ δ δ+ = > + + ≤ +I I . 
When T T≤  we have T T T= +  and thus, 
( )
12 13 12 23
( ) ( )
 ( ) ( ) ( )( )12 12 12           min , min ,T C T C T C T
δ+ =
= + ≤I
By considering separately cases 12T C




≤  and 12T C> , it is easily seen that the right-hand 
side equals . On the other hand, on  we have( )min ,T C 12 13T T>  13T T= , 0δ = , and 
δ+ ( )min ,T C=  immediately follows. This shows U V ( )ii .,  
 
Lemma 2. Let G denote the distribution function of C. For each function φ  we have 
( ) ( )( )( )
,U U V
S
1 G U V
φ δ δρφ δ −




( ) ( )1 G x C x−− = ≥P  is the left-continuous version of ( )1 G x− . 
Proof. 
rite  W
( ) ( ) ( ) ( )( )
12 23
12 12 23 12 13




S T T T T T
T T C T T T





Now, since C is independent of the process, 
 ( ) ( )( )12 23 12 13 23 12 23, , 1T T C T T T G T T −⎡ + ≤ ⎤ = − +⎣ ⎦E I . 
On the other hand,  
 ( ) ( )12 13 12 23T T T T C δρ≤ + =I I . ≤
Since, under 1δρ = , we T=  and  have U 12 23V Tδ = , we get  
 ( ) ( )( )( ) ( )( )( )12 12 2312 23
, ,
1 1
T T T U U V
S
G T T G U V
φ δρ φ δ δρφ δ− −
⎡ ⎤ ⎡⎢ ⎤+ +⎢ ⎥ ⎥= =⎢ ⎥ ⎢ ⎥− + − +⎢ ⎥ ⎢ ⎥⎣ ⎦ ⎣ ⎦
E  E .,  







Let K denote the distribution function of the survival time of the process, T. 
Since T and C are independent, then, Lemma 1 ensures that the Kaplan-Meier product-
limit estimator based on ( ),i i i iU Vδ ν+ , where ( )1i i i i iν δ η δ ρ= − + , is a consistent 
ma 1 guarantees that the Kaplan-Meier product-limit estimator 
based on the 
estimator for K. This estimator, which we denote by lK , is important since, for example, 
it provides an estimator for the occupation probability in state 3, 
( ) ( ) ( )13 0,K t T t p t= ≤ =P . 
Furthermore, Lem
( ),1i i i iU Vδ ν+ − , say lG , is a consistent estimator of G. Then, Lemma 2 
suggests estimating ( )S φ  by the sample average 
 ( ) ( ) ( )( )1
,
1








φ δ δ ρ
δφ −=
+
− += ∑ .      [4.7] 
As a technical remark, we point out that the result in Lemma 2 is valid for those 
functions φ  such that  whenever  is strictly greater than the upper bound ( ), 0uφ =v v
τ  of the support of . Otherwise, the result should be read as  ( )min ,T C






τ φ δ δρφ δ −
⎡ ⎤+⎢ ⎥= ⎢ ⎥− +⎢ ⎥⎣ ⎦
E , 
where ( )Sτ φ  is the expectation defined as  





,s t or  φ φ=  for some . Since s t≤φ φ=
( )  ( ),, , , 0s ts t u u u uφ φ= = , then 
( ) ( ) ( )( ),, 1
,
1












− += ∑ , S
  










 ( )  ( ) ( )( ),, 1
,
1















These expressions show that 
φ
 ( ),s tS φ  and  ( ),s tS φ  are indeed multivariate Kaplan-Meier 
integrals with respect to the measure associated to  (Stute, 1993). This fact will be 
very useful when investigating the asymptotic prope
  We define then, 
lK
rties of the proposed estimators. 
m ( ) l ( )l ( )









< ≤ + >
−
= −












  [4.8] 
and 
δ −+ ,
i i i i
i i iU V
m ( ) l ( )l ( )
( ) ( )
 ( )( )
( ) (

























i i i i i i
i i i i
n
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s t
U s U V t
G U V












where (as mentioned) the indicator i iδ ρ  can be replaced by iν .  
stimators proposed here have fewer jump points but with largE er steps when 
ompared with Aalen-Johansen estimators. These estimators may step down or up only 
at event times (disease occurrence or death) and only when the individuals time is not 
censored. Of course, the number of jump points and the size of the steps will depend on 
the sample size and on the censoring percentage.  
c
 







ase, estimators [4.6], [4.8] and [4.9] give place to “obvious” 
estimators:  






































































p s t .      
 Note that these estimators, 
>∑n i is U VI I
m ( ),hjp s t , can be expressed as the proportion of the 
observations available in state h at time s which ends up in state j at time t: 
m ( )

























 As mentioned before, estimators for the rest of the transition probabilities, 
,
 
( )13p s t  and ,( )23p s t , can be obtained from the above ones. Certainly,  
 m ( ) m ( )23 22, 1 ,p s t p s t= −  
and 


















12 13 12 23 13 12 13
12 12 13 12 23 13 12 13
,
            , ,
, , ,
            ,   
p s t T t Z s
T T T T t Z s T t T T Z s
s T T T T T t s T t T T
Z s Z s
= ⎡ ≤ > ⎤⎣ ⎦
= ⎡ ≤ + ≤ > ⎤ + ⎡ ≤ > >⎣ ⎦ ⎣
< ≤ + ≤ < ≤ >= +






rovide an alternative estimator for ( )13 ,p s tone can certainly p . The first term on the 
ght hand side of [4.10] is the conditional probability of leaving state 1 into state 3 
having visited the diseased state (i.e., 3), denoted by 
ri
1 2→ → ( )13 ,dp s t . The second 
term is the conditional probability of leaving state 1 into te 3 without having visited 
e., ), denoted by 
sta
1 3→ ( )13 ,ndp s tthe diseased state (i. . 
As for the previous transition probabilities, also these two additional quantities, 
( )13 ,dp s t  and ( )13 ,ndp s t , are determined by the joint distribution of . 
Specifically, the knowledge of the distribution of 
( )12 13 23, ,T T T
( )12 13min ,Z T T=  and expectations of 
type T  (considered before) arise when handling ( ) ( ) ( )12 12 23 12 13,S T T T Tφ φ= + ≤⎡ ⎤⎣ ⎦E I
( )13 ,dp s t  ( ) ( ) ( )( ),, , ,s tu u u sφ φ= = >Iv v v t≤ , 




φ= >P , 
( ) ( ) ( )13 13 12 13T Tφ φ= >,D T T⎡ ⎤⎣ ⎦E I  arise when handling whereas the expectations of type 
( )13 ,ndp s t  ( ) ( ) ( )( ),, , ,s tu u u sφ φ t= = > ≤Iv v v , 















 2, suggests that ( )13 ,dp s t  can be eLemma stimated by the sample average, 




U s U V t
G U Vn H s




= ∑ I I .   
For the estimation of the expectation ( ) ( ) ( )13 13 12 13,D T T Tφ φ T>= ⎡ ⎤⎣ ⎦E I  we need the 
following Lemma, 
Lemma 3. For each function 
 
φ  we have  






φ δ ηφ −




) ( ) ( )( )






T C T T









 ( ) ( )( ), 1T C T T G T13 12 13 13 −⎡ ≤ ⎤ = −⎣ ⎦E I
On the other hand,  
. 
( ) ( ) ( )13 12 13 1T T T C δ η< ≤ = −I I . 
Since, under , we have ( )1 1δ η− = 13U T= , we get  
( ) ( )( )( )
( )( )
( )13 13 13
, 1 , 1
1 1
T T U U
D
G T G U
φ δ η φ δ ηφ − −





,   
 
  









Then, ( ) ( ) ( )13 13 12 13,D T T T Tφ φ= >⎡⎣E I ⎤⎦  may be estimated by the sample 
average, 
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)13p s t  can be estimated by 









G Un H s





= ∑ I .   [4.11] 
 Then one possible estimator for ( )13 ,p s t  is given by the following expression, 








U s U V t
n H s
p s t δ
1
i i i i
G U Vδ
ν







Note that, since 
( ) ( )13 ,p s t T t Z s≤ >
then, the above estimator [4.12] can be seen as an estimatio lving the 
= P , 
n problem invo

















 the asymptotic results for the estimated 
transition probabilities 
4.3.1.2. Some asymptotic results. 
 
In this section our main interest is
m ( ),hjp s t . Special attention will be paid to the following issues: 




We first introduce some results f  an es ator of the general expectation 
( ) ( )
( ) ( ) ( ) (12 12 23 12 13 13 13 12 13
,
        , ,
L Z T
T T T T T T T T T
ϕ ϕ
ϕ ϕ
= ⎡ ⎤⎣ ⎦
= + ≤ + >⎡ ⎤ ⎡⎣ ⎦ ⎣
E
E I E I )⎤⎦  [4.13] 
ote that ( )13 ,p s t  is related to this expectation, through the choice 
( ) ( ) (
N
)= = or ,, , ,s tu u u s tϕ φ > ≤Iv v v . Note that f s t≤  we get 
( ) ( ) ( ), , ,s t s t s tL S Dφ φ φ=  Also+ . , for ( ) ( ) ( ),, ss tϕ φ , ,t u u s t= = ≤ >Iv v  and , we 
get 
s t≤
( ) ( ), ,s t sL S tφ φ=  (because ( ), , 0s t u uφ = , the second expectation on the right-hand 
side of [4.13] is zero). ent shows that The same argum ( ) ( ), ,s t sL S tφ φ= . Hence, 
estimators of ( )L ϕ  are of much practical interest in the scope of the illness-death 
model. 
 Now, note that, rather than the pair ( ),Z T  we observe  where ( ),U Y
Y U Vδ= + . Besides, it is known whether the value of  is an uncensored observation 
of T   or not . So the problem of estimating 
Y
( )1ν = ( )0ν = ( )L ϕ  has to do with the 
tegrals in the presence of covariates (here, the role of the 
ill be played by the Z). In contrast with the existing related literature 
es (e.g. Stute, 1993), the Z may be censored too; however, U will 
offer an uncensored value of Z whenever 
evaluation of Kaplan-Meier in
covariate w
developed in the nineti
1ν = , and so any Kaplan-Meier integral based 
  











 and Y U V
on the weights of lK  c
b
 troduce the Kaplan-Meier integral 
  ( ) [ ] ( )( ),Kin iiL W U Yϕ ϕ=∑ , n
1
where  are the ordered values of the ( ) ( ) ( )1 2 ... nY Y Y≤ ≤ ≤ ´siY i i i iδ= + ;  is 





attached to ( )iY  under lK . Explicitly, 
W  stands for the weight which is 









n i n j
ν ν−
=
⎡ ⎤= −⎢ ⎥− + − +⎢ ⎥⎣ ⎦∏ , 
herew  [ ]iν  is the censoring indicator of . Note that ( )iY  0KinW =  for any censored . 
Since  whenever 
( )iY
[ ] [ ]i iU Z= [ ] 1iν = , we may write  
 Y . 
A number of results are availabl or this







L W Zϕ ϕ
=
=∑
  ( )L ϕe f , in the case of complete 
observation on Z. When right-censored values of Z correspond to censored observations 
f T (as in our case), the results are easily adapted. The needed identifiably conditions 
are satisfied in this application (they are consequences of the independence between C 
and , ,T T T  which of course implies the independence between C and 
o
( )12 13 23 ( ),Z T  ), 
since: (a) T and C are independent random variables; (b) ν  is independent of Z 













Z T T ( )Lτ ( ) ( ),ϕ ϕ τ≤ ⎤⎦I , = ⎡⎣E
where τ  stands for the upper bound of the support of . 
Specifically, we have (Stute, 1993): 
 
( )min ,Y U V T Cδ= + =
 ( ) ( )L Lτϕ ϕ→      w. p.   1  as , 
provided that the limit exists. 
 In the previous section, we obtained the following estimators for the transition 
robabilities in the illness-death model: 
n →∞
p














 m ( )  ( ) ( )22
φ= ,, s tLp s t , φ ,s sL










p s t p s t
L
φ
φ= − = − , 






, 1 , , 1
1 1
s tLH tp s t p s t p s t
H s H s
φ−= − − = − −− − . 
 As mentioned before, an alternative estimator for ( )13 ,p s t  (see [4.11]) is now 
 









φ• = − , 
herew  ( ) ( ), , ,s t u v u s tφ = > ≤I v .  
 
  







Estimators m ( )1 ,jp s t , as introduced in [4.6], [4.8] and [4.12], do not satisfy the 
natural restriction  





This problem can be overcome by considering, when estimating the distribution H of Z, 
empirical integrals based on the weights associated to , the estimator of the survival 
time T. Certainly, introduce 
 ≤ ,    
note now that, 
lK




in ini n i n
i i
H t W U t W Z t∗
= =
= ≤ =∑ ∑I I
  ( ) m ( )tL H tϕ ∗=   where  ( ) ( ),t u u tϕ = ≤v . 
Further  fol e general convergence
 
I
more,  ( ) ( )tL H tϕ → lows from th  result above.  
Introduce now the following estimators: 
















































L W Z t
  ( ) [ ] ( )( ), ,n Ks t in iiL W s Z t Y tφ = < ≤ >∑ I
1
  













L W s Z Y tφ
=
= < ≤∑ I .  
Because [ ] ( )ii
[ ] ( ),s t in ii





s t in ii
i
L W s Z t Yφ
=
t= < ≤ ≤∑ I0 , then ≠ . 
herefore, T
 ( )  ( )  ( )
[ ]( ) [ ] ( )( ) [ ] ( )( )
, ,s t s tsL L Lϕ φ φ+ + =
[ ]( ) [ ]( )
[ ]( )
 ( )
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Note that in the case , we obtain  0s = m ( )  ( ) l ( )0,13 0, tp t L K tφ∗ = = , which means 
 distribution function of the survival time of the process, K, may be estimated by that the
 ( )0,tL φ . 
 The main goal in the remainder of this section will be establishing the 
asymptotics for m ( ),hjp s t  and m ( ),hjp s t∗ . 
  
Asymptotics for m ( )11 ,p s t  
First, consider the empirical weighted average 
U
which can be regarded as an estimator for 









i( ) i ( )R Zϕ ϕ⎡ ⎤= ⎣ ⎦E . For simplicity we assume 
ontinuity in the following. Introduce ( ) ( )( )0 0min ,H z Z zτ τ= ≤P , where 0τ  denotes c
  










the upper bound of the support of U . Of co  0H τ  equals  whenever the support 
of Z is contained in that of C (otherwise, we can not expect consistency in the right tail 
of the distribution). Thus if we define  
H




we have (Stute and Wang, 19
l i( ) i( )0R Rτϕ ϕ→     w. p. 1, 
provided that the limit exists. Let N denote the distribution function of U, and 
ored 
ons, respectively; that is,
,  0,1jN j = , for the subdistributions pertaining to the censored and uncens





l i( ) i ( )( ) i ( )( ) i ( ) i( )1 211 11
n
i i





ϕ ϕϕ γ U rϕ η γ η
=
⎧ ⎫⎪ ⎪= + − −⎨ ⎬−⎪ ⎪⎩ ⎭∑  ϕ+
where 
i ( ) ( )





( ) i ( )
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⎡ ⎤<= − ⎣ ⎦















E   
i ( ) ( )
i ( )





ϕ ηη <= −∫ I v v vv  N
and 
 i( ) ( )1 2 ,nr o nϕ −= P  
 
 







rovided that the foll ing condition hold: 
C1.0    
p ow s 




i ( ) ( )
( )( )
0
2 2Z Z U zϕ τ ϕ γ ϕ 2 1
2 21 1 1
dN z
G Z G U G z
⎡ ⎤⎡ ⎤ ⎢ ⎥ < ∞− ⎢ ⎥− −⎢ ⎥⎣ ⎦ ⎣ ⎦
, 
C2.0    
≤ = =⎢ ⎥ ∫IE E
i ( ) ( ) ( ) i ( ) ( ) ( )001 2 1 20 0Z C Z Z z C z dH zτϕ τ ϕ⎡ ⎤≤ = <⎣ ⎦ ∞∫E I  
where ( )0C z  is defined as  
( ) ( ) ( )( ) ( )( )0 0 .1 1
z dG x=C z
N x G x− −∫  
his result, together with the Central Limit Theorem (CLT), immediately leads to  
 
T
l i( ) i( ) i( )( )01 2 00,n R R Nτϕ ϕ σ ϕ⎡ ⎤− →⎣ ⎦     in law, 
where i( ) i( )20 0var ϕσ ϕ ξ=  and 
i ( )
( ) 
i i ( )( ) i ( )0 1 21 .U UG U ϕ ϕξ η γ η+ − −−  
tions we need to consider transfor s such as 
1
Uϕ ϕ γ=
Moreover, in our applica mation
 ( ) l ( ) l ( )( )1 2 2, ,g R 1 Rθ ϕ ϕ ϕ=  where typically ϕ ( ),g x y x y= , ( ) ( ) ( ), 1 1g =x y x y− −  
r )( ) (, 1g x y x y= − . Then, the multivariate  delta method (Serfling, 
age 124) ensure 
CLT and theo
1980, p
 ( ) ( ) ( )( ) ( )( )0 01 2 1 2 1 2 0 1 2, , 0,n g R R Nτ τ ,θ ϕ ϕ ϕ ϕ σ ϕ ϕ⎡ ⎤− →⎣ ⎦     in law, 
where 
( ) ( ) ( ) ( )( ) ( ) ( ) ( )( )
( ) ( ) ( )( )
0 0 0 0
0 0
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0,12 , ,
,
                 2
x y R R x y R R





τ τ τ τ
τ τ
ϕ ϕ ϕ ϕ
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⎡ ⎤∂ ∂⎡ ⎤= + ⎢ ⎥⎢ ⎥∂ ∂⎣ ⎦ ⎣ ⎦
∂ ∂+ ∂ ∂
 
and where  
  









( )2 20,1 0 1σ σ ϕ= , ( )2 20,2 0 2σ σ ϕ= , ( )1 20,12 0 0cov , .ϕ ϕσ ξ ξ=  
We can easily see that 
 
 can be simplified as 0,12σ
( ) ( )











hich can be used for computation of the limiting variances and covariances w 20,1σ , 20,2σ , 
0,12σ . Besides, the first summand is also written as  
( ) ( )
( )( )
( ) ( ) ( )
( ) 01 2 1 22 .11
U U Z Z Z
G ZG U
ϕ ϕ γ ϕ ϕ τ⎡ ⎤ ⎡ ⎤≤⎢ ⎥ = ⎢ ⎥−⎢ ⎥− ⎣ ⎦⎣ ⎦
I
E  E   
m ( ) l i( )( ) l i( )( )11 , 1 1t sp s t R Rϕ ϕ= − −  where i ( ) ( )t u uϕ = ≤I t  and Now note that 
i (ϕ ) ( )s u u s= ≤I . The existence of i ( ) ( )0t Z Zϕ τ⎡ ⎤≤⎣ ⎦E I  is guaranteed since the 
nction i tϕ  is bounded (similarly for i sϕ ). On the other hand, 
i ( ) ( ) ( )
fu
0t τ≤ . Hence, the estimator ,m ( )0t Z Z H tϕ τ⎡ ⎤≤ =⎣ ⎦E I  for each 11p s t  converges 
almost surely to ( )11 ,p s t  provided that 0t τ≤ . We also obtain, for 0t τ≤ ,  
m ( ) ( ) ( )( )11 11 0, , 0, ,n p s t p s t N s tσ⎡ ⎤ 1 2 − →
where 
⎣ ⎦        in law, 
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1 1 1
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σ σ σ σ− −= + −− − − 3 , 
 ( )( )
( ) ( )( ) ( )







H t H UZ t
H t
G Z N U
γσ
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 For the uncensored case, we simply obtain 
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for some estimators lH , lG  and . 
This variance estimator, , can be used to construct an asymptotic normal 
theory confidence interval for 
lN
m ( )0 ,s tσ
( )11 ,p s t . An approximately 1 α−  confidence interval for 
( )11 ,p s t  is given by 
m ( ) m ( ) m ( ) m ( )0 011 2 11, , ,p s t z p s t znα 2
, ,s t s t
nα
σ σ⎡ ⎤− × ×
⎥⎦
. 
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For the uncensored case, we simply obtain 
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In this case, the estimator m*H  is the ordinary empirical distribution function of the iZ , 
and both m ( )11 ,p s t∗  and ,m ( )11p s t  coincide.  
 Note that, unlike in the preceding section, the function tϕ  may or may not 
satisfy conditions C1 and C2 above. Finally, note that it is possible to introduce an 
estimator for the limiting variance of m ( )11 ,p s t∗  by plug-in methods with 
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Regarding technical conditions C1 and C2, we mention that 
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,s tφ  may or may not verify 
these assumptions. Some care will be needed in applications. 
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Note that the above functions ,s tφ  and tϕ  may or may not verify the assumptions C1 
and C2. 
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 In this section, we have introduced and investigated up to six different estim tors 
for the three different transition probabilities: ( ),11p s t , ( ),12p s t  and ( ),22p s t . As 
shown before, more different estimators for these parameters could have been 
introduced, and no general answer regarding their relative efficiency can be given in 
principal. Two main estimators were considered here: using estima rs m ( ),to 11p s t , 
m ( ) m ( )m ( )22 ,p s t12 ,p s t 11 ,p s t∗ and  (see, [4.6], [4.8] and [4.9]); or using estimators , 
m ( )12 ,p s t∗
Kaplan-Meier in
not on T
. For obtaining the asymptotic results, we have used existing theory devoted to 
tegrals. When the expectation to be estimated depends only on Z (but 
), general theory in Stute and Wang (1993) and Stute (1995) is to be used. 
However, the estimation of expectations involving ( ),Z T  requires using the extended 
theory in Stute (1993, 1996). In the following sections, a simulation study and an 
application are performed to illustrate differences between Aalen-Johansen estimators 
and non-Markovian estimators. To emphasize the differences between both approaches, 
we shall use in both cases the transition probability ( )22 ,p s t  and the corresponding 
m ( )22 ,p s t . non-Markov estimator 







4.3.1.3. Simulation study. 
 
model.  
Three settings were considered here, differing on transition from state 2 to state 
3. In the first setting, times 
In this section, simulation studies were undertaken to compare Markovian 
(Aalen-Johansen) and non-Markovian estimators for non-homogeneous illness-death 
( )12 13 23, ,T T T
( )12 13 23, ,T T T
 are exponential distributed and mutually 
independent, yielding a homogeneous Markov process (see Lemma in the appendix A). 
For the second setting, times  are mutually independent,  and  are 
exponentially distributed, but for s were generated from a Weibull distribution 
with shape parameter 2 ter 0.05. In the third setting, independent 
exponentially distributed tim  and , while . 




 and scale parame
es were considered for 12 13 23
12 13
and 0.026 so
T T 121 7.T T= ×
T T
 ( )13 12 0 6.≥ =T TP . In the first setting we used the rate parameter 0.065 
for 
hat settin nd 3 do  fulfill the Markov assumption. 
perform
uncensored case and two different levels of censoring).  For each subject, a censoring 
time was generated from an exponential distribution, with rate parameter 0.013 and 
0.035 (
proportion of individuals with censored 
observations (either in state 1 or state 2) can be found through the following expression: 
23T . 
Note t gs 2 a not
The ance of both Markovian (Aalen-Johansen) and non-Markovian 
estimators was examined under the presence of three levels of censoring (the 
determining the heaviness of the censoring). Subjects alive at this censoring time 
were then censored at that time. The 
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In this section we compare Markovian and non-Markovian approaches through 
the estimation of the transition probabilities ( )22 ,p s t  for some fixed value of s, 
10s =
serve that fixing s, 
( ) and 25s = . We choose to compare both approaches through this transition 
probability to emphasize the differences between them.  Ob
( ) ( )22 , 231 ,p s t p s t= −  is a function of time t alone. For this simulation study,  
m ( ),22p s t  is the non-Markovian estimator examined. 
For the evaluation of the simulations, we shall borrow the work of Couper and 
Pepe (1997), which contain er things, a compreh lation study. As 
 absolute bias, integrated variance and 
the integrated MSE. For each setting we derived the analytic expression of  
s among oth ensive simu
Couper and Pepe (1997), we use the integrated
( )22 ,p s t  
(given in the appendix A) so that the bias and the MSE of the estimator, could be 
For each configuration,
examined.  
 100K =  data sets were generated, with two different 
sample sizes  and .   
k
100N = 200N =
Let 22 ,
m ( )p s t  denote the estimated transition probability at time t for some s 
fixed on the kth generated data set. For each time t considered, we may obtain the mean 
for all generated data sets,  m ( ) m ( )22 22
1
1= ∑, ,K k
=k
p s t p s t . 
K
We then define, for some fixed value of s, the pointwise estimates of the bias, 
variance and Mean Square Error (MSE) as: 
n ( ) ( ) m ( )22 22bias = −, ,t p s t p s t , 

















22 22 22p s t p s t p s tK
, 
and 
n m ( )( ) m ( ) ( )( )222 22 221MSE = −∑, , ,K k
1=k
p s t p s t p s t
K
. 
To summarize the results, we also calculate the integrated absolute bias, 
integrated variance and the integrated MSE, defined in Table 4.1. 
Tables 4.2, 4.3 and 4.4, present the summary statistics for the two estimators 
(Markovian and non-Markovian) for settings 1, 2 and 3, respectively. 
 
Table 4.1. Summary statistics measuring integrated bias, integrated varian
integrated mean square error.  
Statistic Definition Estimator 
ce and 
Integrate ( )1 bias
t
s




∆∑  d absolute bias 
Integrated variance m ( )( )1∫ var ,t
s
22p s t dt  m m ( )( )1 ∆∑var ,t
t s











p s t  n m ( )( )∆
1
 
As shown in Tables 4.2-4.4, the non-Markovian estimator revealed itself to be





(and espe last 
antly more precise in settings 2 and 3 while the Markovian estimator obtains 
better results whenever the process is Markov (setting 1).  
The non-Markovian estimator obtains in all settings a small bias, wh
vian estimator is grossly biased in the last two settings. It is clear that the bias 
clearly dominates the performance of the Markovian estimator in the last two settings 
cially in the one), leading to a larger MSE. In fact, in some cases (see 
Tables 4.3 and 4.4) the performance of the Markovian estimator is disappointing despite 
having obtained a smaller variance than the non-Markovian estimator. The reason for 









the bias in Markovian estimator for settings 3 is that the time spent in state 2 is 
associated with the time of entry into that same state. In this last setting (clearly non-
Markov), individuals who enter state 2 early also leaves this state early, so the 
Markovian estimator will overestimate the time spent in state 2, and therefore ( )22 ,p s t . 
In an analogous way, the individual’s time spent in state 2 will be underestimated for 
individuals with a later entry in state 2.  
to the interval [ ]50,s s + , we verified that, for settings 2 and 3, the enlargement of this 
interval increases at a faster rate in the Markovian estimator for the bias and MSE 
(results are not shown). Furthermore, we verified that for other values of s , our 
estim results whenever the process is not Markov (results are not 
shown). 
The bias for the non-Markovian estimator increases with s for setting 1 and 3 but 
not for setting 2. For the Markovian estimator, the bias increases with s only for setting 
1. In all cases, the variance increases with s and with censoring for both estimators. 
Furthermore, the variance is smaller for the Markovian estimator in setting 1, but our 
estimator revealed to be competitive when the process is not Markov (settings 2 and 3). 
The simulations showed that increasing the sample size reduces the variance for 
both estimators. Apart from setting 1, the bias (and consequently the MSE) in the non-
Markovian estimator, decreases at a faster rate when increasing the sample size.  
In Figure 4.1, we choose to present th es of MSE, bias and variance 
obtained by using Markovian ators for setting 3 with 25s = , 
200=N  and about 32%  of censored observations (see results in Table 4.4). The 
Markov assumption. This figure shows that the MSE of the Markovian estimate is 
disparity in the curves for the MSE and the bias clearly reflects the failure of the 
ator still obtains better 
Although we restrict the integrated bias, variance and mean square error (MSE) 
e curv
and non-Markovian estim







increasing as a function of tim
(slowly) until around tim t =  and then slowly decreases. Curves for the bias are 
clearly different for Markovian and non-Markovian estimators, showing that the 
Markovian estimator is gro  biased. Note however that the variance for the 
Markovian estimator is smaller than that of the non-Ma ator until around 
time 67t = . 




















































Figure 4.1. Curves obtained for setting 3 with 25s = , 200=N  and 32% of censored 
observations for Aalen-Johansen estim ator 
(solid bold line).  





m ( )22 ,p s t  for setting 1, according toTable 4.2. Estimates of integrated absolute bias, integrated variance and integrated mean square error of  
  
fixed value s, censoring and sample size. 
 
10s =  25s =  
 cens ring 0 % 25 % 49 % 0 % 25 % 49 % o









































































































Table 4.3. Estimates of integrated absolute bias, integrated variance and integrated mean square error of m ( )22 ,p s t  for setting 2, according to 
fixed value s, censoring and sample size. 
 
  10s =  25s =  
 censoring 0 % 27 % 52 % 0 2 % 7 % 52 % 





























































































































b 4 s ntegrat bs e , integrated variance and integrated m sq  r 
 
 








s 10=  25s =  
 censo ng 0 %ri  % 54 % 0 32 % 54 32 % % 





























































































































































the liver (Andersen et al., 2000). The PROVA clinical trial was conceived to evaluate 
the effect of propanolol and/or sclerotherapy versus no treatment on risk of bleeding 
episodes and survival in patients with cirrhosis.  In the period between 1985 and 1989, 
286 patients entered the study. Some of these patients developed bleeding episodes, 
while others did not. The occurrence of these intermediate events may affect the patient 
outcome and can be included as a transient state in an illness-death multi-state model 
(see Figure 4.2). 
 
Figure 4.2. Illness-death model for PROVA trial. 
 
From the total of 286 subjects, 50 developed bleeding episodes, and among these 
29 died. On the other hand, 46 patients died without developing bleeding episodes. The 
rest of the patients remained alive and had no bleeding episodes up to the end of the 
follow-up.  
PROVA trial was previously used by Andersen et al. (2000) to compare multi-
odels and simple Cox regression models in regard to their simplicity and 
terpretation. Andersen et al. (2000) first used a Cox Markov model which turned out 
 fit poorly since the process was not Markov. To avoid the failure of the Markov 
ssumption, Cox semi-Markov models were then used.  
.4. Application to PROVA data. 
 
 For illustration purposes we use data from a Danish clinical trial in cirrhosis of 

















trate the differences between the Aalen-
ator and proposed non-Markov estimators of the transition probabilities. 
Here we present some figures to illus
Johansen estim
In Figure 4.3, we present estimated transition probabilities,m ( ),22p s t , for a fixed value 






Figure 4.3. Estimated tr  probabilities for m ( )22 ,p s t , 200s =  (top) and  500s =  
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4.3.1.5. Conclusions.  
 
 When using multi-state models for the analysis of survival data, some care is 
necessary in choosing an appropriate model. Traditionally, statistical methods for 
nalyzing such models depend on the Markov assumption. We have shown through our 
simulation study that unless the process is, in fact, Markov, the non-Markovian 
 the Aalen-  
 departures from the true transition probabilities when 
vival data sets, our estimator always 




Another quantity of interest in multi-state modelling is the cause-specific 
umulative incidence function, as defined by Kalbfleisch and Prentice (1980). In fact, if 
ur interest is the estimation of failure probabilities, cumulative incidence functions are 
. Note that 
a
estimator here proposed is a wise choice. Simulations suggest that Johansen
estimator is highly susceptible to
the process is not Markov. Moreover, for large sur
p
 
4.3.1.6. Cumulative incidence functions. 
c
o
the appropriate quantity to use. We denote the cumulative incidence for disease as 
( ) ( )12 12 12 13= ≤ ≤P ,CI t T t T T ( )12CI t  should not be confused with the 
ansition probability, ( )12 0,p t
 one individual’s bein
tr . The cumulative incidence function represents the 
probability of g or having been in the diseased state at time t, while 
( )12 0,p t  is the conditional probability of a healthy individual’s being at entry time in 
the diseased state at later time t.  
 
  








)( ( ) ( ) ( )12 12 13 12 12 23 12 13ϕ= ≤ ≤ = ⎡ + ≤ ⎤12 ⎣ ⎦, ,tt T t T T T T T T TP E I , 
where ( ) )t v tϕ = ≤I . In the same spirit as above, this quantity can be e  by 

















and it is consistent under the assumption of independence between 
= ∑ In UCI t
( )12 13 23, ,T T T  and C. 
The formal details are omitted. 
 For the uncensored case, it is simplified by 
n ( ) ( )12 1 δ 
1=in
= ≤∑ In i iCI t U t . 
lative incidence function for death is the probability of one 
individual’s being dead within time t. Because death is an absorbing state, the 
cumulative incidence for death is the transition probability from state 1 into state 3, 
The cumu
( ) ( )13 13 0,CI t p t= . 
1.7. Inference on the joint distribution function of 
)T T . 
 
)  purpose, we will assume (besides the 
independence between the censoring variable C and the process) that  and 





( 12T 13 23, ,
Finally, we consider the problem of estimating the distribution functions of  
and  in the illness-death model. For this
13T  
( 12 23,T T
13T ( )12 23,T T  
13F 13Ta
  







simply compute the Kaplan-M it 
, 1U




( )( δ η− . The consistency of this estimator follows from the independence of the 
variables . On the other hand, the joint distribution function of  can 
be written as an expectation:  
)    for 
12T  and 13T ( )12 23,T T
( ) (12 23 12 23, ,T s T t T Tψ≤ ≤ = ⎡ ⎤⎣ ⎦P E ( ) ( ), ,u u s tψ = ≤ ≤Iv v .  
Of course, for i ( ) ( ), ,u u uψ ψ= −v v  we have  
( ) i ( )
i ( ) ( ) i ( ) (
12 23 12 12 23
12 12 23 12 13 12 12 23 12 13
, ,
                          , ,
T s T t T T T
T T T T T T T T T T
ψ
ψ ψ
⎡ ⎤≤ ≤ = +⎣ ⎦
⎡ ⎤ ⎡= + ≤ + + >⎣ ⎦ ⎣
P E
E I E I )⎤⎦
and hence it is seen that 
 
 i( )S ψ  as previously defined would underestimate the target.  
Note that  
( ) i ( )
i ( ) ( ) ( )( ) ( )
12 23 12 12 23
12 13 12 23
12 12 23
12 13 12 23 12 23
, ,
                          ,
,
T s T t T T T
T T T T C
T T T
T T T T C T T
ψ
ψ
⎡ ⎤≤ ≤ = +⎣ ⎦






Now, in order to introduce an estimator for the above expectation, besides the 
sumpas tion that the censoring variable is independent of the process we will need the 
following assumptions: 
H1: 12 13 independent of T T ; 
H2: ( )12 13 23 12 independent of  conditionally on T T T T≤I . 
Of course, H1 and H2 are also valid if we assume independence between  T  
and ( ),T T . Using these assumptions we have, 
13
12 23
( ) ( ) ( ) ( )
( ) ( )( )
12 13 12 23 12 23⎣ ⎦ 12 13 12 23 12 23 12 23
13 12 12 23
, , ,
                                                           1 1
T T T T C T T T T T T T T C T T
F T G T T −−
⎡ ≤ + ≤ ⎤ = ⎡ ≤ ⎤× ⎡ + ≤ ⎤⎣ ⎦ ⎣ ⎦
⎡ ⎤⎡ ⎤= − × − +⎣ ⎦ ⎣ ⎦
E I I E I E I
 
  









On the other hand,  ( ) ( )23T C12 13 12T T T δρ≤ = . Since, under ≤ +I I 1δρ = , we have 
T=  and 12U 23V Tδ = . Then we obtain 
( ) ( )( )
( )
i ( )
i ( )12 23 12 12 23, ,
,
                          




⎡ ⎤≤ ≤ = +⎣ ⎦
+⎢ ⎥= ⎢ ⎥
131 1F U G U Vδ −−
⎡ ⎤




⎣ ⎦ ⎣ ⎦⎣ ⎦
which can be estim he sample average: 
 n ( )
ated through t
i ( )
l ( ) ( )( )131 1 1 .ii i i ii F U G U Vn
ρ
δ −−= − − +⎡ ⎤12,23
,1, i i i i i
n U U VF s t δ δψ += ⎡ ⎤⎣ ⎦⎣ ⎦
 ∑ 
n ( )12,23 ,F s t  is of The formal derivation of the consistency (and further asymptotics) of 




4.3.2. Extension to mor ls. 
 
 Methods presented in the previous sections regarding the scope of the illness-
death model can be extended to more complex multi-state models. Here we will 
consider, merely as an example, the bivariate model and the progressive four-state 
model. Note that the progressive three-state model is a particular case of the
dea y mod
aplan-Meier estimates. 
 s a la
meth  bec
 
e complex multi-state mode
 illness-
th model when 13T = ∞ . For the mortalit el, for the survival analysis, and under 
our approach we obtain K
Note however that if the state structure ha rge number of states, then these 
ods rapidly ame complicated. 







4.3.2  Model. 
 The bivariate model, depicted in Figure 2.8 (page 34), is the multi-state model 
1 dead’, ‘individual 2 
dead’ a
is model, the sto astic b aviour o  proces
that C is independent of 
we may now denote the sample information as  
.1 The bivariate
 
for bivariate parallel data, with states ‘both alive’, ‘individual 
nd ‘both dead’. This model is described in detail in Hougaard (2000). 
 For th ch eh f the s is represented by a 
random variable ( )12 13 24 34, , ,T T T T . Assuming , ( )12 13 24 34, , ,T T T T
( )δ η ρ, , , ,i i i i iU V , 1 i n≤ ≤  
which are assumed to be independent and identically distributed copies of 
( )δ η ρ, , , ,U V , where:  
C  is the observed sojourn time in state 1; 
C  is an indicator of whether a transition  occurs;  
, so that 
( )12 13min , ,U T T=
( )( )12 13δ = ≤min ,T TI  1 2→
( )13η = ≤T CI ( )1 δ η−  is an indicator of whether a transition  occurs; 1 3→
( ) ( )( ) ( ) ( )( )24 12 12 13 34 13 13 12= − ≤ + − <I Imin , min , min , min ,V T C T T T C T C T T T C  is 
the observed sojourn time in the intermediate state (state 2 if 1δ = , or state 3 if 0δ =  
and 1η = ); 
( ) ( )( ) ( ) ( )( )24 12 12 13 34 13 13 12ρ = ≤ − ≤ + ≤ − <min , min ,T C T T T C T C T T T CI I I I  , so that 
δρ  is an indicator of whether a transition 2 4→  occurs; and ( )1 δ ηρ−  is an in
of whether a transition  3 4→  occurs; 
dicator 
0δ = , information on ( ),V ρNote that, under  is still available provided that 
1η = ; while if 1δ = , then observation of η  is not possible.  
  








Again, we consider 
 ( )12 13min ,Z T T=
, and that 
. Furthermore, we assume that H is the 
distribution function of Z lH  is the Kaplan-Meier product-limit estimator of H. 
As for the illness-death model, lH  is based on the ( )( ), 1U δ δ η+ − . 
For the bivariate m del, it is enough to consider the estimation of the transition 
probabilities 
o
( )11 ,p s t , ( )12 ,p s t , ( )22 ,p s t , ( )13 ,p s t  and ( )33 ,p s t . All the others can be 
obtained from these since ( ) ( ) ( ) ( )14 11 12 13, 1 , , ,p s t p s t p s t p s t= − − − , 
( ) ( )24 22, 1 ,p s t p s t= −  and ( ) ( )34 33, 1 ,p s t p s t= − .  
Therefore, we have 
( ) ( )11 12 13 12 13, , ,p s t T t T t T s T s= > > > >P , 
( ) ( )12 12 12 13 12 24 12 13, , , ,p s t T t T T T T t T s T s= ≤ ≤ + > > >P , 
( ) ( )22 12 12 13 12 24 12 12 13 12 24, , , , ,p s t T t T T T T t T s T T T T s= ≤ ≤ + > ≤ ≤ + >P , 
( ) ( )13 13 12 13 13 12 13, , , ,34p s t T t T T T t T s T s= ≤ > + > > >P , 
and 
T
   ( ) ( )33 13 12 13 13 34 13 12 13 13 34, , , , ,p s t T t T T T t T s T T T T s= ≤ > + > ≤ > + >P . 
These quantities are determined by the joint distribution of . 
Specifically, knowledge of the distribution of 
T
( )12 13 24 34, , ,T T T T
( )12 13min ,Z T T=  is enough for the 
ery of ( )11 ,p s trecov , 








while expectations of type ( ) ( ) ( )12 12 24 12 13,S T T T Tφ φ= + ≤ T⎡ ⎤⎣ ⎦E I  arise when handling 
( )12 ,p s t  ( ) ( ) ( )( ),, , ,s tu v u s u t tφ φ= = < ≤ >v vI , 







( ) ( )( ),, s t
S
p s t12 Z s>P
and 
φ= , 
( )22 ,p s t  ( )  ( ) ( )( ),s t I, , ,u u u s tφ φ= = ≤ >v v v , 









In the same spirit, expectations of type ( ) ( ) ( )13 13 34 12 13,D T T T Tφ φ= + >T⎡ ⎤⎣ ⎦E I  are 
needed for ( )13 ,p s t  ( ) ( ) ( )( ),, , ,s tu u s u tφ φ= = < ≤ >v v vI  t





nd for ( )33 ,p s ta , 








D φ= . 
 Using Lemma 2, expectations 
D φ
( )S φ , can be estimated using sample averages 
[4.7], yielding the following estimates for the transition probabilities, 




H tp s t
H s
, 
m ( ) l ( )( ) ( ) ( ) ( )( )12 1 1 11
δ ρ
−
< ≤ + >= ∑ I I, i i i i in s U t U V tp s t , 
( )( )
= − +− i ii G U Vn H s
and 
m
( ) ( )δ ρ




























U s U V s
G U V
s t . 
≤ + >I Ii i i i in U s U V t
p
  








imate of C, denoted by , is now 
ased on
 
 Note that the Kaplan-Meier product-limit est lG
 ( ),1U V ν+ −  with ( )1ν δρ δ ηρ= + −b . 
For the expectations ( )D φ , we need the following Lemma: 
 
Lemma 4. For each function φ , we have 






φ δ ηρφ −
⎡ ⎤+ −⎢ ⎥= ⎢ ⎥− +⎢ ⎥⎣ ⎦
E . 
Proof.  
Analogous to Lemma 2.
 
 Then, estimators for the rest of the transition probabilities may be introduced: 
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p s t , 
)
( )( )
< ≤ + >n s U t U V
−− +− i iG U VH s
and 
( ) ( )(1 δ η ρ
( )
( )( )

































Estimation of other parameters under the bivariate model can be introduced 
following ideas similar to those discussed for the illness-death model. The formal 





≤ + > −I Ii i iU s U V t
 







 The four-state progressive model is fully characterized by three transition 
intensities. We therefore represent the stochastic behaviour of the process by a random 
variable , assuming that C is independent of the process. We denote the 
mple information as  
4.3.2.2 The progressive four-state model. 
 
( )12 23 34, ,T T T
sa
( )12 12 12 23 12 23δ δ δ δ δ δ ρ, , . , ,i i i i i i i i iU V W , 1 i n≤ ≤  
hich are assumed to be independent and identically distributed copies of 
)
w
( 12 12 12 23 12 23δ δ δ δ δ δ ρ,U , . , ,V W , where  
C  is the observed sojourn time in state 1; ( )12=min ,U T
( )12 12δ = ≤T CI  is an indicator of whether a transition 1 2→
( )23 12= −min ,
 occurs; 
V T C T  is the observed sojourn time in state 2; 
( )23 23 12δ = ≤ −T C TI , so that 12 23δ δ  is an indicator of whether a transition 
occurs; 
m
2 3→  
( )34 23−in ,W = T C T  is the sojourn time in state 3; 





Figure 4.4. The four-state progressive model. 
 
3 4→
State 1 State 2 State 3 State 4
  







 For the four-state progressive model, it is enough to consider the estimation of 
the following transition probabilities: 
( ) ( )11 12 12,p s t T t T s= > >P , 
 ( ) ( )12 12 12 23 12, ,p s t T t T T t T s= ≤ + > >P , 
 ( ) ( )13 12 23 12 23 34 12, ,p s t T T t T T T t T s= + ≤ + + > >P , 
 ( ) ( )22 12 12 23 12 12 23, , ,p s t T t T T t T s T T s= ≤ + > ≤ + >P , 
( ) ( )23 12 23 12 23 34 12 12 23, , ,p s t T T t T T T t T s T T s= + ≤ + + > ≤ + >P , 
and 
 ( ) ( )34 12 23 34 12 23 12 23 34, ,p s t T T T t T T s T T T s= + + ≤ + ≤ + + >P . 
 Let  be the distribution function of , and let  denote the Kaplan-Meier 
-lim
12F 12T m12F
product it estimator of 12F . Then, we can introduce the estimator 













Estimators for the rest of the transition probabilities can be obtained as for the 
illness-death model. Certainly, 
m ( ) l ( )( ) ( ) ( ) ( )( )12 12 23121212 1
1
11
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I I δ . 
here  is the Kaplan-Meier product limit estimate based on lGw
( )12 12 23 ,1U V Wδ δ δ ν+ + −  with 12 23 34ν δ δ δ= . 
Investigation of the convergence properties of these estimators is not covered in 
is thesis. Finally, note that like in the previous sections different estimators for the 























































































CM) can be fitted through all the 
major s
menting several functions for fitting continuous-time Markov 
multi-s
meters in non-homogeneous 
(Weibu
inical studies, a model with the 
arkov assumption may be appropriate, while in others the semi-Markov is preferable. 
 some instances, a homogeneous model will be satisfactory, while in others not. 
urthermore, sufficient standard software for fitting non-homogeneous models or for 
mi-Markov (or non-Markov) models is not quite available yet. Possible comparisons 




While the time-dependent Cox model (TD
tatistical packages, multi-state models need specialized software, being most of 
the programs written in FORTRAN, R or SAS. Marshall and Jones (1995) have 
developed a FORTRAN program called MARKOV for fitting multi-state Markov 
models with constant transition intensities and covariates. Later, Alioum and 
Commenges (2001) presented a new computer program, called MKVPCI, which 
extends MARKOV by allowing piecewise-constant intensities with different values at 
three time intervals at most. More recently, Jackson and Sharples (2002) developed the 
R package msm, imple
tate models to categorical processes observed at arbitrary times. Presently, Paes 
and Lima (2004) developed a SAS macro, called PTRANSIT, for estimating transition 
probabilities in semi-parametric models for recurrent events. Hui-Min et al. (2004) have 
developed a SAS macro for estimating transition para
ll distributions, log-logistic, etc.) k-state progressive Markov models.   
Although multi-state models may often be preferable to simple regression 
models, these models present, however, some limitations in practice. Most of the 
existent software for multi-state models assumes that the process is Markov and time-













. In addition, most of the programs available only 
eters estimates and do not supply graphical output for survival 
estimat
riendly R library for the analysis of 
surviva
onding numerical and graphical outputs obtained. In this way, users may easily 
analyze
 and (e) Non-parametric Markov model (NPM).   
After discussing the different proposed models in Chapter 3 and Chapter 4, we 
now focus on the description of tdc.surv, explaining how the data should be introduced 
and how to fit the different models. Finally, using Stanford Heart Transplant data and 
Stomach cancer data (see section 1.3) we provide some numerical results and some 






programs requires its own input data
provide regression param
es and for transition probabilities estimates. 
In this chapter, we present tdc.surv, a user-f
l data with time-dependent covariates. Specifically, the new software may be 
used to fit not only the time-dependent Cox model but also five different multi-state 
models including various transient states and one absorbing state. Advantages of this 
software include the same data input for fitting the different models while providing the 
corresp
 the results offered by the various models in order to compare them and make 
decisions accordingly.  
Our software can be used to fit five different multi-state models in continuous 
time, namely: (a) Cox Markov model (CMM); (b) Cox semi-Markov model (CSMM); 
(c) Homogeneous Markov model (HMM); (d) Non-homogeneous piecewise model 
(NHM);
  








have developed a library tdc.surv in R language to implement some of the 
propos
 (that is, when N=3), we obtain the illness-death 
model. 
 





ed approaches presented in Chapter 3 and 4. 
We consider the situation of having one categorical time-dependent covariate. 
Without loss of generality, we will assume that this covariate represents a treatment 
intervention (change) at a specified time. Continuous time-dependent covariates can be 
also accommodated in this framework, by transforming these variables into categorical 
ones. 
By considering a total of T possible treatments over the whole study period, we 
can use the multi-state model of Figure 5.1, including a total of N states: an initial state 
(e.g., diagnosis of illness), a number of T = N-2  transient (intermediate) states, and an 
absorbing state representing a terminal event of interest (e.g., death). In the particular 















The structure of the data input is as follows: each patient is identified by id. 
represented by two lines. For these patients, the first line represents the time period until 
e treat takes the value zero; the second line 
ge to the end of the follow-up, and 
so on). The remaining covariates (covariate1, covariate2,…) are the 
aking value 1 if there was 

















































Library tdc.surv requires only one input data file. Records in the data file must 
contain the following variables:  id, start, stop, event, treat, covariate1, covariate2,... 
and so on. 
Individuals without change in the time-dependent covariate are represented by only one 
line of data, whereas patients with a change in the time-dependent covariate must be 
change of treatment, and then variabl
represents the time period that passes from the chan
treat takes a new value (1 for the first alternative treatment, 2 for the second alternative 
treatment, and 
same for the two lines. For each row, variables start and stop mark the time interval 
(start, stop] for the data, while event is an indicator variable t
a death at time stop, and 0 otherwise. 
The input data file contains the available information about these patients. For 


























ngth 6, indicating the models to be fitted. Positions 1 to 6, 
corresp
odels TDCM, CMM 
and HM




In R language, programming is based on objects and computations are ba
functions that are specialized to carry out specific calculations. Our library is compose
of 11 functions and can fit all the proposed models by means of the following
li
tdc.surv<-function(mydata, ncov, formula, fixedpars, model, cut, prevalences=FALSE, 
writedata=FALSE,covmat=FALSE, graphcov=0, surv.plot=FALSE, plot.trans=FALSE) 
mydata: data input as described above. 
ncov: number of covariates included in the models. 
formula: vector of length ncov, indicating the column position of the covariates in the 
data file input. 
rs: vector of indices of parameters whose values will be fixed at their initial 
values during the optimisation. By default, fixedpars=NULL. 
model: vector of le
ond to TDCM, CMM, HMM, NHM, CSMM and NPM, respectively. By default, 
model=c(1,1,1,0,0,0). Elements of this vector indicate that only m
M, will be fitted.  
cut: selected cutpoint for fitting the 
nces: provides a rough indication of the goodness-of-fit of a multi-state mo
By default, prevalences=FALSE. 
writedata: provides generated data for the different models. By default, 
writedata=FALSE. 
covmat: provides the variance-covariance matrices. By default, covmat=FALSE. 
graphcov: displays the smoothed hazard ratio for continuous covariates. By default, 








al output for transition probabilities. By default, plot.trans=FALSE. 
Numerical results are printed on the screen. Among other results, the tdc.surv 
utput includes parameter estimations with standard errors for the covariates (for 
odels TDCM, CMM, CSMM, HMM, and NHM), transition rates (for HMM, NHM, 
and NPM
CMM, CS ical output 
includes: s l estimates; transition probabilities estima or HMM, NHM and 
NPM); and the smoothed hazard ratio estimate contin covariates (for TDCM, 
CMM, and CSMM).  
In case of HMM and NHM st can be performed to check for 
differences in the mortality trans e effect of a given covariate for two 
or more tra
To urvival data from the Stanford 
eart Tran ach Cancer study.  
The fit for all the proposed models for the Stanford data can be obtained easily 
y using the following command,  
tdc.surv(stanford, ncov=3, formula=c(6,7,8), model=c(1,1,1,1,1,1), cut=90) 
This command line yields a large output with numerical results for all models. 
e have chosen to present some of the results for the first three models (i.e., TDCM in 
able 5.2, HMM in Table 5.3 and CMM in Table 5.4). Results for all the output are 
own in Appendix B. We can also obtain some graphical outputs, such as the estimates 
f survival or the smooth hazard ratio for age at acceptance (continuous covariate). This 
 
surv.plot: graphical output for survival estimates. By default, surv.plot=FALSE. 
plot.trans: graphic




), hazard rates with corresponding 95 percent confidence intervals (for TDCM, 
MM, HMM, and NHM), and prevalence tables (for HMM). Graph
urviva tes (f
 for uous 
, Wald’s te
itions or to assess th
nsitions. 
illustrate this, we have used tdc.surv to fit s















output is sho e following 
input command: 




Table e-dependent Cox 
regress ata. 
***** ************* 
       * l   ******** 
********************************************************* 
 
wn in Figure 5.2. To obtain this graphical output, we use th
 ncov=3, formula=c(6,7,8), model=c(0,1,0,0,0,0), graphcov=1
5.2. Sample of the output for the tim
ion model.  Stanford Heart Transplantation d
***************************************















y -0.6376 0.3670 -1.74 0.
coef se(coef) z 
-0.0271 0.0134 2.02 0.









y 0.529 0.257     1.085   
 95% Confidence Interval  
coef) lower      upper 
1.027 1.001      1.055 
0.864           0.753     0.992 
Rsquare= 0.084  (max possible= 0.969) 
Likelihood ratio test = 15.1 on 3 df, p-value =0.00172 
Wald test = 14.5 on 3 df, p-value =0.00230 




















anford Heart Transplantation data. 
 
Table 5.3. Sample of the output for the homogeneous Markov 
model. St
***************************************************** 
  ** MULTI-STATE HOMOGENEOUS MARKOV MODEL ** 
***************************************************** 
**** UNDERGOING TRANSITIONS **** 
        T
from    2     3 
   1 69   30 
   2 24   45 
o 
     1  
        4    
        0    






         Stage 1         ge 3 
Stag 1907839   -0. 98618 
Stage 2  -0.00000000   -0.001761965   0.001761965 
   -0.000000000   0.000000000 
2           Stage 3 
.00000000    0.06581947    0.05447583 
Stage 2    0.00000000    0.00000000    0.07356488 
Stage 3    0.0
 
                        95% Confidence Interval 
                       Lowe  
Sta ge 2      1.       1.0391 97725 
Sta ge 3      1.       1.0199 93318 
Stage 2  Stage 3      1. 24528 
*** Estimat nts **** 
eline: 
              Stage 2            Sta
e 1  -0.0 013679774   0.0053
Stage 3  -0.00000000
 
For age: 
                    Stage 1           Stage 
Stage 1    0
0000000    0.00000000    0.00000000 
                            
      HR    r          Upper
ge 1 - Sta 068034 46      1.0
ge 1 - Sta 055987 30      1.0




















Table 5.4. Sample of the output for the Cox Markov model. Stanford Heart 
Transplantation data. 
************************************************************************************ 
  ** COX MARKOV MODEL. SEPARATED FITTED COX MODELS FOR EACH TRANSITION ** 
************************************************************************************ 





































95% Confidence Interval 
Lower        Upper 
1.004           1.060 
0.873           1.150 
0.565           1.940 
  
 
Rsquare= 0.054  (max possible= 0.993) 
Likelihood ratio test = 5.77 on 3 df, p-value =0.123 
Wald test = 5 on 3 df, p-value =0.172 
Score (logrank) test = 5.06 on 3 df, p-value =0.167 
-2*Log-likelihood: 509.5638 
 































Lower       Upper 
0.984         1.057 
0.606         0.936 
0.229         2.768 
 
exp(co







Wald test = 8.19 on 3 df, p-value=0.0422 
-2*Log-likelihood: 214.9848 
= 0.08  (max possible= 0.886) 
od ratio test = 8.62 on 3 df, p-value=0.0347 
Score (logrank) test = 8.67 on 3 df, p-value =0.034 
 





























95% Confidence Interval 






1.008      1.100 
0.808      1.180 
0.181      1.080 
 
Rsquare= 0.151  (max possible= 0.987) 
Likelihood ratio test = 11.3 on 3 df, p-value =0.0102 
Wald test = 10.2 on 3 df, p-value =0.0167 


















Smooth hazard ratio (along with 95%CI) for age (CMM)
From stage 1 to stage 2






Smooth hazard ratio (along with 95%CI) for age (CMM)
From stage 1 to stage 3






Smooth hazard ratio (along with 95%CI) for age (CMM) Survival estimate (CM













From stage 2 to stage 3
M)
 




e should notice that, although the Stanford dataset requires a multi-state model 
with only two transient states, the software we offer can be used in more general 
situations, which can be formulated by the model represented in Figure 5.1. For this 
purpose, we shall use the stomach cancer data. In this study, patients may pass from the 
initial state (surgical intervention time) through one of two mutually exclusive states 
(‘metastases’ and ‘recurrence’) to an absorbing state (death). We therefore may use the 












. Multi-state m or Stomach cancer data. 
For this data e p t a s  the output from the CMM (Table 5.5) 
. The complete output is shown in Appendix B. We also 












Figure 5.3 odel f
 
base w resen ample of
and HMM (Table 5.6) approach






1. Alive and 
disease-free

























* FROM  1 TE   
c p 
0 0.93 
0 1. 0. 0.76 
exp(coef) oef) r.95 r.95 
 p .80
st  2 5
 =  2 5
core (logrank) test = 0.09  on 2 df,   p=0.955 
*Log-likelihood: 567   
T A
ef p 
ex 0.6585 1.93 0.3391 1.94 0.052 
ge 0.0169 1.02 0.0127 1.33 0.180 
 
 
 exp(coef) exp(-coef) lower.95 upper.95 
Sex 1.93 0.518 0.994 3.76 
Age 1.02 0.983 0.992 1.04 
 
Rsquare= 0.015   (max possible= 0.716 ) 
Likelihood ratio test= 5.21  on 2 df,   p=0.074 
Wald test                 = 4.9  on 2 df,   p=0.0862 
Score (logrank) test = 5   on   2 df,   p=0.0822 
 
-2*Log-likelihood: 428.8344  
 
 
Table 5.5. Sample of the output for the Cox Markov model. Stomach Cancer da
***********************************************************************




****  STATE TO STA  2  *****
n= 345  
 












 exp(-c lowe uppe
Sex 1.03 0.975 0.593 1.77 
Age 1.00 0.997 0.982 1.02 
 
Rsquare= 0   (max
Likelihood ratio te
ossible= 0
= 0.09  on
7 ) 
df,   p=0.9 5 







n= 345  
E 1 TO ST TE 3  *****  
 















able 5.6. Output for the homogeneous Markov model. Stomach Cancer data. 
****************************************************************************  
                   ***** MULTI-STATE HOMOGENEOUS MARKOV MODEL *****      
****************************************************************************  
**** Estimated coefficients *****  
baseline 
Stage 1 Stage 2 Stage 3 Stage 4
tage 1 -0.00066 0.00010 7.587e-05 0.00048
tage 2 0.00000 -0.00189 0.00000 0.00189
tage 3 0.00000 0.00000 -1.768e-03 0.00176
tage 4 0.00000 0.00000 0.00000 0.00000
sex 
HR L95 U95 
tage 1 - Stage 2 1.06251 0.61473 1.83645 
tage 1 - Stage 3 2.01196 1.03213 3.92198 
tage 1 - Stage 4 0.97368 0.75767 1.25128 
tage 2 - Stage 4 0.41117 0.21701 0.77905 
tage 3 - Stage 4 1.22044 0.55678 2.67513 
age 
HR L95 U95 
tage 1 - Stage 2 1.01033 0.98880 1.03233 
tage 1 - Stage 3 1.02516 0.99925 1.05174 
tage 1 - Stage 4 1.01400 1.00398 1.02411 
tage 2 - Stage 4 1.00520 0.97407 1.03732 















































Probability estimates for the mortality intensity (HMM)













Transition Probability estimate from stage 1 to stage  2 (HMM)
















Transition Probability estimate from stage 1 to stage  3 (HMM)















Figure 5.4. Graphical output for the homogeneous Markov model. Stomach Cancer 
data. 
  












































































Concluding remarks and future research 









s for survival 




We have presented and discussed the application of event history analysis using 
multi-state models for several medical applications. The work described in this thesis 
contains several contributions to the development of multi-state model
data. First, we have presented a comprehensive survey of multi-state models. Secondly, 
this work contains a comparison of different multi-state models, including in its 
comparisons the commonly used Cox model. Advantages and disadvantages for both 
methods have been discussed. Possible advantages of using multi-state models are 
illustrated through simulation studies, addressing some issues that cannot be fully 
explored through the Cox model. Thirdly, new software has been developed to fit both 
Markov and semi-Markov models. These models have been applied to data from 
clinical studies, providing some guidance about the use of these methodologies for 
studying the evolution of the disease (e.g. hypothesis testing procedures, methods for 
model checking, goodness-of-fit, etc.). Finally, the main methodological contribution of 
this thesis has been the proposal of a new approach for the inference in multi-state 
modelling which overcomes the Markov assumption problem. We believe that this is 
the first non-parametric modelling approach completely free from the Markov 
assum
applied to data from the PROVA clinical trial. Some asymptotic results were obtained 












This constitutes a topic for our future research. Besides, we 
conside
practical situations, however, it might be interesting to use the individual characteristics 
tion probabilities conditionally on covariates. The issue 
f how to incorporate covariates in the transition probabilities has already been 
conside
covariates. These authors 
direct estimation of the . Thi
previously using a Cox proportional hazards model (Andersen et al., 1991; Aalen et al., 
2001). We believe that similar procedures can also be used for our estimators. 
 
tion methods proposed for the transition probabilities. In 
 
6.2 Future research 
 
As mentioned in Chapter 4, some asymptotic results for the introduced 
estimators are still missing. 
r now some open questions that will be investigated in the future. 
 
The inclusion of covariates in the estimation methods proposed for the transition 
probabilities. The estimation methods developed in Chapter 4 provide important 
measures for making long-term predictions. Since these quantities do not depend on 
patients’ characteristics, we are assuming that they are the same for all subjects. In 
to obtain estimates of the transi
o
red for the Aalen-Johansen estimators. For example, Helms et al., (2004) use 
pseudo-values to obtain a relationship between the Aalen-Johansen estimator and the 
use the approach suggested by Andersen et al. (2003) for a 
transition probabilities s problem has also been studied 
Non-Markovian estima
Chapter 4, we introduced two different possibilities for the estimation of transition 
probabilities, denoted by m ( ),hjp s t  and m ( ),hjp s t∗ . Remaining is the question of the 
relative efficiency of the different possible estimates. 
 







commonly used. The simplest Markov assumption is that future evolution only depends 
on the current state at time t; in other words, the history of the process is summarized by 
6). For simplicity, we consider the illness-death model, for which the Markov 
ssumption is only present on transition from the disease state into the death state. We 
consider the null hypothesis that the data come from a Markov process: 
, 
. 
Testing the Markov assumption. In multi-state modelling, the Markov assumption is 
the state occupied at time t. 
Traditionally, the Markov assumption may be checked, among others, by 




against the general alternative, 
:  The Process is MarkovH
1 :  The Process is not MarkovH 
Then we must show that the time spent in the healthy state (past) is not 
important on the transition from the disease state to death. For doing that, let 
 "time spent in state 1"Z = , and t the current time. Fitting a model 
( ) ( ) { }23 230 expt t Zα α β= , we now need to test 0β = , i.e., we have the null hypothesis, 
0 :  =0H β , 
gainst the general alternative, a
1 :  0H β ≠ . 
his would assess the assumption that the transition rate from the disease state into 
eath is unaffected by the time spent in the previous state.  
Our aim is to use the estimation methods developed in Chapter 4 for testing the 




( )22 ,p s t  under the Markov assumption (Aalen-Johansen estimator, see [3.7]), 
  







xpressed by n ( )22 ,AJp s t , and through non-Markov approach (see [4.9]), denoted by e
n ( )22 ,NMp s t . We therefore consider the null hypothesis that the data come from a Markov 
ected that the difference between the two 
uantities, 
process. Under the null hypothesis, it is exp
n ( )22 ,AJp s t  and n ( )22 ,NMp s tq  are, in some sense, smaller. Here, one main 
ifficulty arises from the fact that those transition probabilities depend on both times s 
nd t.    
Software implementation. Multi-state non-Markov models have not been widely 
applied in medicine. Methodological contributions for analysing such models are still 
scarce in the literature. One main difficulty is the unavailability of software. Work is in 
progress to provide software for the estimation methods developed in Chapter 4.    
pplication to other datasets. It would also be interesting to apply some of the models 
escribed in this thesis to other datasets, particularly ones with non-linear covariate 
ffect on the transition intensities. We plan to consider the application of these methods 
 a breast cancer dataset from Galicia and to a dataset on AIDS (“Registro Galego de 















































































nalytic expressions for the transition probabilities in the 
vario
Here we present the analytic expressions for the transition probabilities, 
A.1 A
us setting schemes presented in section 4.3.1.3. 
 
( )22 ,p s t  in the various setting schemes presented in section 4.3.1.3. In all settings, 
and  are exponentially distributed with rate parameter 
12T  
13T 12α  and 13α  respectively, 
assuming that ( )12F ⋅  and ( )13F ⋅  are the distribution functions of 12T  and 13T , 
respectively.  
Assuming that ( )12 13 23, ,T T T  are mutu ly independent times, the expression f
the tr nsition iti
al or 
a  probabil es, ( )22 ,p s t  is 
( ) ( )( )
( ) ( )
( ) ( )
( ) ( ) ( )
( ) ( ) ( )
12 23 12 13 12
22
12 23 12 13 12
23 13 12 120
23 13 12 120
23 13 120
23 13 120
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T s u T u T u dA
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where  is the cumulative hazard of  .  
 
Lemma. Assume that 
( )12A ⋅ 12T
( )12 13 23, ,T T T
23T
 are mutually independent times. Then, the process 












Assume that the process is Markovian. Then, because equation [4.4] is valid for 
all 
Proof. 
( ]0, s , and since ( )12 13 23, ,T T T  are mutually independ0s ∈ ent times, we obtain, 
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distribution, the unique distribution function satisfying this property. 
On the other hand, if we assume that  is exponentially distributed, then for 
any  with 
23 >TP
12 23 12 23 12+ > + > =, ,T T t T T s T sP
)
23 12 12 13
                         −t s
This lack of memory is referred to as the Markovian property from 
23T
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F i  is the conditional distribution function of  given that s  and 
. 
Thus, satisfying [4.4], the process is Markovian.
  
Analytic expression for setting 1. 
Assuming that  are mutually independent and  is exponentially 
distributed with rate parame
12T 12 23+ ≥T T
13 12≥T T
,  
( )12 13 23, ,T T T 23T
ter 23α , from the above expression we have 
( ) ( ) ( ) ( )( )( ) ( ) ( ) ( )
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Analytic expression for setting 2. 
 According to the above Lemma this sampling scheme leads to a non-Markovian 
process, since we assume that  is Weibull with shape parameter 2 and scale 
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Analytic expression for setting 3. 
Assuming that  for some constant , , it is clear that the 
process is non-Markovian.  Furthermore, times 
23 12T c T= × c 0c >
( )12 13 23, ,T T T  are not mutually 
independent, since  and  are dependent. Then, the expression for the transition 
probabilities,
12T 23T
 ( )22 ,p s t  is now given by 
( ) ( )( )
( ) ( )
( ) ( )
( ) ( ) ( )( )( )
( ) ( ) ( )
12 23 12 13 12
22
12 23 12 13 12
23 13 12 120
23 13 12 120
13 12 12 121
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Figure A.1: Curves obtained for setting 1 with , 10=s 100=N  and 0% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 
























































Figure A.2: Curves obtained for setting 1 with , 25=s 100=N  and 0% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 



















































Figure A.3: Curves obtained for setting 1 with , 10=s 200=N  and 0% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 

























































Figure A.4: Curves obtained for setting 1 with , 25=s 200=N  and 0% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 





















































Figure A.5: Curves obtained for setting 1 with , 10=s 100=N  and 25% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 
















































Figure A.6: Curves obtained for setting 1 with 25=s , 100=N  and 25% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 









































r Aalen-Johansen estimator (solid line) and non-Markovian estimator 




































































observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 



























































r Aalen-Johansen estimator (solid line) and non-Markovian estimator 



















































: Curves obtained for setting 1 with , 25=s 100=N  and 49% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 



















































observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 


















































Figure A.12: Curves obtained for setting 1 with 25=s , 200=N  and 49% of censored 
bservations undeo r Aalen-Johansen estimator (solid line) and non-Markovian estimator 




















































10=s , 100=N  and 0% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 




















































Figure A.14: Curves obtained for setting 2 with 25=s , 100=N  and 0% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 

















































Figure A.15: Curves obtained for setting 2 with 25=s , 100=N  and 27% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 























































Figure A.16: Curves obtained for setting 2 with , 10=s 100=N  and 52% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 




















































25=s , 100=N  and 52% of censored Figure A.17: Curves obtained for setting 2 with 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 
























































Figure A.18: Curves obtained for setting 2 with , 10=s 200=N  and 52% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 
























































Figure A.19: Curves obtained for setting 2 with 25=s , 200=N  and 27% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 





















































Figure A.20: Curves obtained for setting 3 with , 10=s 100=N  and 0% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 























































Figure A.21: Curves obtained for setting 3 with , 25=s 100=N  and 0% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 

























































Figure A.22: Curves obtained for setting 3 with , 10=s 100=N  and 32% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 

























































Figure A.23: Curves obtained for setting 3 with , 25=s 100=N  and 32% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 





















































Figure A.24: Curves obtained for setting 3 with , 10=s 200=N  and 32% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 






























































25=s , 200=N  and 32% of censored 
 
 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 

















































10=s , 100=N  and 32% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 
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Time
Figure A.27: Curves obtained for setting 3 with 25=s , 100=N  and 54% of censored 
bservations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 























































Figure A.28: Curves obtained for setting 3 with , 10=s 200=N  and 54% of censored 
observations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 

























































Figure A.29: Curves obtained for setting 3 with 25=s , 200=N  and 54% of censored 
bservations under Aalen-Johansen estimator (solid line) and non-Markovian estimator 
























































































B.1 Complete output for the Stanford Heart Transplantation 
study. 
Command line: 




                       ***** TIME-DEPENDENT COX REGRESSION MODEL *****      
*****************************************************************************  
 
 coef exp(coef) se(coef) z p 
Age 0.0271 1.027 0.0134 2.02 0.043 
Year -0.1463 0.864 0.0704 -2.08 0.038 
Surgery -0.6376 0.529 0.3670 -1.74 0.082 
 
 exp(coef) exp(-coef) lower.95 upper.95 
age 1.027 0.973 1.001 1.055 
year 0.864 1.158 0.753 0.992 
surgery 0.529 1.892 0.257 1.085 
 
Rsquare= 0.084   (max possible= 0.969 ) 
Likelihood ratio test= 15.1  on 3 df,   p=0.00172 
Wald test                 = 14.5  on 3 df,   p=0.00230 























































tdc.surv(s rd, nc m 6,7,8), model=c(0,1,0,0,0,0), surv.plot=TRUE, 
hcov= t.tr
 
** ** **** ** *** ***************************  
**** COX M I  MODELS FOR EACH TRANSITION *****  
******** * ******************************** 
O TE 1 ATE *  
= 103  




oef) lower.95 upper.95 
1.03 0.969 1.004 1.06 
year 1.00 0.999 0.873 1.15 
surgery 1.05 0.954 0.565 1.94 
 
 
Rsquare= 0.054   (max possible= 0.993 ) 
Likelihood ratio test= 5.77  on 3 df,   p=0.123 
Wald test                  = 5  on 3 df,   p=0.172 
Score (logrank) test = 5.06  on 3 df,   p=0.167 
 
-2*Log-likelihood: 509.5638  
 
***** FROM STATE 1 TO STATE 3  *****  
n= 103  
 
 coef exp(coef) se(coef) z p 
age 0.0198 1.020 0.0181 1.094 0.270 
year -0.2833 0.753 0.1110 -2.553 0.011 
surgery -0.2288 0.796 0.6361 -0.360 0.720 
 
 exp(coef) exp(-coef) lower.95 upper.95 
age 1.020 0.98 0.984 1.057 
year 0.753 1.33 0.606 0.936 
surgery 0.796 1.26 0.229 2.768 
 
Rsquare= 0.08   (max possible= 0.886 ) 
Likelihood ratio test= 8.62  on 3 df,   p=0.0347 
Wald test                 = 8.19  on 3 df,   p=0.0422 
core (logrank) test = 8.67  on 3 df,   p=0.034 





















***** FR M STA  TO ST  2  ****
n
 
 coef exp(coef) se(coe
age 0.03111 1.03 0.0140 
year 0.00075 1.00 0.0695 
















***** FROM STATE 2  TO STATE 3  *****  
= 69  
14 2.318 0.020 
-0.0230 0.977 0.0969 -0.238 0.810 
ge 1.051 0.952 1.008 1.10 
08 1.18 
0.442 2.263 0.181 1.08 
 
Rsquare= 5  (m os e= 0.987 ) 
ikelihood ratio test= 11.3  on 3 df,   p=0.0102 
ald test                 = 10.2  on 3 df,   p=0.0167 
3 df,   p=0.0137 
n
 
 coef exp(coef) se(coef) z p 
ge 0.0496 1.051 0.02a
year 
surgery -0.8165 0.442 0.4549 -1.795 0.073 
 
 exp(coef) exp(-coef) lower.95 upper.95 
a
year 0.977 1.023 0.8
surgery 
 
0.1 1  ax p sibl
L
W









Smooth haz alo 5% e (CMM)ard ratio ( ng with 9 CI) for ag
From stage 1 to stage 2






Smooth hazard ratio (along with 95%CI) for age (CMM)
From stage 1 to stage 3






Smooth haz l % e (CMM)ard ratio (aong with 95 CI) for ag
From stage 2 to stage 3



























c.surv(stanford, n 3, fo =c(6 , model=c(0,0,1,0,0,0), surv.plot=TRUE, 
t RU
*********************************************************************  
  ***** MUL ATE GENE S MARKOV MODEL *****      
***************** *** **** ***********************************  
 T  **
rom 1 2 3 
1 4 69 30 
d: 1727.033  




Stage 1 Stage 2 Stage 3 
8467
 Stage 3 
age 1 -0.01907 0.01367 0.00539 
176 0.00176 
000 0.00000 
HR L95 U95 
 1 - Stage 2 1.06803 1.03914 1.09772 
598 1.01993 1.09331 
633 1.03021 1.12452 
 
td cov= rmula ,7,8)











***** Undergoing ransitions ***  
             to 
f





***** Estimated coefficients *****  
$logbaseline 
 Stage 1 Stage 2 Stage 3 
Stage 1 0.00000 -4.29183 -5.22161




 Stage 1 Stage 2 St
Stage 1 0.00000 0.06581 0.05447 
Stage 2 0.00000 0.00000 0.07356 
00 0.00000 Stage 3 0.00000 0.000
 
$
 Stage 1 Stage 2 Stage 3 
Stage 1 0.00000 -0.02495 -0.3
Stage 2 0.00000 0.00000 0.10324 




Stage 1 0.00000 0.31318 -0.04225
Stage 2 0.00000 0.00000 -1.1
Stage 3 0.00000 0.00000 0.00000 
 
 $baseline 
 Stage 1 Stage 2
St
Stage 2 0.00000 -0.00





Stage 1 - Stage 3 1.05







 HR L95 U95 
Stage 1 - Stage 2 0.97535 0.85212 1.11639 
Stage 1 - Stage 3 0.73929 0.59477 0.91892 
Stage 2 - Stage 4 1.10876 0.92804 1.32467 
 
$surgery 
 HR L95 U95 
Stage 1 - Stage 2 1.36776 0.73678 2.53911 
Stage 1 - Stage 3 0.95862 0.27721 3.31492 
Stage 2 - Stage 4 0.30584 0.12812 0.73005 
 
 
***** Estimate of the ratio of the progression rate 1-3 *****  
***** into   death   to   the  corresponding  rate  2-3 *****  
Estimate: 3.063975  
SE: 0.7976103  
 
 
**** WALDS TEST TO CHECK FOR DIFFERENCES BETWEEN MORTALITY INTENSITIES 
****   
LET H0 BE THE HYPOTHESIS OF NON-DIFFERENCES BETWEEN MORTALITY INTENSITIES  
H0 produces a chisquare statistic of: 18.50131  
ith a p-value of: 1.697872e-05  
*** WALDS TEST TO CHECK FOR DIFFERENCES BETWEEN COVARIATE  1  IN THE 
RANSITION INTENSITIES ****   
YPOTHESIS OF NON-DIFFERENCES BETWEEN COVARIATE  1  IN THE 
ENSITIES  
DS TEST TO CHECK FOR DIFFERENCES BETWEEN COVARIATE  2  IN THE 
ION INTENSITIES ****   
E 
K FOR DIFFERENCES BETWEEN COVARIATE  3  IN THE 
****   
NON-DIFFERENCES BETWEEN COVARIATE  3  IN THE 
e statistic of:   
ith a p-valu 22
jour *
e 
e 1        Stage 2  
2    5
    






LET H0 BE THE H
RANSITION INTT
H0 produces a chisquare statistic of: 0.4884893  





LET H0 BE THE HYPOTHESIS OF NON-DIFFERENCES BETWEEN COVARIATE  2  IN TH
TRANSITION INTENSITIES  
H0 produces a chisquare statistic of: 8.112579  
with a p-value of: 0.01731314  
 
 
**** WALDS TEST TO CHEC
TRANSITION INTENSITIES 
LET H0 BE THE HYPOTHESIS OF 
TRANSITION INTENSITIES  
H0 produces a chisquar
e of: 0.02
7.608883





n times ** **  
$


























robability estimates for the mortality intensity (HMM)
From s
P













Transition Probability estimate from stage 1 to stage  2 (HMM)
















rd, , fo odel=c(0,0,0,1,0,0), surv.plot=TRUE, 
=1, cut=90, plot.trans=TRUE) 
** ** * *******************************  
                    ***** MULTI-STATE NON-HOMOGENEOUS MODEL *****                
****************************************************************************  
























***** Estimated coefficients *****  
$logbasel
 Stage 1 Stage 2 Stage 3 
Stage 1 0.00000 -3.94184 -4.99322
Stage 2 0.00000 0.00000 
Stage 3 0.00000 0.00000 0.00000 
 
$age 
 Stage 1 Stage 2 Stage 3 
Stage 1 0.00000 0.02836 0.02265 








 Stage 1 Stage 2 Stage 3 
surgery 
7449
Stage 1 Stage 2 Stage 3 
41 0.00678 
0.00000 -0.00488 0.00488 
0.00000 0.00000 
age 
HR L95 U95 
.02876 1.00070 1.05761 
.02291 0.98461 1.06269 
tage 2 - Stage 4 1.05230 1.00008 1.10724 
year 
HR L95 U95 
tage 1 - Stage 2 0.97264 0.84709 1.11679 
0.57169 0.91410 
tage 2 - Stage 4 0.97477 0.78384 1.21221 
H U95 
 Sta 0 97309 
 Sta 8 94325 
 Sta 1 03844 
at atio of n rate 1-3 *****  
* into   d  t po te  2-3 *****  
 1.3
244
*** WALDS TEST TO CHECK FOR DIFFERENCES BETWEEN MORTALITY INTENSITIES 
ET H0 BE T O  O IFFERENCES BETWEEN MORTALITY INTENSITIES  
ces e statistic of 6  
valu 7
LD O  F ERENCES BETWEEN COVARIATE  1  IN THE 
RANSITION INTENSITIES ****   
E THE HYPOTHESIS OF NON-DIFFERENCES BETWEEN COVARIATE  1  IN THE 
RANSITIO S
ces e statistic o 33  
valu 8
Stage 1 0.00000 -0.02773 -0.32448
Stage 2 0.00000 0.00000 -0.02554
 0.00000 Stage 3 0.00000 0.00000
 
$
 Stage 1 Stage 2 Stage 3 
Stage 1 0.00000 0.04078 -0.1
Stage 2 0.00000 0.00000 -1.96772




Stage 1 -0.02619 0.019
Stage 2 




Stage 1 - Stage 2 1










 R L95 
Stage 1 - ge 2 1. 4162 0.54989 1.
Stage 1 - ge 3 0. 3987 0.23966 2.
Stage 2 - ge 4 0. 3977 0.01881 1.
 
 
***** Estim e of the r





Estimate: 88920  
SE: 0.467 3  
 
*
****   








**** WA S TEST T  CHECK OR DIFF
T
LET H0 B
T N INTEN ITIES  
H0 produ a chisquar f: 0.80749







**** WALDS TEST TO CHECK FOR DIFFERENCES BETWEEN COVARIATE  2  IN THE 
RANSITIO S **
BE O O IFFERENCES BETWEEN COVARIATE  2  IN THE 
TIO S
ces f   
valu 3
*** WALDS TEST T ECK IFFERENCES BETWEEN COVARIATE  3  IN THE 
TE  **
- NCES BETWEEN COVARIATE  3  IN THE 
TE   
48
p-value of: 0.1737698  
e
e 












T N INTEN ITIES **    






e statistic o : 4.945467
with a p- e of: 0.084 5396  
 
 
* O CH FOR D
TRANSITION IN NSITIES **   
LET H0 BE THE HYPOTHESIS OF NON DIFFERE
TRANSITION IN
0 produces a chisqu
NSITIES




***** Sojourn tim s *****  
$estimate 




 Stage 1       Stage 











***** Estimated coefficients *****  
$logbaseline 
 Stage 1 Stage 2 Stage 3 
824 -7.92574Stage 1 0.00000 -9.42




 Stage 1 Stage 2 Stage 3 
Stage 1 0.00000 -0.05918 -0.03598
00 0.04552 Stage 2 0.00000 0.000
age 3 0.00000 0.00000 0.St
 
$year 
 Stage 1 Stage 2 Stage 3 
Stage 1 0.00000 2.76868
Stage 2 0.00000 0.00000 -0.03432
Stage 3 0.00000 0.00000 0.
 
$surgery 
 Stage 1 Stage 2 Stage 3 
Stage 1 0.00000 1.29376 -5.42610
Stage 2 0.00000 0.00000 -0.23792







 Stage 1 Stage 2 Stage 3 
0.00008 0.00036 
 2 0.00000 -0.00065 0.00065 
0.00000 0.00000 
HR L95 U95 
age 1 - Stage 2 0.94253 0.80882 1.09835 
Stage 1 - Stage 3 0.96465 0.84461 1.10175 
Stage 2 - Stage 4 1.04657 0.97389 1.12468 
 
$year 
 HR L95 U95 
Stage 1 - Stage 2 15.93763 0.81377 312.1337
Stage 1 - Stage 3 1.48374 0.62133 3.54317 
Stage 2 - Stage 4 0.96626 0.68381 1.36536 
 
$surgery 
 HR L95 U95 
Stage 1 - Stage 2 3.64650 2.937e-01 4.526e+01
Stage 1 - Stage 3 0.00440 1.024e-37 1.889e+32
Stage 2 - Stage 4 0.78825 2.637e-01 2.35627 
 
       
***** Estimate of the ratio of the progression rate 1-3 *****  
***** into   death   to   the  corresponding  rate  2-3 *****  
Estimate: 0.5493616  
SE: 5.539668  
 
**** WALDS TEST TO CHECK FOR DIFFERENCES BETWEEN MORTALITY INTENSITIES 
****   
LET H0 BE THE HYPOTHESIS OF NON-DIFFERENCES BETWEEN MORTALITY INTENSITIES  
0 produces a chisquare statistic of: 0.003528584  
ith a p-value of: 0.952632  
T TO CHECK FOR DIFFERENCES BETWEEN COVARIATE  1  IN THE 
0 produces a chisquare statistic of: 2.159090  
RANSITION INTENSITIES ****   
ET H0 BE THE HYPOTHESIS OF NON-DIFFERENCES BETWEEN COVARIATE  2  IN THE 
ces a chisquare statistic of: 4.037749  
ith a p-value of: 0.1328048  
 WAL T F FE BE N COVARIATE  3  IN THE 
SITI NS *
 BE PO SIS O DIF CE EEN COVARIATE  3  IN THE 
TI NS
0 produces a chisquare statistic of: 1.212583  
ith a p-value of: 0.5453697  
Stage 1 -0.00044 
Stage










TRANSITION INTENSITIES ****   
LET H0 BE THE HYPOTHESIS OF NON-DIFFERENCES BETWEEN COVARIATE  1  IN THE 
TRANSITION INTENSITIES  
H
with a p-value of: 0.3397500  
 
**** WALDS TEST TO CHECK FOR DIFFERENCES BETWEEN COVARIATE  2  IN THE 
T
L
























 1       e 2  
    424  
SE 








  Stage 1          Stage 2  















0 50 100 150 200 250 300 350
From stage 1
From stage 2
 estimates for the mortality intensity (NHM, first branch)
 
mand
(s  n , for (6 odel=c(0,0,0,0,1,0), surv.plot=TRUE, 
raphcov= a
** **** **** * **************************************  
 SE RKO EL. S TED OX MODELS FOR EACH TRANSITION ***  
** **** **** * **************************************  
ef) se(coef) z p 
0.0140 2.2255 0.026 
ear 0.00075 1.00 0.0695 0.0108 0.990 







tdc.surv tanford, cov=3 mula=c ,7,8), m












******* ****** ****** ******** *****
 
 
***** FROM STATE 1 TO STATE 2  *****  
n= 103  
 
 coef exp(co









 exp(coef) exp(-coef) lower.95 upper.95 
age 1.03 0.969 1.004 1.06 
year 1.00 0.999 0.873 1.15 
surgery 1.05 0.954 0.565 1.94 
 
 
Rsquare= 0.054   (max possible= 0.993 ) 
Likelihood ratio test= 5.77  on 3 df,   p=0.123 
Wald test                  = 5  on 3 df,   p=0.172 
Score (logrank) test = 5.06  on 3 df,   p=0.167 
 
-2*Log-likelihood: 509.5638  
***** FROM STATE 1 TO STATE 3  *****  
n= 103  
 
 coef exp(coef) se(coef) z p 
age 0.0198 1.020 0.0181 1.094 0.270 
year -0.2833 0.753 0.1110 -2.553 0.011 
surgery -0.2288 0.796 0.6361 -0.360 0.720 
 
 exp(coef) exp(-coef) lower.95 upper.95 
age 1.020 0.98 0.984 1.057 
year 0.753 1.33 0.606 0.936 
surgery 0.796 1.26 0.229 2.768 
 
Rsquare= 0.08   (max possible= 0.886 ) 
Likelihood ratio test= 8.62  on 3 df,   p=0.0347 
ald test                 = 8.19  on 3 df,   p=0.0422 
core (logrank) test = 8.67  on 3 df,   p=0.034 
*Log-likelihood: 214.9848  
TE 2  TO STATE 3  *****  
coef) z p 
0.0477 1.049 0.0217 2.203 0.028 
-0.0343 0.966 0.0966 -0.355 0.720 
ear 0 1.0 0.8 1.17 
sur 0. 34 17 04 
 
Rsqu = 0. p
Likel od r 1















n= 69  
 
 coef exp(coef) se(
age 
year 
surgery -0.8512 0.427 0.4522 -1.882 0.060 
 
 exp(coef) exp(-coef) lower.95 upper.95 




gery 7 2. 3 0. 6 1.
are 154   (max ossible= 0.991 ) 
iho atio test= 1 .6  on 3 df,   p=0.00906 
             = 10.4  on 3 df,   p=0.0155 
e (l nk) test = 1 .9  on 3 df,   p=0.0124 










Smooth hazard ratio (along with 95%CI) for age (CSMM)
From stage 1 to stage 2






Smooth hazard ratio (along with 95%CI) for age (CSMM)
From stage 1 to stage 3






Smooth hazard ratio (along with 95%CI) for age (CSMM)
From stage 2 to stage 3

























                         ***** NON-PARAMETRIC MULTI-STATE MODEL *****                
*****************************************************************************  
 
Times Survival P11 P12 P13 
0 1 1 0 0 
1 0,990291 0,970874 0,019417 0,009709
2 0,961165 0,912621 0,048544 0,038835
3 0,932039 0,854369 0,07767 0,067961
4 0,932039 0,834951 0,097087 0,067961
4,5 0,932039 0,825243 0,106796 0,067961
5 0,912621 0,796117 0,116505 0,087379
6 0,902913 0,776699 0,126214 0,097087
8 0,893204 0,747573 0,145631 0,106796
9 0,883495 0,737864 0,145631 0,116505





11 0,883495 0,718447 0,165049 0,116505
12 0,873786 0,679612 0,194175 0,126214
13 0,873786 0,669903 0,203884 0,126214
16 0,84466 0,650485 0,194175 0,15534 
17 0,834952 0,631068 0,203884 0,165049
18 0,825243 0,61165 0,213592 0,174757
19 0,825243 0,601942 0,223301 0,174757
20 0,825243 0,592233 0,23301 0,174757
21 0,805825 0,543689 0,262136 0,194175
23 0,805825 0,533981 0,271845 0,194175
25 0,805825 0,524272 0,281553 0,194175
26 0,805825 0,504854 0,300971 0,194175
27 0,805825 0,485437 0,320388 0,194175
28 0,796117 0,466019 0,330097 0,203883
30 0,786408 0,466019 0,320388 0,213592
31 0,786408 0,446602 0,339806 0,213592
32 0,776699 0,417476 0,359223 0,223301
33 0,776699 0,407767 0,368932 0,223301
35 0,76699 0,398058 0,368932 0,23301 
36 0,757282 0,368932 0,38835 0,242718
37 0,747573 0,339806 0,407767 0,252427
38 0,747573 0,330097 0,417476 0,252427
39 0,737864 0,330097 0,407767 0,262136
40 0,718447 0,31068 0,407767 0,281553
41 0,718447 0,291262 0,427184 0,281553
43 0,708738 0,291262 0,417476 0,291262
45 0,699029 0,291262 0,407767 0,300971
46 0,699029 0,271845 0,427184 0,300971
50 0,68932 0,262136 0,427184 0,31068 
51 0,679612 0,242718 0,436893 0,320388
53 0,669903 0,242718 0,427184 0,330097
57 0,669903 0,23301 0,436893 0,330097
58 0,660194 0,223301 0,436893 0,339806
60 0,660194 0,213592 0,446602 0,339806
61 0,650485 0,213592 0,436893 0,349515
66 0,640777 0,213592 0,427184 0,359223
67 0,640777 0,194175 0,446602 0,359223
68 0,621359 0,194175 0,427184 0,378641
69 0,611651 0,184466 0,427184 0,38835 
71 0,611651 0,174757 0,436893 0,38835 
72 0,592233 0,174757 0,417476 0,407767
77 0,582524 0,174757 0,407767 0,417476
78 0,572816 0,165049 0,407767 0,427184
80 0,563107 0,165049 0,398058 0,436893
81 0,553398 0,165049 0,38835 0,446602
83 0,553398 0,145631 0,407767 0,446602
85 0,543689 0,135922 0,407767 0,456311
90 0,533981 0,135922 0,398058 0,466019
96 0,524272 0,126214 0,398058 0,475728
100 0,514563 0,126214 0,38835 0,485437





109 0,504854 0,116505 0,38835 0,495146
110 0,495146 0,116505 0,378641 0,504854
131 0,495146 0,116505 0,378641 0,504854
139 0,495146 0,106796 0,38835 0,504854
149 0,485437 0,097087 0,38835 0,514563
153 0,475728 0,097087 0,378641 0,524272
160 0,475728 0,087379 0,38835 0,524272
165 0,466019 0,087379 0,378641 0,533981
180 0,466019 0,087379 0,378641 0,533981
186 0,456311 0,087379 0,368932 0,543689
188 0,446602 0,087379 0,359223 0,553398
207 0,436893 0,087379 0,349515 0,563107
210 0,436893 0,07767 0,359223 0,563107
219 0,427185 0,07767 0,349515 0,572816
263 0,417476 0,067961 0,349515 0,582524
265 0,417476 0,067961 0,349515 0,582524
285 0,398058 0,067961 0,330097 0,601942
308 0,38835 0,067961 0,320388 0,61165 
310 0,38835 0,058252 0,330097 0,61165 
334 0,378641 0,058252 0,320388 0,621359
… … … … … 
1800 0,281553 0,048544 0,23301 0,718447 
 





























Estimates of probability transition from state 1 to state  1 (NPM)
From stage 1 to stage  1











Estimates of probability transition from state 1 to state  2 (NPM)
From stage 1 to stage  2

















Estimates of probability transition from state 1 to state  3 (NPM)




















                      ***** TIME-DEPENDENT COX REGRESSION MODEL *****      
*****************************************************************************  
n= 439  
 
 coef exp(coef) se(coef) z p 
sex -0.0327 0.968 0.11397 -0.287 0.7700 
age 0.0147 1.015 0.00463 3.185 0.0014 
 
  
 exp(coef) exp(-coef) lower.95 upper.95 
sex 0.968 1.033 0.774 1.21 
age 1.015 0.985 1.006 1.02 
 
Rsquare= 0.024   (max possible= 0.999 ) 
Likelihood ratio test= 10.9  on 2 df,   p=0.00435 
Wald test                 = 10.8  on 2 df,   p=0.00464 





















Smooth hazard rate (along with 95%CI) for age
TDCM






























***** FROM STATE 1 TO STATE 2  *****  
n= 345  
 
 coef exp(coef) se(coef) z p 
sex 0.02482 1.03 0.2791 0.089 0.93 






 exp(coef) exp(-coef) lower.95 upper.95 
sex 1.03 0.975 0.593 1.77 
age 1.00 0.997 0.982 1.02 
 
    Rsquare= 0   (max possible= 0.807 ) 
Likelihood ratio test= 0.09  on 2 df,   p=0.955 
Wald test            = 0.09  on 2 df,   p=0.955 
Score (logrank) test = 0.09  on 2 df,   p=0.955 
 
-2*Log-likelihood: 567.5803  
 
 
***** FROM STATE 1 TO STATE 3  *****  
n= 345  
 
 coef exp(coef) se(coef) z p 
sex 0.6585 1.93 0.3391 1.94 0.052 
age 0.0169 1.02 0.0127 1.33 0.180 
 
 
 exp(coef) exp(-coef) lower.95 upper.95 
sex 1.93 0.518 0.994 3.76 
age 1.02 0.983 0.992 1.04 
 
Rsquare= 0.015   (max possible= 0.716 ) 
Likelihood ratio test= 5.21  on 2 df,   p=0.074 
Wald test                 = 4.9  on 2 df,   p=0.0862 
Score (logrank) test = 5   on   2 df,   p=0.0822 
 
-2*Log-likelihood: 428.8344  
 
 
***** FROM STATE 1 TO STATE 4  *****  
n= 345  
 
 coef exp(coef) se(coef) z p 
sex -0.0351 0.966 0.12846 -0.273 0.78000 
age 0.0174 1.018 0.00525 3.307 0.00094 
 
 exp(coef) exp(-coef) lower.95 upper.95 
sex 0.966 1.036 0.75 1.24 
age 1.018 0.983 1.01 1.03 
 
Rsquare= 0.034   (max possible= 0.999 ) 
Likelihood ratio test= 11.8  on 2 df,   p=0.0028 
Wald test                  = 11.6  on 2 df,   p=0.00308 
Score (logrank) test = 11.6  on 2 df,   p=0.003 
 
-2*Log-likelihood: 2336.422  
 
 
***** FROM STATE 2  TO STATE 4  *****  
n= 53  
 
 coef exp(coef) se(coef) z p 
sex -0.636464 0.529 0.3491 -1.82302 0.068 






 exp(coef) exp(-coef) lower.95 upper.95 
sex 0.529 1.89 0.267 1.05 
age 1.000 1.00 0.967 1.03 
 
Rsquare= 0.062   (max possible= 0.961 ) 
Likelihood ratio test= 3.38  on 2 df,   p=0.185 
Wald test                 = 3.34  on 2 df,   p=0.188 
Score (logrank) test = 3.44  on 2 df,   p=0.179 
 
-2*Log-likelihood: 168.3983  
 
 
***** FROM STATE 3  TO STATE 4  *****  
n= 41  
 
 coef exp(coef) se(coef) z p 
sex 0.59128 1.81 0.4233 1.397 0.16 
age -0.00926 0.99 0.0157 -0.591 0.55 
 
 exp(coef) exp(-coef) lower.95 upper.95 
sex 1.81 0.554 0.788 4.14 
age 0.99 1.009 0.961 1.02 
 
Rsquare= 0.061   (max possible= 0.949 ) 
Likelihood ratio test= 2.57  on 2 df,   p=0.277 
Wald test                 = 2.45  on 2 df,   p=0.294 













Smooth hazard rate (along with 95%CI) for age (CMM)
From stage 1 to stage 2







Smooth hazard rate (along with 95%CI) for age (CMM)
From stage 1 to stage 3













Smooth hazard rate (along with 95%CI) for age (CMM)
From stage 1 to stage 4





Smooth hazard rate (along with 95%CI) for age (CMM)
From stage 2 to stage 4





Smooth hazard rate (along with 95%CI) for age (CMM)
From stage 3 to stage 4

























                     ***** MULTI-STATE HOMOGENEOUS MARKOV MODEL *****      
*****************************************************************************  
 
***** Undergoing Transitions *****  
             to 
from 1 2 3 4 
1 0 53 41 251 
2 0 15 0 38 
3 0 0 11 30 
 
 
 *** convergence ***  
 









***** Estimated coefficients *****  
$logbaseline 
 Stage 1 Stage 2 Stage 3 Stage 4 
Stage 1 0.00000 -9.18644 -9.48641 -7.63157
Stage 2 0.00000 0.00000 0.00000 -6.26611
Stage 3 0.00000 0.00000 0.00000 -6.33772
Stage 4 0.00000 0.00000 0.00000 0.00000 
 
$sex 
 Stage 1 Stage 2 Stage 3 Stage 4 
Stage 1 0.00000 0.06063 0.69911 -0.02666
Stage 2 0.00000 0.00000 0.00000 -0.88873
Stage 3 0.00000 0.00000 0.00000 0.19921 
Stage 4 0.00000 0.00000 0.00000 0.00000 
 
$age 
 Stage 1 Stage 2 Stage 3 Stage 4 
Stage 1 0.00000 0.01028 0.02485 0.01390 
Stage 2 0.00000 0.00000 0.00000 0.00519 
Stage 3 0.00000 0.00000 0.00000 0.00035 
Stage 4 0.00000 0.00000 0.00000 0.00000 
 
$baseline 
 Stage 1 Stage 2 Stage 3 Stage 4
Stage 1 -0.00066 0.00010 7.587e-05 0.00048
Stage 2 0.00000 -0.00189 0.00000 0.00189
Stage 3 0.00000 0.00000 -1.768e-03 0.00176
Stage 4 0.00000 0.00000 0.00000 0.00000
 
 $sex 
 HR L95 U95 
Stage 1 - Stage 2 1.06251 0.61473 1.83645 
Stage 1 - Stage 3 2.01196 1.03213 3.92198 
Stage 1 - Stage 4 0.97368 0.75767 1.25128 
Stage 2 - Stage 4 0.41117 0.21701 0.77905 
Stage 3 - Stage 4 1.22044 0.55678 2.67513 
 
$age 
 HR L95 U95 
Stage 1 - Stage 2 1.01033 0.98880 1.03233 
Stage 1 - Stage 3 1.02516 0.99925 1.05174 
Stage 1 - Stage 4 1.01400 1.00398 1.02411 
Stage 2 - Stage 4 1.00520 0.97407 1.03732 
Stage 3 - Stage 4 1.00035 0.97341 1.02804 
 
  
**** WALDS TEST TO CHECK FOR DIFFERENCES BETWEEN MORTALITY INTENSITIES 
****   
LET H0 BE THE HYPOTHESIS OF NON-DIFFERENCES BETWEEN MORTALITY INTENSITIES  
H0 produces a chisquare statistic of: 88.81685  









**** WALDS TEST TO CHECK FOR DIFFERENCES BETWEEN COVARIATE  1  IN THE 
TRANSITION INTENSITIES ****   
LET H0 BE THE HYPOTHESIS OF NON-DIFFERENCES BETWEEN COVARIATE  1  IN THE 
TRANSITION INTENSITIES  
H0 produces a chisquare statistic of: 33.07575  
with a p-value of: 3.104323e-07  
 
 
**** WALDS TEST TO CHECK FOR DIFFERENCES BETWEEN COVARIATE  2  IN THE 
TRANSITION INTENSITIES ****   
LET H0 BE THE HYPOTHESIS OF NON-DIFFERENCES BETWEEN COVARIATE  2  IN THE 
TRANSITION INTENSITIES  
H0 produces a chisquare statistic of: 2.485001  
with a p-value of: 0.4780079  
 
 
***** Sojourn times *****  
$estimate 
  Stage 1       Stage 2      Stage 3  
1507.8521  526.4247  565.5079  
 
$SE 
  Stage 1      Stage 2     Stage 3  
 81.74408  88.43626 109.27736  
 
 
















Probability estimates for the mortality intensity (HMM)













Transition Probability estimate from stage 1 to stage  2 (HMM)
















Transition Probability estimate from stage 1 to stage  3 (HMM)







































***** FROM STATE 1 TO STATE 2  *****  
n= 345  
 
 coef exp(coef) se(coef) z p 
sex 0.02482 1.03 0.2791 0.089 0.93 
age 0.00321 1.00 0.0107 0.300 0.76 
 
 exp(coef) exp(-coef) lower.95 upper.95 
sex 1.03 0.975 0.593 1.77 
age 1.00 0.997 0.982 1.02 
 
 
Rsquare= 0   (max possible= 0.807 ) 
Likelihood ratio test= 0.09  on 2 df,   p=0.955 
Wald test                 = 0.09  on 2 df,   p=0.955 
Score (logrank) test = 0.09  on 2 df,   p=0.955 
 
-2*Log-likelihood: 567.5803  
 
 
***** FROM STATE 1 TO STATE 3  *****  
n= 345  
 
 coef exp(coef) se(coef) z p 
sex 0.6585 1.93 0.3391 1.94 0.052 
age 0.0169 1.02 0.0127 1.33 0.180 
 
 exp(coef) exp(-coef) lower.95 upper.95 
sex 1.93 0.518 0.994 3.76 
age 1.02 0.983 0.992 1.04 
 
 Rsquare= 0.015   (max possible= 0.716 ) 
Likelihood ratio test= 5.21  on 2 df,   p=0.074 
Wald test                 = 4.9  on 2 df,   p=0.0862 
Score (logrank) test = 5  on 2 df,   p=0.0822 
 
-2*Log-likelihood: 428.8344  
 
***** FROM STATE 1 TO STATE 4  *****  
n= 345  
 
 coef exp(coef) se(coef) z p 
sex -0.0351 0.966 0.12846 -0.273 0.78000 






 exp(coef) exp(-coef) lower.95 upper.95 
sex 0.966 1.036 0.75 1.24 
age 1.018 0.983 1.01 1.03 
 
     
 
Rsquare= 0.034   (max possible= 0.999 ) 
Likelihood ratio test= 11.8  on 2 df,   p=0.0028 
Wald test                 = 11.6  on 2 df,   p=0.00308 
Score (logrank) test = 11.6  on 2 df,   p=0.003 
 
-2*Log-likelihood: 2336.422  
 
 
***** FROM STATE 2  TO STATE 4  *****  
n= 53  
 
 coef exp(coef) se(coef) z p 
sex -0.549876 0.577 0.3337 -16.476 0.099 
age -0.000862 0.999 0.0153 -0.0564 0.960 
 
 exp(coef) exp(-coef) lower.95 upper.95 
sex 0.577 1.73 0.30 1.11 
age 0.999 1.00 0.97 1.03 
 
Rsquare= 0.05   (max possible= 0.989 ) 
Likelihood ratio test= 2.74  on 2 df,   p=0.254 
Wald test                  = 2.73  on 2 df,   p=0.255 
Score (logrank) test = 2.8  on 2 df,   p=0.247 
 
-2*Log-likelihood: 237.0028  
 
 
***** FROM STATE 3  TO STATE 4  *****  
n= 41  
 
 coef exp(coef) se(coef) z p 
sex 0.5082 1.66 0.406 1.25 0.21 
age 0.0165 1.02 0.015 1.10 0.27 
 
 exp(coef) exp(-coef) lower.95 upper.95 
sex 1.66 0.602 0.751 3.68 
age 1.02 0.984 0.987 1.05 
 
Rsquare= 0.059   (max possible= 0.986 ) 
Likelihood ratio test= 2.47  on 2 df,   p=0.290 
Wald test                 = 2.42  on 2 df,   p=0.298 


















Smooth hazard rate (along with 95%CI) for age (CSMM)
From stage 1 to stage 2







Smooth hazard rate (along with 95%CI) for age (CSMM)
From stage 1 to stage 3













Smooth hazard rate (along with 95%CI) for age (CSMM)
From stage 1 to stage 4






Smooth hazard rate (along with 95%CI) for age (CSMM)
From stage 2 to stage 4





Smooth hazard rate (along with 95%CI) for age (CSMM)
From stage 3 to stage 4


























                      ***** NON-PARAMETRIC MULTI-STATE MODEL *****                
*****************************************************************************  
 
Times Survival P11 P12 P13 P14 
0 1 1 0 0 0 
5 0.997101 0.997101 0 0 0.002899
8 0.994203 0.994203 0 0 0.005797
9 0.991304 0.991304 0 0 0.008696
10 0.991304 0.988406 0.002899 0 0.008696
11 0.988406 0.985507 0.002899 0 0.011594
14 0.988406 0.982609 0.002899 0.002899 0.011594
15 0.985507 0.97971 0.002899 0.002899 0.014493





30 0.982609 0.973913 0.002899 0.005797 0.017391
36 0.97971 0.971014 0.002899 0.005797 0.02029 
44 0.97971 0.968116 0.005797 0.005797 0.02029 
48 0.97971 0.965217 0.005797 0.008696 0.02029 
61 0.976812 0.962319 0.005797 0.008696 0.023188
63 0.973913 0.95942 0.005797 0.008696 0.026087
75 0.971014 0.956522 0.005797 0.008696 0.028986
88 0.968116 0.953623 0.005797 0.008696 0.031884
90 0.968116 0.950725 0.005797 0.011594 0.031884
99 0.965217 0.947826 0.005797 0.011594 0.034783
101 0.965217 0.944928 0.008696 0.011594 0.034783
104 0.965217 0.942029 0.008696 0.014493 0.034783
110 0.965217 0.942029 0.008696 0.014493 0.034783
112 0.962319 0.93913 0.008696 0.014493 0.037681
119 0.956522 0.936232 0.008696 0.011594 0.043478
120 0.953623 0.933333 0.008696 0.011594 0.046377
124 0.950725 0.930435 0.008696 0.011594 0.049275
129 0.947826 0.927536 0.008696 0.011594 0.052174
152 0.944928 0.924638 0.008696 0.011594 0.055072
156 0.942029 0.921739 0.008696 0.011594 0.057971
158 0.93913 0.918841 0.008696 0.011594 0.06087 
159 0.936232 0.915942 0.008696 0.011594 0.063768
164 0.933333 0.913043 0.011594 0.008696 0.066667
165 0.933333 0.910145 0.014493 0.008696 0.066667
175 0.930435 0.907246 0.014493 0.008696 0.069565
180 0.927536 0.901449 0.017391 0.008696 0.072464
181 0.924638 0.901449 0.014493 0.008696 0.075362
184 0.924638 0.898551 0.017391 0.008696 0.075362
187 0.921739 0.892754 0.02029 0.008696 0.078261
190 0.918841 0.889855 0.02029 0.008696 0.081159
206 0.915942 0.889855 0.017391 0.008696 0.084058
209 0.913043 0.884058 0.017391 0.011594 0.086957
210 0.910145 0.884058 0.014493 0.011594 0.089855
213 0.910145 0.881159 0.014493 0.014493 0.089855
219 0.907246 0.878261 0.014493 0.014493 0.092754
220 0.904348 0.875362 0.014493 0.014493 0.095652
221 0.901449 0.872464 0.014493 0.014493 0.098551
227 0.898551 0.869565 0.014493 0.014493 0.101449
229 0.898551 0.866667 0.017391 0.014493 0.101449
239 0.895652 0.863768 0.017391 0.014493 0.104348
240 0.895652 0.857971 0.023188 0.014493 0.104348
244 0.892754 0.855072 0.023188 0.014493 0.107246
247 0.889855 0.852174 0.023188 0.014493 0.110145
… … … … … … 
5292 0.086957 0.011594 0.043478 0.031884 0.913043
5419 0.084058 0.008696 0.043478 0.031884 0.915942
5427 0.081159 0.005797 0.043478 0.031884 0.918841
5440 0.078261 0.002899 0.043478 0.031884 0.921739
































Estimates of probability transition from state 1 to state  1 (NPM)
From stage 1 to stage  1









Estimates of probability transition from state 1 to state  2 (NPM)













Estimates of probability transition from state 1 to state  3 (NPM)











Estimates of probability transition from state 1 to state  4 (NPM)
















































































































Resumen de la tesis 
 
 
La progresión de una cierta enfermedad puede describirse a través de los 
modelos multi-estado. Estos modelos pueden considerarse como una generalización del 
proceso de supervivencia donde varios eventos (intermedios) ocurren consecutivamente 
en el tiempo. En este contexto, algunos problemas de interés son: la estimación de tasas 
de progresión, la evaluación de los efectos de factores de riesgo individuales, o la 
estimación de la tasa de supervivencia. La influencia de estos eventos intermedios en la 
supervivencia es analizada habitualmente a través del  modelo de regresión de Cox. Esta 
tesis contiene una revisión exhaustiva de los modelos multi-estado más habituales para 
estudiar la progresión de la enfermedad. Se discuten las diferencias entre estos modelos 
y el modelo de regresión de Cox, enfatizando las posibles ventajas y desventajas de 
cada método. 
La supervivencia de un paciente puede pensarse como un proceso que consta de 
dos estados, con una posible transición del estado “vivo” al estado “muerto”. En 
algunos estudios, sin embargo, el estado que representa a los pacientes “vivos” puede 
dividirse en dos o más estados intermedios, correspondiendo cada uno de ellos a una 
fase particular en el progreso natural de la enfermedad. A menudo, la influencia de estos 
eventos en la supervivencia es importante en el resultado del paciente y puede 
manejarse usando el modelo de regresión de Cox. En estos casos, el evento de interés se 
considera el evento principal, mientras que los eventos intermedios son incluidos 
frecuentemente como covariables dependientes del tiempo, en un modelo de riesgos 
proporcionales. El proceso termina cuando el paciente entra en el estado absorbente, 
“muerto”, que corresponde al evento de interés. Ninguna otra observación es necesaria 
después de que este evento ocurra. Así, en análisis de supervivencia sólo considera dos 
estados, y el evento de interés es la transición de un estado a otro. Aunque el modelo de 
regresión de Cox presenta ciertas ventajas (fácil interpretación y  disponibilidad en la 
mayoría de los paquetes estadísticos), este modelo proporciona estimaciones constantes 
de los efectos de las covariables a lo largo del estudio, lo que puede considerarse como 









Los modelos multi-estado pueden ser considerados como una generalización de 
la herramienta básica que trata con datos de supervivencia. En estos modelos la 
supervivencia es el último resultado de interés, pero donde se identifican también 
estados intermedios. En contraste con los datos de supervivencia, en estos modelos se 
observa una sucesión de eventos y se registra más de una observación por individuo. En 
medicina, los estados intermedios podrían basarse en síntomas clínicos (episodios 
sangrantes), marcadores biológicos (recuentos de células CD4; el nivel de 
hemoglobina), alguna escala de la enfermedad (estadios de cáncer o de infección HIV) o 
una complicación no-fatal en el transcurso de la enfermedad (p.e., un transplante). Se 
llama transición, o evento, a un cambio de estado. Los estados pueden ser transitorios o 
absorbentes, si ninguna transición sale del estado (por ejemplo, muerte). La estructura 
de los estados, no necesariamente única, identifica los estados y las transiciones 
permitidas de un estado al otro. 
Los modelos multi-estado presentan una serie de ventajas sobre el modelo de 
regresión de Cox. En primer lugar, aportan una perspectiva comprensiva del proceso de 
la enfermedad, y proporcionan una utilización más eficaz de la información incompleta, 
cuando solamente parte de la historia de la enfermedad de un individuo es conocida 
(manejando eficazmente datos con elevado porcentaje de censura). Además, con esta 
herramienta, las intensidades de transición (que proporcionan el riesgo instantáneo de 
pasar de un estado al otro) pueden utilizarse para determinar (entre otros parámetros) el 
tiempo de permanencia en un determinado estado de enfermedad, el número de 
individuos en diferentes estados en un determinado momento, y las tasas de 
supervivencia en cada estado. Finalmente, las covariables en las intensidades de 
transición también pueden explicar diferencias en el curso de la enfermedad entre la 
población. De este modo, los modelos multi-estado pueden revelar distintos efectos de 
un conjunto de covariables en las diferentes transiciones, algo que no sería posible con 
otros modelos como, por ejemplo, el modelo de regresión de Cox. De hecho, es muy 
improbable que el riesgo de muerte en pacientes que recibieron tratamientos distintos 
sea el mismo. Además, los factores de pronóstico asociados con el riesgo de muerte 
pueden ser diferentes en estos grupos de pacientes. En conclusión, los modelos multi-
estado evalúan el progreso de la enfermedad del paciente dinámicamente dependiendo 









En los últimos años, existe un creciente interés en métodos estadísticos para 
estudiar la progresión de la enfermedad. Algunas enfermedades que se han estudiado 
usando los modelos multi-estado incluyen: Infección por VIH (Lagakos et al., 1988; 
Longini et al., 1989 y 1991; Gentleman et al., 1994; Satten y Longini, 1996; Aalen et 
al., 1997), cáncer de mama (Duffy y Chen, 1995; Chen et al., 1996; Pérez-Ocón et al., 
2001), cirrosis  (Kay, 1986; Andersen et al., 2000), leucemia (Klein et al., 1984 y 1994; 
Andersen et al., 1999; Keiding et al., 2001; Chevret et al., 2000), asma (Saint-Pierre et 
al., 2003), Alzheimer (Commenges et al., 2004), transplantes (Hansen et al., 1994; 
Klotz y Sharples, 1994; Jackson y Sharples, 2002), diabetes (Andersen, 1988), 
retinopatía diabética (Andersen, 1991; Marshall y Jones, 1995), malaria (Gottschau y 
Hogh, 1995) y esclerosis múltiple (Esbjerg et al., 1999). Estos modelos también se han 
utilizado en otros campos como el análisis de Fiabilidad (Su et al., 2000). 
Una vez introducidos los modelos multi-estado, el Capítulo 2 de esta tesis 
proporciona una revisión más profunda de dichos modelos. En particular, en este 
capítulo introducimos estos modelos como procesos estocásticos; presentamos algunos 
de los modelos multi-estados más frecuentemente utilizados; consideramos diferentes 
patrones de censura y discutimos las hipótesis de simplificación más comunes.    
En un modelo multi-estado general, los individuos cambian de un estado a otro a 
través de tiempo. El siguiente estado para cual el individuo cambia, y el tiempo de 
cambio,  se especifican a través de intensidades de transición que proporcionan el riesgo 
instantáneo de movimiento de un estado al otro. Estos modelos se basan en procesos 
estocásticos en tiempo continuo permitiendo que los individuos se muevan entre un 
número finito de estados. 
Formalmente, representaremos el estado de un individuo por un proceso 
estocástico ( ){ },  iX t t∈T , donde ( )iX t  puede tomar un número finito de valores 
{ }1,..., N , ∞ , y verificando ciertos presupuestos de simplificación. Así,  [ )0, ,  τ τ= ≤T
( )iX t  denota el estado ocupado por el i-ésimo individuo y { }1,...,S N=  es un espacio 
de estados finito. Por consiguiente, ( ){ },  iX t t∈T  contiene la información de las 
diferentes transiciones del individuo a lo largo del tiempo, así como el tiempo en que 











filtración, , se generará conteniendo toda la información sobre el proceso en el 
intervalo 
so multi-estado se caracteriza completamente por intensidades de 
transi  por probabilidades de transición entre estados h y j, que nosotros 
expresaremos respectivamente por 
t−F
[ )0, t . 
Este proce
ción o
( )α −hj tt F  y ( ) ( ) ( )( )−= = =P, ,hj sp s t X t j X s h F , 
siendo  la historia observada del proceso en tiempo l. Así, mientras que las 
probabilidades de transición proporcionan medidas importantes para hacer predicciones 
nsidad de transición, 
−lF
a largo plazo, cada inte ( )α −hj tt F  representa el riesgo instantáneo 
de progresión de un estado al otro.     
La complejidad de un modelo multi-estado depende del número de estados y de 
las transiciones permitidas entre dichos estados. En análisis de supervivencia, la forma 
más simple de modelo multi-estado es el modelo de mortalidad. Este modelo se 
representa en la Figura 1.  
 
 
Figura 1: modelo de mortalidad para el análisis de supervivencia. 
 
Otro modelo posible para describir la progresión de la enfermedad es el modelo 
enfermedad-muerte (illness-death). Este modelo se caracteriza totalmente por sus tres 
intensidades de transición, cada una de ellas describiendo el riesgo instantáneo de 
progresión de un estado al otro: la intensidad de la enfermedad, la intensidad de 
mortalidad sin la enfermedad, y la intensidad de mortalidad después de la ocurrencia de 
la enfermedad. Estos modelos se usan ampliamente en la literatura médica y pueden 
utilizarse en el estudio de la incidencia de enfermedad y/o muerte. Estos modelos serán 
tratados extensamente a lo largo de esta tesis. 
 
 











Figura 2: modelo enfermedad-muerte (Illness-death). 
 
En el Capítulo 3 revisamos varios métodos que siguen la metodología de los 
modelos multi-estado con el presupuesto de Markov. Específicamente, revisamos los 
modelos siguientes: (i) modelo de Cox Markov (Andersen et al., 2000), donde las 
intensidades de transición usan separadamente diferentes modelos de Cox; (ii) modelos 
de Markov homogéneos en tiempo (Kay, 1986); y (iii) modelos de Markov con 
intensidades constantes a trozos (Pérez-Ocón et al., 2001). Los métodos revisados se 
ilustran con los datos de transplante de corazón de Stanford, proporcionando un guía 
sobre el uso de estas metodologías para el estudio de la evolución de la enfermedad.  
El estudio de transplante de corazón de Stanford comenzó en octubre de 1967. 
Los datos disponibles en el artículo de Crowley y Hu (1977) cubren el período hasta el 
1 de abril de 1974. Algunos pacientes murieron antes de que se dispusiera de un 
corazón apropiado para el transplante. De los 103 pacientes, 69 recibieron un 
transplante de corazón. El número total de muertes fue de 75. Para cada individuo, se 
encuentra registrado un indicador de su estado vital final (censura o no), los tiempos de 
supervivencia desde la entrada del paciente en el estudio (en días), y un vector de 
covariables incluyendo la edad a la aceptación, año de aceptación, cirugía anterior, y 
transplante. Transplante es la única covariable dependiente en tiempo.  En el contexto 
de un planteamiento multi-estado podemos considerar la covariable “transplante” como 
un estado de riesgo asociado y entonces utilizar un modelo multi-estado para investigar 
el efecto del transplante en la supervivencia.  Para los datos de Stanford, es interesante 
comparar el riesgo de muerte antes y después del transplante. También podemos 
explorar los efectos de las restantes covariables en cada una de las transiciones. En este 
capítulo, también utilizamos estos datos para discutir posibles contrastes de hipótesis y 
métodos para chequear el modelo, como el presupuesto de homogeneidad en el tiempo o 
la propiedad de Markov. Además, al examinar los datos, es interesante comprobar 
diferentes hipótesis sobre el modelo (hipótesis sobre las intensidades de transición, 









coeficientes de regresión, bondad de ajuste, etc.). Se discuten diferencias entre estos 
modelos y el modelo de regresión de Cox con covariables dependientes en tiempo y 
enfocamos las posibles ventajas y desventajas para cada método. A través de esta 
ilustración mostramos como los modelos multi-estado pueden proporcionar nuevas 
perspectivas, al tiempo que confirman los resultados obtenidos mediante el modelo de 
regresión de Cox.    
Una atención especial debe prestarse cuando se está interesado en evaluar el 
efecto de una covariable. Como se ha mencionado anteriormente, el modelo de Cox 
proporciona estimaciones constantes del efecto de la covariable a lo largo del periodo de 
estudio. Para evitar este problema utilizamos métodos de suavización spline (P-splines) 
para obtener un modelo de Cox dinámico. Además, introducimos estos métodos spline 
en modelos multi-estado para averiguar los posibles efectos no-lineales de las 
covariables en las intensidades de transición. El uso de estos métodos en modelos multi-
estado es novedoso. 
Mientras que los modelos multi-estado proporcionan estimaciones no-sesgadas 
de la importancia y capacidad de las covariables para explicar el curso de la 
enfermedad, estos problemas no pueden ser totalmente explorados utilizando modelos 
de Cox. Para ilustrar los posibles beneficios del uso de los modelos multi-estado, se 
realizaron varios estudios de simulación. A través de estos estudios, se explica por qué 
el modelo de Cox puede no ser apropiado (con interpretación difícil) cuando se utiliza 
en presencia de covariables dependientes del tiempo. De este modo, mostramos cómo 
los modelos multi-estado permiten un análisis más concluyente que el modelo de Cox 
sobre los efectos de las covariables.    
Al analizar los datos de transplante de corazón de Stanford utilizando la 
metodología multi-estado, el presupuesto de Markov se reveló satisfactorio. Se utilizó 
un test de bondad de ajuste para comparar los distintos modelos utilizados, indicando 
que el modelo de Cox Markov y el modelo homogéneo a trozos son más apropiados que 
el modelo homogéneo. Al utilizar el modelo homogéneo se verificó que dicho modelo 
infravalora a corto plazo la mortalidad. La razón por la cual este modelo ajustó 
pobremente a los datos de Stanford se debe al hecho de que el proceso de supervivencia 
no es homogéneo a lo largo del tiempo. Mientras que el modelo de regresión de Cox 
con covariables dependientes en tiempo presentó un efecto despreciable del trasplante, 









significativamente a una disminución en el riesgo de mortalidad. La aplicación del 
modelo homogéneo a trozos sólo confirmó tal asociación cuando se analizaba la 
supervivencia a largo plazo.   
 A través de un estudio de simulación, hemos mostrado que el efecto de las 
covariables en la supervivencia puede verse profundamente afectado por el efecto de 
dichas covariables a través de una única transición. De hecho, al analizar los datos de 
Stanford, verificamos que el efecto de la covariable “tiempo de aceptación” (año), 
considerado el predictor más importante en el modelo de Cox, sólo obtuvo un efecto 
estadísticamente significativo en la transición de mortalidad para los pacientes sin 
trasplante. Algunos de los modelos multi-estado estudiados mostraron una influencia 
negativa de la covariable “cirugía” en el riesgo para la transición . Por otro lado, 
la edad a la aceptación, ha presentado un efecto significativo en la supervivencia en 
cualquiera de los modelos estudiados, y su efecto positivo en el riesgo indica que los 
pacientes más jóvenes tienen una supervivencia mejor.  
  Tradicionalmente, los métodos estadísticos para analizar los modelos multi-
estado dependen del presupuesto de Markov. Bajo la propiedad de Markov, las 
intensidades de transición dependen del tiempo actual y del estado actualmente ocupado 
pero no dependen de la historia del paciente (el tiempo de permanencia en el estado 
actual; los tiempos de transición de un estado al otro, etc.). Ignorando la historia de la 
enfermedad, estos modelos pueden presentar serias limitaciones, llevando entonces a 
una mala especificación. Un planteamiento alternativo consiste en utilizar el 
presupuesto de semi-Markov, con  el cual el futuro del proceso no depende del tiempo 
actual,  si no  tan sólo de la duración en el estado actual. En el Capítulo 4 se revisa el 
modelo de Cox semi-Markov y se propone un nuevo planteamiento no-Markoviano, el 
cual permite que las intensidades de transición puedan depender no sólo del tiempo 
actual, sino también del tiempo de transición al estado actual. Nuestra investigación 
sobre modelos no-Markovianos tiene dos objetivos  principales. El primer objetivo es 
desarrollar un nuevo planteamiento basado en presupuestos menos restrictivos que 
aquéllos basados en la propiedad de Markov. El segundo objetivo es comparar los 
estimadores desarrollados aquí para las probabilidades de la transición con las 
estimaciones de Aalen-Johansen (derivadas bajo el presupuesto de Markov). Para este 
propósito, consideramos el modelo enfermedad-muerte (illness-death). Posteriormente, 










   Asumamos un modelo enfermedad-muerte (ver Figura 2). Sea 
( ) ( ){ }0 0 1, ,X t t X≥ =
observa un núme
comportamiento estocástico del pro
 un proceso estocástico no-homogéneo y asumamos que se 
ro finito de historias independientes del proceso. Representamos el 
ceso por un vector aleatorio ( )12 13 23, ,T T T  donde
es el tiempo potencial de permanencia en el estado h antes de la transición al estad
Obsérvese que los tiempos de permanencia en estado 1 y 2 son dados por 
 hjT  
o j. 
( )12 13min ,Z T T=  y  respectivamente. Un individuo en el estado sano se expone a dos 
eventos mutuamente excluyentes, "enfermedad" y "muerte", que no pueden ocurrir 
simultáneamente, obs rvando tan sólo el primero de estos eventos. Solamente los 
individuos para los cuales  entran  en estado 2 en algún tiempo . Por 
supuesto, existen varios problemas que afectan a la observación de las variab . 
Puede ocurrir una censura por la derecha debido a la limitación de tiem
seguimiento, pérdida de casos, etc. Por otro lado, siempre que 
23T
e
12 13≤T T 12T
les hjT
po en el 
13 12T T< , se obtiene un 
valor censurado por la derecha para , no disponiéndose de ninguna información sobre 
. De lo mismo modo, siempre que 
12T
23T 12 13T T≤  se obtiene un valor censurado por la 
derecha de . Al largo de este trabajo denotamos por  el tiempo potencial de 
censura. De este modo, los tiemp e 
la enfermedad  o después de la enfermedad 
. Asumiremos que la variable C es independiente 
 Nuestro objetivo es la estimación de la probabilidad de transición 
13T C
os de los individuos pueden estar censurados antes d
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de ( )12 13 23, ,T T T . 
( ) ( ) ( )( ),hjp s t X t j X s h= = = s tP , < , que representa la probabilidad condicional de 
que el individuo esté en el estado po t sabiendo que estaba en el estado h en 
tiempo s.  Para el modelo de enfer uerte, es suficiente considerar la estimación 
de las siguientes probabilidades de transición: 
 j en tiem
medad-m
( )11 ,p s t , ( )12 ,p s t  y ( )22 ,p s t . Las 
probabilidades restantes pueden obtenerse a partir de estas: 
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Estas cantidades son determinadas por la distribución conjunta de . En 
particular, el conocimiento de la distribución de Z es suficiente para 
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mientras que esperanzas del tipo ( ) ( ) ( )12 12 23 12 13,S T T T Tφ φ= + ≤ T⎡ ⎤⎣ ⎦E I  surgen para 
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 Para la estimación de estas probabilidades, consideremos C , 
I
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Las variables U y V representan los tiempos de perm
respectivamente; 
( )13η = ≤T CI
anencia en estados 1 y 2, 
δ  nos indica si ocurrió una transición del estado 1 al estado 2; el 
indicador ρ  nos ofrece la misma información para la transición ; finalmente, 
cuando 
2 3→
0δ = , el evento 1η =  nos indica que ocurrió una transición . La muestra 
observada se representa por 
1 3→
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η . Como Z y C son independientes, el estimador 
Kaplan-Meier basado en los γ ’s, digamos lH , estima consistentemente la 
distribución H de Z ador para . Entonces un posible estim ( )11 ,p s t  viene dado por,  
















Para introducir un estimador para ( )S φ  notemos que  
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donde G denota la distribución de la variable C. Además, si 
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proceso, entonces tenemos ( )i  
 denota el tiempo de supervivencia del 
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dor Kaplan-Meier basado en los 
. 
Como T y C son independientes, el estima
( ),1i i i iU Vδ ν+ − ’s con i i i i i( )1ν δ η δ ρ+  estima consistentemente G. Denotamos este 
estimador por . Entonces, proponemos estimar 
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 Podemos ahora introducir estimadores para las restantes probabilidades de 
transición: 
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Los estimadores aquí propuestos difieren de los propuestos por Aalen y 
Johansen (1978), excepto para el caso de . De hecho, los estimadores de Aalen-
Johansen presentan un sesgo sistemático en situaciones no-Markovianas, debido a que 
están basados en la suposición de Markov. Nuestra propuesta de estimación vence esta 
dificultad, si bien a costa de resultar en una estimación con mayor varianza. 
Otro punto de interés son los resultados asintóticos para las probabilidades de 
transición estimadas. Se estudiaran: (i) consistencia; (ii) convergencia en distribución a 
la distribución normal; y (iii) estimación (límite) de la varianza. 
 Se realizaron estudios de simulación para comparar los estimadores no-
Markovianos propuestos con los estimadores de Aalen-Johansen (Markovianos) para el 










verificado que,  a menos que el proceso satisfaga el presupuesto de Markov, los 
estimadores no-Markovianos aquí propuestos constituyen una buena opción. Estos 
métodos fueron ilustrados utilizando datos de un ensayo clínico danés en cirrosis del 
hígado.  
 Una limitación importante para la aplicación de modelos multi-estado es la poca 
disponibilidad de software “amigable” para estos modelos. La mayoría del software 
disponible presenta algunas dificultades y limitaciones en práctica.  Además, en algunos 
estudios clínicos el presupuesto de Markov puede ser apropiado, mientras que para otros 
un modelo con la propiedad de semi-Markov (o no-Markov) es preferible. En algunos 
casos, un modelo homogéneo en tiempo es satisfactorio, mientras que en otros no. 
Además, las posibles comparaciones entre los distintos modelos multi-estado son 
difíciles de llevar a cabo, ya que cada uno de ellos tiene su propia estructura de datos de 
entrada (input). Además, la mayoría de los programas disponibles sólo proporcionan 
estimaciones de los parámetros de regresión y no proporcionan gráficas para la 
estimación de supervivencia y para las probabilidades de transición estimadas.  Por todo 
ello, hemos desarrollado un programa en R, llamado tdc.surv, que puede ser utilizado 
para ajustar de una manera sencilla y compacta la mayoría de los modelos estudiados. 
Las ventajas de este software incluyen la misma entrada de los datos para ajustar a los 
distintos modelos, proporcionando los resultados numéricos y gráficos 
correspondientes. De este modo, los usuarios pueden analizar los resultados ofrecidos a 
través de diferentes modelos, compararlos entre sí y tomar decisiones. En el  Capítulo 5 
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